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Abstract 
Liver fibrosis, or liver scarring, is a consequence of dysregulated wound healing 
which leads to excessive extracellular matrix (ECM) accumulation. Fibrosis is the 
hallmark of chronic liver disease (CLD), and its progression can eventually result in 
cirrhosis and the development of hepatocellular carcinoma (HCC). CLD is 
associated with chronic inflammation which is orchestrated by a network of 
proinflammatory cytokines/chemokines, inflammatory infiltrates, and tissue resident 
cells. Recent evidence suggests that fibrosis is a reversible process that can be 
promoted through attenuation of the initiating insult or dissolution of the 
accumulated ECM itself. Currently, there are no effective anti-fibrotic treatments 
available. Thus, there remains a clear need for an increased understanding of the 
factors which promote fibrosis to allow for the strategic development of novel 
therapeutics to limit the impact of fibrotic disease.   
 
There are various pre-clinical models available to study the pro-inflammatory 
cellular and molecular mediators that contribute to liver fibrosis. Long-term oral 
administration of the hepatotoxin thioacetamide (TAA) provides a model in which 
fibrosis is induced in two phases. An early phase of fibrosis occurs following 1-6-
week TAA administration and is characterized by inflammation associated with 
pericentral monocyte accumulation, HSC activation, and collagen deposition. 
Following 6-12-week TAA administration, disease is associated with exponentially 
increased collagen deposition and an expanding ductular reaction (DR) in 
association with an increase in DR/macrophage interactions. 
 
The Interleukin-17 (IL-17) cytokine family has established roles in multiple diseases 
which are characterized by fibrosis. Of all IL-17 family cytokines IL-17A, IL-17E, and 
IL-17F are most well studied. Previous studies have identified a role for IL-17A in 
the development of liver fibrosis in both preclinical models and human disease. In 
this regard, IL-17A can both directly activate hepatic stellate cells (HSCs) to 
promote collagen production, and indirectly promote their activation through evoking 
proinflammatory cytokine expression by multiple cell types. Although elevated IL-
17F expression has been found to be associated with liver fibrosis, whether this 
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cytokine represents a mechanistic mediator remains to be elucidated. The role of 
IL-17E during liver fibrosis is controversial with reports of both pathogenic and 
regulatory functions. Hence, We investigated the relative, temporal and mechanistic 
contribution of the IL-17A, IL-17F, and IL-17E cytokines to the initiation and 
perpetuation of liver fibrosis using the TAA model. In In vivo experiments using mice 
deficient in these cytokines or their receptors we investigated the contribution of 
each signaling pathway to the two phases of TAA-induced fibrosis.   
 
In Chapter 3, we identified a critical role of IL-17RA, the receptor subunit required 
for IL-17A, IL-17F and IL-17E signaling, in both the early and late phases of TAA-
induced liver fibrosis. In contrast, no pathogenic role for IL-17F was observed. We 
demonstrate that either IL-17A or IL-17E signaling was sufficient to induce the early 
inflammatory phase (1-6 weeks), however, both cytokines were required for the 
development of a mature ductular reaction and progression to cirrhosis.  Thus, we 
demonstrate the redundant nature of these cytokines in the inflammatory phase of 
disease, but their synergistic roles in the later progressive phase (6-12 weeks) of 
fibrosis.  Importantly, these data highlight the potential of IL-17RA blockade, rather 
than IL-17A or IL-17E individually, as an optimal therapeutic strategy for the 
treatment of liver fibrosis.  
 
In mechanistic studies, we demonstrated that IL-17A production was increased 
following 1-week TAA and identified CCR2+γδ T cells as the primary IL-17A 
producing liver leukocyte population. We observed IL-17A signaling was found to 
facilitate the expression IL-6 and TNF in the liver, both of which are established 
mediators of fibrosis. Furthermore, we demonstrate that both IL-17A and IL-17E 
function to promote monocyte recruitment in the early phase. Although IL-17A 
deficiency did not alter the absolute number of infiltrating monocytes, IL-17A 
signalling was required for the sequestration of monocytes around the central vein 
(CV). In contrast, in the absence of IL-17E, monocyte infiltration into the liver was 
markedly attenuated. We demonstrate that after 1 week of TAA treatment, IL-17E 
signalling, specifically within the non-haematopoietic compartment, significantly 
increased liver CCL2 levels. Furthermore, we demonstrate that, CCL2 produced 
from macrophages and eosinophils, but not monocytes was IL-17E dependant. 
Moreover, the administration of IL-17E to naïve mice induced elevated circulating 
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and liver CCL2 levels, promoted monocytic infiltration into the liver which was 
associated with HSC activation and sinusoidal fibrosis. In addition to monocytes, we 
confirmed CCL2 also promoted the infiltration of CCR2+IL17A+TNF+γδ T cells into 
the liver. Thus, IL-17E through CCL2 production promotes the recruitment of 
pathogenic monocytes and IL-17+γδ T cell infiltration into the liver, whereas, IL-17A 
signaling contributes to the sequestration of these cells at the central vein, the site 
of injury initiation in the TAA model. These studies highlight distinct but synergistic 
roles for IL-17A and IL-17E in driving the inflammatory responses which underpin 
fibrogenesis. 
 
B cells play a pathogenic role in autoimmune diseases through multiple 
mechanisms. The mechanisms include secretion of autoantibodies, secretion of 
inflammatory cytokines and the promotion T cell responses through antigen 
presentation. Although the contribution of B cells in liver fibrosis is poorly studied, 
the limited literature suggests innate B cell activation and antibody production as 
pathogenic mechanisms in liver fibrosis. However, to date, a pathological role for B 
cells in the TAA liver fibrosis model is undescribed. Here we demonstrated a critical 
role for B cells in this model. Mechanistically we demonstrated increased B cell 
activation (CD44 and CD86) associated with elevated TNF production in livers from 
TAA treated mice when compared to that of naïve mice. Moreover, serum IgG 
levels were increased in response to TAA treatment, the pathogenicity of which was 
confirmed using B cell deficient (µMT-/-) mice. IgG deposition in the livers of TAA 
treated mice was noted and shown to be localized to the scar regions within the 
liver parenchyma where macrophages sequester. IgG ligation of FcR on 
macrophages has previously been shown to elicit pathogenic responses. Using 
FcγR deficient mice we demonstrate, that while IgG production in response to TAA 
remained unchanged, the development of fibrosis was significantly attenuated. 
Thus, B cells contribute to TAA-induced liver fibrosis through B cell activation and 
cytokine production, IgG deposition and binding to FcγR.  
 
Rho-associated kinase 2 (ROCK2) is a serine–threonine kinase that plays a central 
role in the control of intracellular signaling cascades involved in the regulation of 
cytoskeletal reorganization and the secretion of proinflammatory cytokines. ROCK2 
has an established role in regulating IL-17A and IL-21 production and macrophage 
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plasticity. Additionally, through the promotion of T follicular helper cell (TFh) 
differentiation and IL-21 production, ROCK2 drives germinal center B cell 
development and antibody production. Increased ROCK2 activity is associated with 
autoimmunity, and targeted ROCK2 inhibition was recently shown to attenuate 
pathology in the chronic GVHD, a complication of allogeneic stem cell 
transplantation which presents with autoimmune like symptoms. To date, the role of 
ROCK2 in liver fibrosis remains largely unexplored, although increased ROCK2 
activity has been shown to correlate with disease severity in the bile duct ligation 
(BDL) model of liver fibrosis. Chapter 5 outlines our findings from our investigations 
of the mechanistic contribution of ROCK2 in prevention and treatment of TAA-
induced liver fibrosis. We report that KD025, a selective ROCK2 inhibitor, both 
attenuates fibrogenesis and promotes fibrolysis in the TAA liver fibrosis model. 
Mechanistically, KD025 inhibited signal transducer and activator of transcription 3 
(STAT3) and RAR-related orphan receptor gamma (RORγt) signaling pathways in 
the liver which in turn attenuated IL-17 production. Furthermore, in addition to 
pSTAT3, KDO25 inhibited B-cell lymphoma 6 (BCL6) expression, both of which are 
required for TFh differentiation and function. In line with this, splenic B cell germinal 
center formation was diminished, resulting in significantly reduced IgG production 
and deposition in the liver. Additionally, KD025 administration significantly 
decreased liver macrophage TNF production and altered macrophage distribution.  
As both IL-17A signalling and IgG FcγR ligation are know to drive inflammatory 
responses in macrophages, the attenuation of these pathways represents indirect 
mechanisms by which KD025 inhibits pathogenic macrophage programming. 
However, in in vitro studies we demonstrated KD025 significantly diminishes STAT3 
phosphorylation in bone marrow derived macrophages (BMDM)  in response to IL-
17A demonstrating additional direct effects on macrophage differentiation. 
Additionally, the cofilin pathway, another ROCK2 target, was also perturbed by 
KD025 administration in vivo. Cofilin is a actin-binding protein which regulates 
cytoskeletal reorganization required for cytokine production, adhesion and 
migration. Again, using BMDM in vitro we demonstrated KD025 markedly 
diminished pCofilin levels, which was associated with reduced TNF production and 
altered MMP profiles.  Taken together, we demonstrate the efficacy of ROCK2 
inhibition in attenuating the development of TAA-induced liver fibrosis and 
promoting its regression through direct and indirect effects on macrophage function.  
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Overall, the data presented in this thesis identifies the synergistic contribution of IL-
17A and IL-17E cytokines to liver fibrosis by promoting myeloid recruitment and 
pathogenic differentiation. Moreover, we identify a critical role for B cells in this 
model, where aberrant B cell activation results in pathogenic IgG production, tissue 
deposition, and FcγR ligation. Finally, we identified ROCK2 as a potential 
therapeutic target to inhibit pathogenic responses induced by different cellular 
(monocytes/macrophages and B cells) and molecular (STAT3, BCL6, IL-17A, 
Cofilin) mediators 
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Nature Reviews Immunology 14, 181–194 (2014)
Figure1-1 Phases of liver injury during chronic liver disease: Chronic inflammation leading to 
fibrosis, cirrhosis and eventually hepatocellular carcinoma (HCC). Nature reviews immunology 14, 
181-194 (2014) 
Chapter 1: Review of the literature 
1.1     CHRONIC LIVER DISEASE (CLD) 
Chronic liver disease (CLD) represents a significant global health burden. CLD 
occurs in response to injury induced by multiple insults such as alcohol exposure, 
obesity, diabetes, viral infection, autoimmune, chronic inflammatory conditions and 
drug toxicity.  Fibrosis is the hallmark of CLD, and its progression eventually results 
in cirrhosis and can lead to hepatocellular carcinoma (HCC) (Figure. 1-1) [1]. 
Though HCC is the sixth most common neoplasm worldwide, poor prognosis makes 
it the principal cause of cancer-related mortality, responsible for 6 million deaths 
annually [2-4]. In the developed world, CLD is a growing clinical burden due in part 
to an escalating obesity epidemic [2]. Importantly, it is now clear that fibrosis is a 
reversible process that can be promoted through attenuation of the initiating insult 
or fibrosis itself; however, there are currently no effective anti-fibrotic treatments 
available. Thus, there remains a clear need for an increased understanding of the 
factors which promote fibrosis to allow for the strategic development of novel 
therapeutics to limit the impact of the fibrotic disease.  
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1.2 PATHOGENIES OF LIVER FIBROSIS 
Extracellular matrix and scar formation: In response to injury, the liver exhibits a 
unique capacity for repair whereby cellular components are regenerated, leaving no 
lasting evidence of damage. However, in the setting of chronic inflammation, this 
repair process becomes pathogenic due to dysregulation of the wound healing 
response, leading to significant alterations in the extracellular matrix (ECM). 
Multiple cellular and molecular mediators orchestrate the initiation and progression 
of liver fibrosis. In response to injury, inflammation rapidly ensues and is 
characterized by leukocyte infiltration into the liver. The interplay between the 
inflammatory infiltrates, and tissue-resident cell populations (e.g., epithelial cells, 
fibroblast, and macrophages) invokes fibrogenesis. Fibrosis is characterized by 
changes in the amount and composition of collagens and other ECM components 
(e.g., laminin and fibronectin). In steady state, the ECM is a dynamic structure that 
undergoes constant remodeling through the actions of matrix metalloproteinases 
(MMP) and their specific inhibitors, tissue inhibitors of metalloproteinases (TIMP). In 
the setting of fibrosis, the expression of MMP’s and TIMPS is dysregulated which, 
together with increased collagen production, favors the accumulation of ECM. ECM 
accumulation, or scarring, results in the disruption of tissue architecture and 
function and eventually organ failure. In all tissues, myofibroblasts present in the 
portal tracts and in the sinusoids represent the primary ECM producing cells. In the 
liver following injury, hepatic stellate cells (HSC) located in the sinusoids are driven 
to proliferate and differentiate into myofibroblasts which can produce copious 
amounts of collagen [5]. Therefore, identifying the mechanisms that promote HSC 
activation and matrix production should identify points of intervention to allow the 
development of new preventive and therapeutic approaches to treat liver fibrosis. 
1.3 ANIMAL MODELS OF LIVER FIBROSIS 
Multiple pre-clinical murine models are available to study liver diseases including 
diet, surgery, genetic, infection, and chemical based models. Diet-based models 
include methionine-deficient, choline-deficient (MCD) and high fat defined diets 
promote CLD resembling non-alcoholic steatohepatitis (NASH) and non-alcoholic 
fatty liver disease (NAFLD) [6, 7]. Non-alcoholic steatohepatitis (NASH) is part of 
the spectrum of non-alcoholic fatty liver disease (NAFLD), currently the most 
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common form of the chronic liver disease in the United States and in many parts of 
the world. However, each of these models have associated limitations. Even though 
these diets provoke marked inflammation, only inconspicuous and mild-stage 
fibrosis has been reported with these diet modifications [8] and surgical 
complications such as bile leakage in the bile duct ligation (BDL) model can 
confound interpretation and thus limit utility [9] [10]. Genetically modified animals 
are also used to gain understanding regarding the involvement of specific proteins 
and signalling pathways during liver fibrosis and thus identify potential new drug 
targets [11]. However, genetic models hardly develop liver fibrosis due to the 
genetic perturbation alone, as such require a second stimulus for disease induction 
[12]. Hence, the process of fibrosis development in genetically modified animals 
specifies the communication between the environment and the genotype to 
manifest the disease, as is the case for NASH. The Schistosoma mansoni infection 
model is commonly used to study immune-mediated liver fibrosis stimulated by the 
parasitic eggs, but utility is limited by the complexity of delivery of parasite eggs that 
causes infection  [13, 14].  Multiple models of hepatotoxin induced liver fibrosis 
have been developed. The administration of concanavalin A (ConA) [15, 16] causes 
inflammation and centrilobular fibrosis resembling autoimmune hepatitis. However, 
the consistence of induction and progression of fibrosis in the ConA model is 
variable and is influenced by multiple factors including compound preparation. In all 
animal models the genetic background of the mice, gender, age and the microbiota 
which can differ vastly between institutions [17]. The administration of ethanol, 
carbon tetrachloride (CCl4), thioacetamide (TAA), dimethylnitrosamine (DMN) or 
diethylnitrosamine (DEN) are also used to induce liver fibrosis. The CCl4 and TAA 
liver fibrosis models are most widely utilized and generally well characterized. 
These models are often selected based on their manifestation of features which 
recapitulate the pattern of disease in liver fibrosis patients including inflammation, 
followed by fibrosis and progression to HCC. Additionally, these models also exhibit 
evidence of fibrotic regression [18]. An unfortunate limitation of CCl4 treatment is 
early mortality [19]. Notably, fibrosis induced by TAA differs depending upon the 
route of administration. Thus, intraperitoneal administration of TAA leads to rapid 
induction of liver fibrosis whereas oral delivery allows the temporal examination of 
progressive fibrosis and gradual development of HCC. Long-term oral 
administration of TAA induces CLD characterized by centrilobular fibrosis 
progressing to fibrous septation and cirrhosis [20].   
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1.4 MEDIATORS OF LIVER FIBROSIS 
1.4.1 RESIDENT LIVER POPULATION IN FIBROSIS 
The liver consists of approximately 80% parenchymal hepatocytes and 20% non-
parenchymal cells, including stellate cells, sinusoidal endothelial cells, 
macrophages (Kupffer cells), biliary epithelial cells and recruited peripheral 
immune cells. In response to insult, whether it be chemical, infectious or 
mechanical, the initiation and perpetuation of fibrosis is a consequence of complex 
interactions between the various lineages of liver-resident and infiltrating immune 
populations [21]. Studies over the last two decades, predominantly using preclinical 
models, have greatly increased our understanding of the distinct contributions of 
these hepatic population to fibrogenesis. 
 
Hepatocytes: Hepatocytes account for over 80% of the liver volume. One of the 
hepatocyte’s primary functions is in the metabolism of xenobiotics (foreign 
substances such as TAA, alcohol metabolites, hepatitis viruses) circulating in the 
blood. Xenobiotics target hepatocytes to induce the production of reactive oxygen 
species (ROS) that cause hepatocyte death [22] [23]. Apoptotic hepatocytes release 
damage-associated molecular patterns (DAMPs) including nucleic acids, high 
mobility group box-1 (HMGB1)[24], adenosine triphosphate, (ATP), which act as 
endogenous stimulators of immune responses following tissue damage. They also 
work as danger signals in recruiting immune cells (neutrophils, monocytes) to initiate 
inflammatory responses [25-27]. Furthermore, hepatic stellate cells (HSCs) 
phagocytose apoptotic hepatocytes for their survival, suggesting the mechanism for 
fibrosis propagation [28, 29]. It has also been reported that ROS from damaged 
hepatocytes has a definite role in HSC’s migration [30, 31]. Above findings suggest 
an active role for the hepatocyte in the progression of liver fibrosis. 
 
Hepatic Stellate Cells (HSCs): As the predominant ECM producing liver 
population, HSCs play a crucial role in the pathogenesis of liver fibrosis [31-33]. 
HSCs are located between hepatocytes and the endothelial cells in the space of 
Disse [34]. HSCs are distinguished from other resident liver cells by their expression 
on the of cell-surface protein platelet-derived growth factor receptor-β (PDGFRβ), the 
enzyme lecithin retinol acyltransferase (LRAT) [35],  and the cytoskeletal proteins 
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Figure 1-2 Molecules involved in hepatic stellate cells (HSC’s) 
activation: Nature Reviews Gastroenterology & Hepatology 14,397–
411 (2017) 
 
desmin and glial fibrillary acidic protein (GFAP) [36].  The activation of HSCs and 
their differentiation into extracellular matrix-producing myofibroblasts represents a 
critical step on the path to fibrosis. Expression of alpha-smooth muscle actin (αSMA) 
characterizes activated HSCs. Multiple factors trigger the activation, proliferation, and 
survival of HSCs (Figure 1-2) [37].  
 
Transforming growth factor-β (TGFβ) [38-40], platelet-derived growth factor (PDGF) 
[41, 42], vascular endothelial growth factor (VEGF) [43], and connective tissue 
growth factor (CTGF) contribute to extracellular matrix production, differentiation, 
migration, adhesion, and survival of HSCs [44-46]. Also, phagocytosis of apoptotic 
hepatocytes increases the production of ROS in HSCs [47] which in turn promotes 
expression of fibrosis-associated genes leading to the production of type 1 collagens, 
CCL2 and TIMP-1 from HSCs [48, 49].  HSCs express a wide range of toll-like 
receptors (TLRs) and cytokine receptors (IL-15, IL-17A, IL-20, and TNF), which 
makes them highly responsive during immune responses. Notably, as a result of gut 
leakage in response to injury, lipopolysaccharide (LPS) derived from gut bacteria 
activates HSC through TLR4 signaling [50]. TLR4 can also signal DAMPs (e.g., 
HMGB1) released from damaged hepatocytes to enhance inflammatory responses 
[51]. These findings highlight multiple molecular mediators that contribute to HSC 
function, differentiation, and survival.  
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Liver endothelial cells (LSECs): LSECs have a highly permeable phenotype 
allowing the passage of cells and having constant interaction with other liver cells 
[52]. They have an excellent interface between blood cells, hepatocytes, and HSCs. 
In normal liver in their differentiated form, LSECs are considered gatekeepers of 
fibrosis as they maintain HSC quiescence [53]. Differentiation of LSEC is 
maintained by VEGF [54]. After liver injury, capillarization (loss of LSEC 
differentiation) attenuates the capacity of LSECs to inhibit the activation of HSCs 
[54]. These findings suggest that maintenance of LSEC’s differentiation can be 
used as a therapeutic option.   
 
 LSECs can promote either liver fibrosis or regeneration depending on the context 
of injury. During acute liver injury, LSECs encourage regeneration, whereas in 
chronic liver injury they are implicated in the initiation and progression of disease 
[55, 56]. Angiocrine signals from LSECs promote regeneration immediately after the 
injury, but after chronic injury expression of the stromal cell-derived factor 1 
receptors, CXCR4 and CXCR7 promote fibrosis [57]. The former drives the 
fibrogenic pathway which stimulates HSCs whereas the latter promotes pro-
regenerative pathways [57].  
The ductular reaction (DR): In most chronic liver diseases progressive portal 
and septal fibrosis are closely associated with a ductular reaction (DR) [58-60]. 
During DR strings of cholangiocytes will form as canals of Hering and small bile 
ductules, in a niche of inflammatory and stromal cells near portal tract (PT) [60-63]. 
Hepatic progenitor cells (HPC) will give rise to these reactive ductules. When 
mature hepatocyte proliferation is impaired these small bipotential ductules are 
capable to proliferate, migrate, and differentiate into either hepatocytes or 
cholangiocytes [58]. During injury, the DR expands dramatically, and its intensity is 
closely correlated to the extent of fibrosis. HPCs are closely associated with the 
fibrogenic activity, and they exist in a niche comprised of myofibroblasts, 
macrophages and other leukocytes and ECM components. Cellular and matrix 
components present in the DR niche contributed to HPC activation and fate. HPCs, 
in turn, influence myofibroblasts and inflammatory cells. However, further studies 
are required to understand the signals that control the induction and progression of 
the DR [62, 64, 65]. 
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Figure 1-3Interplay between hepatic stellate cells and immune cells: Multiple immune 
cells produce many factors that modulate property of HSC and vice-versa. Details about 
the interaction of HSC with individual immune cell subpopulations and their role for liver 
fibrosis are given section 1.4.2. 
 
1.4.2    IMMUNOBIOLOGY OF LIVER FIBROSIS 
It is increasingly clear that that the immune system plays a central role in the 
regulation of fibrosis. Residing in or patrolling the liver at steady state are distinct 
subsets of immune cells (myeloid and lymphoid cells), and many studies have 
implicated a role for these cells in the pathogenesis of fibrosis in this organ. 
 
 
 
 
1.4.2.1. Myeloid populations 
Monocytes and Macrophages: Monocytes are established critical mediators 
of fibrosis although the mechanism by which these cells promote fibrosis remain 
undefined.  Monocytes are circulating precursors of macrophages which comprise 
two major subsets, Ly6chi and Ly6clo which can be additionally differentiated by the 
differential expression of the chemokine receptor CCR2 [66]. Thus, Ly6chi 
monocytes express CCR2 and are commonly referred to as inflammatory 
monocytes. These monocytes are rapidly recruited into inflamed tissues where they 
secrete inflammatory cytokines [67]. Ly6clo monocytes lack expression of CCR2 but 
express high levels of the chemokine receptor CX3CR1 and are commonly referred 
to as patrolling monocytes or tissue-resident macrophage precursors. Whether 
these cells are recruited to sites of tissue inflammation from the circulation or 
differentiate from the infiltrating CCR2+ inflammatory monocytes is unclear. 
Macrophages
Ly6chi Ly6cl0
Granulocytes
Eosinophils
Th1
Th2
γδ
Hepatocytes
CD4
G-CSF
GM-CSF
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However, recent literature supports the notion these cells are derived from CCR2+ 
monocytes at sites of injury [68].  In both steady state and during inflammation 
Ly6Clo monocytes differentiate into tissue resident macrophages under the 
influence of colony stimulating factor- 1 (CSF-1) [69]. During inflammation, these 
Ly6clo monocytes can also enter tissue and differentiate into macrophages [70]. In 
parasite-induced liver infection, CCR2 dependent Ly6chi monocytes are observed in 
liver and blood [70]. Recent studies using preclinical rat models of acute liver injury 
suggested that monocytes infiltrate into the liver in a CCR2 and CCL2 dependent 
manner [68, 71-75].  Also, CCl4  treated CCR2-/- mice demonstrated reduced 
monocyte infiltration [76]. However, during liver fibrosis we showed that fibrosis was 
CCL2 dependent but independent of CCR2, suggesting a controversial role of 
CCL2 signaling [20]. 
 
The liver contains a large population of tissue-resident macrophages (Kupffer cells) 
which originated from yolk sac precursors with the capacity of self-renewal 
throughout adult life [77]. Following inflammation, these macrophages are 
expanded through the recruitment and differentiation of circulating monocytes 
(Ly6chi). Recently, the expression of the T-cell Immunoglobulin and Mucin (TIM)-4 
receptor by KC, was shown to distinguish these liver resident macrophages from 
infiltrating bone marrow-derived macrophages. Thus, in response to injury, 
monocytes and monocyte-derived tissue-resident macrophages precursors all 
contribute to fibrogenesis  [78]. Indeed, the depletion of macrophages, either 
genetically or pharmacologically, has been shown to attenuate myofibroblast 
activation and fibrosis in multiple murine models of CLD [79]. In the fibrotic liver, 
macrophages localize near activated myofibroblasts in areas of tissue scarring [80]. 
Through their production of TGFβ and PDGF macrophages promote HSC activation 
[81]. Importantly, however, due to their marked functional plasticity, macrophages 
also play a key role in fibrotic regression. Thus, in the CCl4 model of liver fibrosis, 
macrophage depletion during the recovery phase after CCl4 withdrawal led to the 
persistence of injury [75, 82]. A deeper understanding of the contribution of these 
myeloid populations is important because phenotypically and functionally distinct 
monocyte/macrophage populations may play opposing roles in liver fibrosis and 
repair.  
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Neutrophils: Neutrophils are early responders in injury-induced inflammatory 
responses. During infection, they serve to clear pathogens through phagocytosis, 
production of ROS and proinflammatory cytokines [83]. Neutrophils are reported as 
pathogenic mediators of liver fibrosis. Therefore, neutrophil depletion in mice 
administered with acetaminophen demonstrated reduced liver fibrosis [84]. 
Mechanistically, neutrophils that are recruited during liver injury will become 
activated and exacerbate inflammation through their cytotoxic activity and ROS 
production during ischemia-reperfusion injury and alcoholic hepatitis preclinical 
models [85, 86]. During injury, activation of resident macrophages and dendritic 
cells promoted neutrophil (and monocyte) recruitment through their release of G-
CSF, CXCL8 (IL-8), CXCL1, 2, 3, CCL2, 3, 4 [86-88]. Additionally, IL-17 produced 
by γδ T cells and CD4+ T helper cells (Th17) also promoted neutrophil recruitment 
through the induction of the neutrophil chemokine IL-8 from fibroblasts in renal 
failure diseases [89]. Once in the liver, neutrophils adhere to parenchymal cells via 
ICAM-1/Mac-1 interactions which trigger the formation of ROS and release of 
proteases and hydrogen peroxide through degranulation [90]. Whether neutrophils 
contribute in all settings of liver fibrosis is unclear as, in the bile duct ligation model, 
neutrophils have shown a limited contribution [91]. 
  
Eosinophils: Activated eosinophils play an essential role in the pathogenesis of 
various liver diseases including primary cholestatic diseases [92], hepatic allograft 
rejection [93], hepatitis C and drug-induced liver injury [94]. Eosinophils are 
recruited into the liver via CCL11, CCL22, IL-2, IL-3, IL-5, and GM-CSF produced 
by other immune cells [95]. BALB/c mice that are deficient in eosinophils exhibited 
reduced injury during halothane-induced liver injury [96].  When exposed to necrotic 
liver cells, eosinophils become activated by upregulating the expression of CD107a 
[97]. Eosinophil activation following necrotic liver exposure induced the release of 
IL-1β and IL-18 mediated by caspase-1[97]. Additionally, activated eosinophils also 
produce TNF, IL-4, and IL-5 in Schistosoma mansoni infected patients [98]. IL-4 
produced from eosinophils promoted hepatocyte proliferation in regenerating liver 
[99], suggesting a role in liver regeneration. There are only limited number of 
studies which investigated the contribution of these cells in liver fibrosis. Thus 
further studies are required. 
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1.4.2.2. Lymphoid populations 
CD4+ T cells upon activation can differentiate into multiple effector lineages 
depending on the cytokine milieu. Thus, CD4+ effector cells can be divided into Th1, 
Th2, Th17, Th9, follicular helper T cells (Tfh), or regulatory T cells (Treg) based on 
their cytokine expression and function. It is noteworthy that CD4+ T cells also 
contributes of liver fibrosis. It has been reported that IL-4, IL-5, and IL-13 induced 
by Th2 cells linked to the development of Schistosomiasis infection-induced liver 
fibrosis [100]. Conversely, cytokines such as IL-12 and interferon γ (IFNγ) which 
initiates the downstream signaling cascade to develop Th1 cells have demonstrated 
anti-fibrotic effect in Schistosomiasis infection-induced liver fibrosis when compared 
to Th2 induced cytokines [100]. Also, the imbalance in the production of cytokines 
by Th1 and Th2 cells lead to liver fibrosis and is demonstrated both in-vitro and in-
vivo BALB/c mice treated with CCL4 or TAA [101]. Splenectomy in these mice partly 
inhibited the progression of fibrosis by restoring Th1/Th2 balance [102]. The 
contribution of other CD4+ T cells in liver fibrosis is discussed below. 
 
CD8+ T cells play a major role in the pathogenesis of liver fibrosis induced 
following hepatitis C virus (HCV) and hepatitis B virus (HBV) infection [103]. 
However, results indicated that in the presence of HCV-specific IFNγ-secreting  
CD8+ T  cells patients demonstrated less fibrosis suggesting the anti-fibrotic 
property of CD8+ cells [104]. Conversely, pro-fibrotic property if CD8+ is reported in 
another study where patients with HCV showed increased expression of RAR-
related orphan receptor gamma (RORγt) and IL-17 secretion from Tc17 cells in 
association with increased disease pathogenesis  [105, 106]. CD8+ cell-mediated 
liver fibrosis is also observed in chemically (CCl4 and TAA) induced liver fibrosis 
models [107, 108].  These findings suggest both pro and anti-fibrotic properties of 
CD8+ cells. 
 
Th17 cells and their secreted cytokines have a significant role in fibrosis. 
Proinflammatory cytokines that are dominantly produced by Th17 cells include IL-
17, IL-21, IL-22, and TNF. TGFβ and IL-6 or IL-21 contributes to the differentiation 
of Th17 cells from naïve T cells [109], and differentiated Th17 cells are stabilized by 
IL-23 [110]. Transcription factors such as signal transducer and activator of 
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transcription 3 (STAT3) and RAR-related orphan receptor gamma t (RORγt) are 
involved in the development of Th17 cells. In the liver, Th17 responses have been 
found during fibrosis associated with NASH, alcoholic liver disease, cholestatic liver 
diseases, antimicrobial defense, and BDL [111]. Halofuginone (HF) and KD025 
inhibit the expression of STAT3, RORγt and IL-17 production [112, 113]. A more in-
depth discussion of Th17 cells can be found in section 1.6. 
 
Regulatory T cells (Treg) are critical in the maintenance of peripheral 
tolerance and the regulation of immune responses.  Broadly, CD4+ Treg can be 
classified into two subsets: natural Treg (nTreg) which are produced in the thymus 
and induced Tregs (iTreg) that are generated in the periphery. Both nTreg and iTreg 
are characterized by their expression of the transcription factor forkhead box P3 
(FoxP3), and the majority of Tregs express high levels of CD25. The high-affinity of 
IL-2R expressing Tregs are implicated as participants in a variety of fibrotic 
diseases. Foxp3-expressing Treg cells are important producers of 
immunosuppressive cytokines, such as IL-10 and TGF-β1which control effector cell 
function [114]. One study has suggested that IL-10-secreting Treg cells protected 
mice from fibrosis [115]. Also, in cholestasis-induced liver injury, FoxP3+ Treg 
inhibited Th17  induced liver injury [116]. Tregs were also involved in immune 
regulation of  CCL4 induced liver fibrosis by suppressing pathogenic property of 
macrophages, Th1 and natural killer (NK) cells [117, 118]. Hence these findings 
suggest that Treg cells may inhibit progressive fibrotic disease by negatively 
regulating the inflammatory responses. Conversely, Treg cells are also an important 
source of TGF-β1, with at least a few studies reporting that TGF-β–producing Treg 
induce rather than inhibit fibrosis [119, 120]. However, it remains unclear that why 
Treg cells have antifibrotic activity in some situations and profibrotic activity in 
others.  
 
Gamma delta (γδ) T cells have been implicated in various liver diseases and 
models that are associated with fibrosis including fulminant hepatitis [121], 
autoimmune hepatitis [122], HBV [123] and HCV [124-126]. They secrete large 
amounts of pro-inflammatory cytokines, including IFNγ, IL-17, IL-4, IL-5, IL-10, IL-
13, TGFβ and GM-CSF [127]. Through this secretion, γδT cells link the innate and 
adaptive immune systems [128]. IL-17 secretion is of significance, and a pathogenic 
role of IL-17-producing γδT cells has been implicated in autoimmune liver diseases 
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[122, 129] and Schistosoma japonicum infection [130]. IL-17-producing γδT cells 
originating in the gut were shown to contribute to fibrosis and inflammation of bile 
ducts in animal models and patients with chronic biliary disease [131].  Recently it 
has also been reported that hepatocyte-derived exosomes activated TLR3 in HSC 
and exacerbated liver fibrosis by inducing IL-17A production in γδT cells [132]. 
Conversely, γδT cells are shown to be protective through their inhibition of NKT 
cells in immune-mediated liver disease induced by ConA but this protective function 
appeared to be independent of IL-17 [121]. However, the anti-fibrotic pathway of IL-
17+ γδT cells expressing CCR6 is reported during chronic liver injury by inhibiting 
the inflammatory reaction and the activation of collagen-producing HSCs [133].  
Further mechanistic studies related to tumour microenvironment revealed that 
CCR2 and CCL2-deficient mice displayed reduced γδT cell infiltrates [134]. 
However, the association of CCL2/CCR2 recruited γδT cell in association with liver 
fibrosis is not clear. Above findings suggest both protective and pathogenic 
properties of γδT cells. However, it is not clear whether this diverse property of γδT 
cells during liver diseases is due to the specific receptors they express or due to the 
redundant cytokine profile of γδT cells. Thus, it is important to define different γδT 
cell subsets in acute and chronic liver inflammation as well as the cytokines they 
produce to assess whether these cells might be useful as a therapeutic target for 
the treatment of liver disease. 
Mucosal-associated invariant T cells (MAIT) are non-conventional T cells 
with both adaptive and innate immune properties [135]. These cells respond to 
vitamin B metabolites derived from bacteria that are presented on MR1 which MHC 
is class 1 like molecule [136]. MAIT cells are enriched in liver tissue as well as the 
gastrointestinal tract and are characterized by high-level expression of cell surface 
CD161 and secretion of IL-17A [137]. These cells are found to be associated with 
unique anti-bacterial function [138]. MAIT cells express receptors such as CXCR6 
and CCR6, that allow them to home to the liver [139, 140]. In addition to MR1, IL-18 
and IL-12 cytokines also activate MAIT cells because these innate-like T cells 
express receptors for IL-18 and IL-12 [141-143]. During HCV infection MAIT cells 
were activated in an IL-18 dependent manner and increased disease severity [144]. 
Activated MAIT cells promote HSC activation in patients with the autoimmune liver 
disease [145]. Conversely, IFN-α mediated MAIT cell activation was associated with 
therapeutic responses through the induction of IFN-γ [144]. MAIT cells are 
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predominant IL-17 producers targeting multiple cell types in the liver to produce pro-
inflammatory cytokines and chemokines [137, 146][136]. Hence MAIT cells could be 
important contributors to hepatic inflammation and fibrosis. Further studies are 
needed to understand the nature and type of ligands produced by MAIT cells that 
could be involved in liver diseases.  
 
Natural killer (NK) cells are abundant in liver and provide the first line of 
defense against invading microbes, pathogens and toxic substances [147]. During 
HCV and CCL4 induced liver fibrosis, NK cells in the liver can induce apoptosis of 
activated HSC in a TNF-related ligand (TRAIL), Fas-L and NKG2D dependent 
manner and also produce antifibrotic mediators such as IFN-γ that protect against 
fibrosis. [148-150]. In support of these studies mice depleted of NK cells had 
demonstrated increased liver fibrosis [151]. Thus, these findings suggest an 
antifibrotic property of NK cells.  Conversely, the fibrotic property of IL-17A 
secreting NK cells was documented in ischemia-reperfusion liver injury (IRI) [152]. 
Since NK cells are reported to be a mediator of liver fibrosis, further investigations 
are required to fully appreciate the protective vs. pathogenic roles of NK cells in 
fibrotic liver injury. 
 
Natural killer T (NKT) cells play a diverse role in liver injury due to the 
heterogeneity of NKT cells and the variety of cytokines produced. They are 
classified as CD1d-restricted invariant NKT and non-invariant NKT cells [153]. In 
liver, antigen presenting cells present antigens to CD1d on NKT cells, leading to the 
release of Th1 (IFN, TNF), Th2 (IL-4, IL-5, IL-10) or Th17 (IL-17, IL-22) cytokines 
which in turn activate other innate immune cells and adaptive T cells [154].  
Accumulation of NKT cells was observed in NASH through activation of Hedgehog 
pathway [155].  The profibrotic effect of NKT cells is implicated in HBV transgenic 
mice [156, 157], TAA-induced liver fibrosis [156], primary biliary cholangitis [158], 
and NASH [155] through HSC activation and immune modulation [156, 157]. Similar 
to NK cells, NKT cells are also reported to be antifibrotic by inhibiting HSC 
activation and IFN-γ production through direct killing [159, 160].  Further studies are 
required to understand the complex role of NKT cells in liver injury and fibrosis 
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Innate Lymphoid cells (ILC) are heterogeneous innate immune cells. There 
are three subsets of ILCs based on cytokines (type 1, type 2, and Th17 cell 
cytokines) they produce: group 1 ILC (consists of ILC1s and conventional NK (cNK) 
cells); group 2 ILC (consists of ILC2s); and group 3 ILC (consists of ILC3s and 
lymphoid tissue inducer (LTi) cells) [161]. ILCs are detected abundantly in the liver, 
with the dominant subsets of ILC being cNK cells and ILC1s ( comprising of nearly 
95% of all ILCs) [162]. Although ILC2s and ILC3s in the liver are quite rare 
(comprising of nearly 5% of all ILCs), the roles of these different ILC subpopulations 
in liver disease have gained recent interest.  Hepatic cNK cells contributed to HBV 
or Con A-induced liver fibrosis by promoting the antiviral activity of CD8+ T cells 
[161, 163]. Depletion of ILC2s significantly ameliorated murine immune-mediated 
hepatitis [164]. Despite the low percentage, hepatic ILC3s are involved in the 
pathogenesis of murine and human liver diseases via secretion of proinflammatory 
cytokines (IL-22 and IL-17) [165, 166]. Thus, above findings suggest that excessive 
activation of ILCs can lead to chronic pathologies (e.g., inflammation, liver injury, or 
fibrosis). Further research is required to understand the protective or pathogenic 
mechanisms of different ILCs in liver diseases. 
 
B cells represent half of the intrahepatic lymphocyte population [167] that induce 
hepatic fibrosis through cytokine release and antibody production [167]. Patients 
with CLD have increased B cells in their livers. In the CCl4 model, the frequency of 
activated B cells (CD44 and CD86) were elevated with increased TNF production 
[168, 169]. This suggests the role of B cell activation and cytokine production during 
liver fibrosis. B cells that are activated in T-cell dependent manner will promote 
germinal center (GC) formation to induce antibody or immunoglobulin production 
[170] [171]. Supporting this, recently increased production of immunoglobulin (IgG) 
was documented in the livers of CCL4 treated mice [168, 169]. Also, auto-antibodies 
from B cells were detected in the sera of patients with alcoholic liver disease, 
NAFLD, viral hepatitis, drug-induced hepatitis, HCC including autoimmune liver 
diseases for which these are essential for disease diagnosis and to judge prognosis 
[172]. This suggests a role for antibodies during liver fibrosis, however association 
of GC formation during liver fibrosis is not known.  
 
It has already been reported that (chronic graft versus host disease) T follicular 
helper cells (Tfh) through upregulation of B-cell lymphoma 6 (Bcl6) transcription 
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factor and IL-21 production will activate B cells to promote B cell differentiation and 
GC formation [173, 174]. Additionally, under the influence of IL-21, γδ T cells will 
acquire Tfh cells phenotype to induce GC formation [175]. However, the association 
of these cellular and molecular mediators (Tfh, Bcl6, IL-21) in promoting GC 
formation during liver fibrosis is not clear. Given that activated B cells and GC B 
cells will induce antibody production, the mechanism through which these 
antibodies contribute to liver fibrosis is not clear. Evidence suggests that, after 
antibody binding to target antigen, the possible mechanisms include ‘complement 
activation’ and ‘antibody-mediated cellular cytotoxicity. During complement 
activation, a number of distant plasma proteins will either directly attack pathogen or 
antibody bound pathogen to induce inflammatory responses that can help fight 
infection whereas during antibody-mediated effector function, antibodies will form as 
immune complexes and signal through FcγR (expressed by immune cells) to trigger 
both pro and anti-inflammatory immune responses [176]. FcγR consists of both 
activating and inhibitory receptors [176]. Signaling through activating FcγR may 
trigger cellular cytotoxicity, cytokine release, and phagocytosis whereas signaling 
through inhibitory receptors downregulates effector functions [176]. Previously, it 
has been observed that mice deficient in FcγR demonstrated reduced cartilage 
damage during rheumatoid arthritis [177] which highlights the role of FcγR in 
disease pathogenesis. However, the association of FcγR during liver fibrosis is not 
clear.  Even though the role of B cells has been implicated in liver fibrosis, the 
mechanisms that activate B cells and induce immunoglobulin deposition during 
hepatic fibrosis need further investigation. 
1.5     IL-17 IN LIVER FIBROSIS 
Cytokines and their receptors. The IL-17 family of cytokines plays an 
important role in host defence against microbial organisms and also contributes to 
the pathology of multiple inflammatory disease settings including autoimmunity and 
liver fibrosis (discussed in IL-17A section). Functionally, IL-17 family cytokines alter 
cell differentiation pathways and induce the expression of a variety of pro-
inflammatory cytokines, chemokines, and cell adhesion molecules in a wide range 
of cell types. The IL-17 cytokine family is comprised of 6 established members: IL-
17/IL-17A, IL-17B, IL-17C, IL-17D, IL-17E/IL-25, and IL-17F. These cytokines are 
produced by multiple cell types of both hematopoietic and non-hematopoietic origin 
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and are secreted as disulfide-linked homo or heterodimers, except IL-17B, which is 
secreted as a non-covalent homodimer. The biological function of the IL-17 family 
cytokines is mediated through the IL-17 receptor (IL-17R) family expressed on the 
surface of target cells. The IL-17R family members include IL-17RA, IL-17RB, IL-
17RC, IL-17RD and IL-17RE which are expressed on cells of both hematopoietic 
(e.g., monocytes/macrophages, granulocytes and eosinophils) and non-
hematopoietic (e.g., fibroblasts, hepatocytes, endothelial cells, HSC) origin [178].  
 
 
 
 
 
 
 
 
 
The IL-17 family cytokine/receptor interactions required for downstream signaling 
are unique in that IL-17RA utilizes a common recognition strategy to bind to several 
IL-17 family members and subsequently pairs with a second IL-17R subunit 
required for signaling (Figure: 1-3). Thus, initial IL-17RA receptor binding by IL-17 
cytokines alters that cytokines affinity and specificity for a second IL-17 receptor, 
resulting in heterodimeric receptor complex formation. In this way, IL-17RA acts as 
a shared receptor with multiple different signaling complexes [179]. IL-17E, also 
known as IL-25, signals through a heterodimeric receptor comprised of IL-17RA and 
IL-17RB. It is also established that IL-17C signals through the IL-17RA/IL-17RE 
receptor complex, but the cognate receptors for IL-17B and IL-17D are less defined. 
IL-17B signals through a receptor comprised of an IL-17RB subunit complexed with 
undefined subunit, and the receptor for IL-17D remains to be elucidated [180].  
Relatively little is known regarding the physiological roles of IL-17B, IL-17C or IL-
17D, however, similar to IL-17A, signaling by these cytokines in target cells is 
reported to promote proinflammatory responses. The known functions and 
expression of various IL17 family cytokines are detailed in (Table 1-1).  
Figure 1-4 Signalling of IL-17 family ligands and its receptors Nature Reviews 
Immunology volume9, pages 556–567 (2009) 
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Table 1-1 IL-17 cytokines and receptors expression.  
Cytokine Receptor Producers Responders Function 
IL17A IL17RA CD4[181],CD8[182], 
mast cells, 
macrophages[183], B 
cells[184] 
Eosinophils[18
5], CD4[186], 
G-CSF, IL6, IL18[187], 
CXCL5[188], GROα, 
and MIP-1β[185],  
 IL17RC Macrophages[183] , 
γδT cells, NKT, 
MAIT cells[189], 
LTicells and 
neutrophils[190] 
HSC, 
monocytes[191] 
CCL20[192], MMP3, 
MMP13, collagen 
IL17E IL17RA Eosinophils[193], 
Lung epithelial 
cells 
Monocytes[193] IL13, IL4, IL10, G-
CSF[193] 
 IL17RB alveolar 
macrophages 
macrophages[194] 
Fibroblasts[195], 
naïve T cells 
CCL5,CCL11,CXCL-
8[195] 
IL17F IL17RA  CD4, CD8, B 
cells[184], 
mastcells,  
Eosinophils[185] G-CSF[196], CCL20, 
IL-1β, IL-6, IL-8,  
 IL17RC macrophages[183]γ
δT cells, NKT 
cells, LTi cells, 
basophils, 
activated 
monocytes, 
Hepatic stellate 
cells[197] 
Bronchial 
epithelial 
cells[198], 
endothelial 
cells, 
fibroblasts, 
GROα, and MIP-
1β[185], IL-11[198] and 
IGF[199] 
IL17A/F IL17RA  CD4[181],CD8[182], 
mast cells, 
macrophages[183],  
 
Eosinophils[185],  CXCL5[188],CXCL1, 
IL6[200] 
 IL17RC B cells[184], γδT 
cells, NKT cells, 
LTi cells, 
Kupffer cells 
[200], CD4 
cells[201] 
 
IL17B IL17RB - - TNF[202], IL-6[202] 
IL17C IL17RA  Epithelial  cells[203, 
204],CD4Tcells, 
DC, and  
- TNF, IL-6 
 IL17RE Macrophages CD4  IL-2 
IL17D - - Endothelial 
cells 
IL-6, IL-8, and GM-
CSF  
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IL-17A. IL-17A shares 50% structural homology with IL-17F and is formally 
referred as IL-17 in the literature [205]. IL-17A and IL-17F form IL-17A-IL-17A and 
IL-17F-IL-17F homodimers or together form IL-17A/IL-17F heterodimeric cytokines 
and signal through the receptors IL-17RA and IL-17RC. Noticeably, IL-17A and IL-
17F exhibit differential binding affinity and specificity to the IL-17RA/RC receptor. 
The IL-17A homodimer preferentially binds IL-17RA whereas IL-17F preferentially 
associates with IL-17RC [206]. However, IL-17A/ IL-17F heterodimer interacts 
equally with either the IL-17RA or IL-17RC receptor chain complexes. Functionally, 
IL-17A and IL-17F mediate pro-inflammatory responses. However, evidence 
suggests that these cytokines have overlapping yet distinct roles in host immune 
and defense mechanisms [207].  
 
T cells, neutrophils, macrophages [208], NK cells [209], γδT cells [210, 211], 
activated CD4+ and CD8+ T cells (Th17 and Tc17 respectively), lymphoid tissue 
inducer (LTi) [212] and MAIT cells have all been demonstrated to produce IL-17A. 
IL-17A has been implicated in several autoimmune [210, 213] and inflammatory 
diseases [214, 215] including rheumatoid arthritis (RA) [215, 216], psoriasis [217], 
atherosclerosis [217] and graft versus host diseases (GVHD) [218]. During 
inflammatory responses, IL-17A-producing T cells increased the production of TNF 
and IL-12 [219-222] suggesting a role in inducing inflammatory cytokines. 
Moreover, in experimental autoimmune encephalomyelitis (EAE), IL-6 secreted 
from fibroblasts in response to IL-17A signaling had amplified inflammation in an 
autocrine manner [223]. This suggests that IL-17A signaling induces a positive 
feedback loop for IL-6 signaling to maintain the inflammatory cycle. It has also been 
reported that IL-17A synergizes with B-cell activating factor (BAFF) to protect B 
cells from apoptosis, thereby increasing the number of autoantibody-producing cells 
[224] in the setting of systemic lupus erythematosus (SLE). Sometimes during 
chronic inflammation such as arthritis, disease continues in the presence of reduced 
IL-17A producing cells which can occur due to molecular changes induced during 
early exposure of mesenchymal (synoviocytes, fibroblasts) cells to IL17A is 
sufficient to maintain cell survival by inducing the anti-apoptotic molecule synovolin 
[205, 225] [226]. This means that the use of IL-17A inhibitors during the early stage 
of inflammation is sufficient to induce a long-lasting reduction of arthritis [226]. 
During acute and chronic inflammation, IL-17A has a modest effect, whereas its 
effect is greatly increased when combined with other cytokines [227]. IL-17A and 
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TNF have synergic interactions, where IL-17 increases the expression of TNF 
receptor to enhance its effect [228]. The combination of inhibitors to both TNF and 
IL-17 represents a strong therapeutic approach in inflammatory disorders [225]. A 
role for IL-17A  has been reported in monocyte to macrophage differentiation 
(osteoclasts) through NFkB ligand (RANKL) in rheumatoid arthritis [229, 230]. Apart 
from pathogenic effects, IL-17A has also been reported to be protective in T cell-
mediated intestinal inflammation by suppressing Th1 differentiation [231].  
 
In addition to other inflammatory and autoimmune diseases, IL-17A has also been 
implicated as an important mediator of liver fibrosis in various pre-clinical models of 
chronic liver disease. In ConA hepatitis (which is T cell-mediated), mice deficient in 
IL-17A developed the same degree of injury as wild-type controls, suggesting that 
IL-17A plays no significant role in this type of liver injury [232]. IL-17 has been 
linked to bacterial infections in the liver, where it is believed to play a protective role 
rather than being pathogenic [233].  Conversely, in parasitic infection models, mice 
infected with the helminth Schistosoma mansoni developed fibrosis in an IL-17 
dependent manner [234]. In BDL and CCl4-induced liver injury, IL-17A signaling in 
inflammatory cells promoted liver fibrosis with increased expression of pro-
inflammatory and pro-fibrogenic mediators such as IL-6, TGFβ, MMP-3, TNF, TIMP-
1, and αSMA [211, 235]. IL-17A also induced collagen production by activated 
myofibroblasts through the STAT3 signaling pathway [211]. Additionally, it promoted 
liver neutrophil infiltration with increased liver enzymes in an ischemia-reperfusion 
model [236, 237]. Signaling through IL-17RA contributed in peripheral blood 
monocyte differentiation [238] noticeably. This supports a role for IL-17 in 
recruitment and differentiation of immune cells. While a lot of work has been done 
regarding the contribution of IL-17A in different autoimmune and inflammatory 
diseases, however, the association of IL-17A with other immune cells in liver 
fibrosis is yet to be investigated. 
 
IL-17F: Amongst IL-17 family members, IL-17F shows the highest homology to IL-
17A, and both can exist as heterodimers. Former findings suggest that IL-17A 
negatively regulates the production of IL-17F [239]. Signaling triggered by IL-17F is 
10-30-fold weaker than IL-17A regarding downstream gene activation, whereas the 
IL-17A /F heterodimer acts at an intermediate level. 
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IL-17F is produced by γδ and other T cells, activated monocytes [197], B cells, 
basophils, mast cells and bronchial epithelial cells and is induced in response to IL-
33 [240]. T cells treated with TGFβ transiently upregulated the expression of IL-17F 
but not IL-17A at both gene expression and protein levels [241, 242]. IL-17F is 
reported to be associated with asthma, chronic obstructive pulmonary disease[243], 
EAE, colitis and Crohn's disease [244]. Additionally, during early stages of bacterial 
infections, IL-17F and IL-17A are equally important in controlling the bacterial 
burden, whereas at later stages IL-17F appears to be more critical [245]. Although 
IL-17F is pathogenic in various diseases, mice deficient with IL-17F displayed 
similar onset of EAE as wild-type controls [240].  IL-17F has been reported to 
induce the production of GCSF, TNF [246], CCL2, CCL5, CCL7 [240], TGFβ and IL-
2 from endothelial cells [197], GM-CSF from human bronchial epithelial cells, and 
IL-6 and CXCL1 from fibroblasts [243, 247, 248], suggesting wide-ranging effects of  
IL-17F signaling in inducing inflammatory mediators.  
 
IL-17F has also been implicated in liver fibrosis. Clinically patients with HCV-
associated HCC have increased levels of IL-17F [249]. This suggests the potential 
usage of IL-17F as a biological marker of fibrosis progression and HCV-associated 
HCC. In-vitro studies using human hepatocarcinoma cell lines demonstrated the 
role of IL-17F in reducing the expression of pro-angiogenic factors such (IL-6, IL-8, 
and VEGF) which led to the inhibition of tumor angiogenesis [250], demonstrating a 
protective role for IL-17F. Though there is limited research regarding the role of IL-
17F in liver fibrosis, further studies are required to understand the mechanistic role 
of IL-17F during liver fibrosis. 
 
 IL-17E/IL-25: IL-17E signals through binding the IL-17RA and -RB heterodimeric 
receptor complex [251, 252]. Its signaling requires both receptors and the absence 
of either blocks IL-17E signaling. IL-17E is defined as a Th2 cell-derived cytokine 
[253]. IL-17E only shares 16-20% amino acid sequence identity with IL-17A [254].  
IL-17E is produced by T cells, macrophages [194], basophils, epithelial cells [255], 
endothelial cells [256] pulmonary eosinophils [193, 257] and mast cells [258]. IL-
17E is reported in various diseases models which include DSS-induced colitis [259], 
asthma [257, 260], colon cancer [261], breast cancer [262], pulmonary fibrosis [263, 
264], systematic sclerosis [265], and inflammatory bowel disease [266]. 
Mechanistically, IL-17E promoted type 2-based immune reactions, with increased 
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expression of IL-5, IL-4,  IL-13, serum IgG, IgE and recruitment of eosinophils into 
the lung during airway inflammation [253, 254, 267-269] [270, 271]. ILC2s produce 
these type 2 cytokines IL-4, IL-5, and IL-13 in response to IL-17E stimulation [272]. 
IL-17E is also described to play a pathogenic role in colonic inflammation with 
increased production of IL-13 and IL-6 [273]. In-vitro studies showed that IL-17E 
signaling induced up-regulation of IL-13 and TNF in T84 colonic epithelial cells [259] 
and IL-8, MIP-1, MCP-1 and IL-6 from both epithelial cells [259] and activated 
eosinophils [274]. This highlights the role of IL-17E in inducing inflammatory 
cytokines that promote cellular infiltration. Conversely, the protective of IL-17E is 
reported during DSS-induced colitis, associated with reduced inflammation and 
increased survival [275]. Therefore, the above findings indicate both a protective 
and pathogenic role of IL-17E depending on the disease or model.  
 
IL-17E also contributes to liver fibrosis. IL-17E from macrophages potentially 
induced collagen production from HSC during C. sinensis liver fibrosis [276]. 
C.sinensis-will induce lysophospholipase A (CsLysoPLA) which upregulated the 
expression of pro-fibrotic genes in a HSC cell line (LX-2) [277]. In addition to C. 
sinensis, hepatocyte-specific Autotaxin (ATX) expression also induced 
lysophospholipase to activate HSC in CCl4-induced liver fibrosis [278]. These 
findings suggest that lysophospholipase from hepatocytes following liver injury and 
also from C. sinensis  will induce HSC activation through IL-17E. Conversely, a 
protective role of IL-17E has been described in mice with fulminant hepatitis [279] 
and bile duct ligation-induced liver fibrosis which is associated with increased 
immunosuppressive Gr1+CD11b+ cells and decreased proliferation of T cells [280]. 
Though IL-17E is well studied in allergic asthma and colonic inflammation, its 
function in the context liver disease needs further investigation. 
 
IL-17B: IL-17B signals through IL-17RB which couples with an orphan receptor.  
Expression of IL-17B is organ-specific; it is expressed in human pancreas, small 
intestine, and stomach [281]. Expression of IL-17B is found in activated T cells 
[282], neutrophils [283], germinal center B cells [284]  or chondrocytes [285]. The 
protective role of IL-17B has been described in a murine model of collagen-induced 
arthritis [286].  As discussed earlier, deficiency of IL-17E led to decreased DSS-
induced colitis, whereas deficiency of IL-17B showed opposite phenotype by 
increasing IL-6 and IL-13 production [287]. This suggests that IL-17B inhibits IL-17E 
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signaling by suppressing its ability to bind to IL-17RB. IL-17B enhanced TNF 
induced G-CSF and IL-6 secretion from fibroblasts in patients with RA [283]. 
Recently it has been reported that patients with pulmonary inflammation or SLE  
have increased IL-17B expression [288, 289]. These studies discovered the role of 
IL-17B as a proinflammatory cytokine implicated in the pathogenesis of 
inflammatory and autoimmune diseases. In addition to this, there are several other 
studies which highlight a strong contribution of IL-17B in tumor development. For 
instance, IL-17B/IL-17RB promoted breast and pancreatic tumorigenesis by 
inducing the production of anti-apoptotic factor Bcl2, and other inflammatory 
mediators such as CCL20, CXCL1, IL-8, and  TFF1 to promote cancer cell survival 
and leukocyte recruitment cell recruitment in distant organs [290] [291]. Blocking of 
the IL-17RB/IL-17B signaling pathway has reduced tumorigenicity of breast cancer 
and pancreatic metastasis [290, 291]. There is some evidence regarding the 
contribution of IL-17B in inflammatory and autoimmune diseases, but further 
research is needed to understand the biological function of IL-17B in liver fibrosis. 
 
IL-17 C, D: Far less is known about the cellular sources, receptors/target cells 
and biological functions of the remaining IL-17 family cytokines. IL-17C signals 
through IL-17RE and IL-17RA [292]. IL-17C is detected in keratinocytes and 
tracheal epithelial cells [203, 204].  IL-17C expression has been reported in some 
bacterial infections and autoimmune diseases like psoriasis [293, 294]. Also, 
elevated levels of IL-17C are observed in mice with autoimmune hepatitis. IL-17D is 
another cytokine whose function is not well defined. Similar to IL-17B, IL-17D is also 
expressed in a variety of organs and tissues, including heart, pancreas, and 
adipose tissue [295]. It can stimulate endothelial cells to induce the expression of 
IL-6, IL-8, and GM-CSF [295]. Though there is some evidence regarding the 
contribution of these cytokines under inflammatory conditions, however, the role of 
these cytokines in liver diseases is not well described. 
 
IL-17 Receptors (IL-17R):  
The IL-17 receptors are shown in Figure 1.3. 
IL-17RA signal IL-17A, IL-17F, IL-17E and IL-17C with different binding affinities 
along with other co-receptors IL-17RB, IL-17RC, IL-17RD, and IL-17RE. IL-17RA is 
expressed on both hematopoietic and non-hematopoietic cells [178]. Blocking IL-
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17RA is a therapeutic option in patients with asthma by decreasing airway 
hyperreactivity and pulmonary inflammation [296]. IL-17RA has also been 
implicated in liver fibrosis. In Schistosoma japonicum-induced liver fibrosis, IL-
17RA-/- mice showed reduced injury with a significant reduction in the expression of 
IL1β, IL-6, TNF, CXCL1, IL-14 and IL-17E after 8 and 15 weeks of infection [297]. 
Previous findings indicated that blocking of IL-17RA signaling reduced Ly6clow 
monocytes in blood, spleen and peritoneal cavity [238]. As mentioned above Ly6clow 
are important in the pathogenesis of liver fibrosis. Further investigations have 
shown that reduced Ly6clow monocytes are due to the defect in Ly6chigh to Ly6clow 
transition in the absence of IL-17RA signaling [238]. These findings suggest a 
contribution of IL-17RA signaling in cell homeostasis and promoting hepatic 
fibrogenesis.. 
 
IL-17RB IL-17RB is expressed on NKT cells [257, 260], activated portal 
myofibroblasts [298], innate lymphoid cells 2 (ILC2) [263], eosinophils [274], and 
macrophages [299]. IL-7RB signaling in ILC 2 ’s has been reported to induce 
collagen deposition during lung fibrosis [263]. It also induces the production of 
CCL20, CXCL1, and IL-8 to promote pancreatic cancer metastasis [300]. These 
findings suggest the role of IL-17RB signaling in inducing pro-inflammatory and pro-
fibrogenic mediators. L-17RB signals both IL-17B and IL-17E with higher binding 
affinity for IL-17E when compared to IL-17B [254]. It has been reported that IL-17B 
dampens IL-17E signaling by restricting its binding to IL-17RB and IL-17RA and 
stopping IL-6 production. The opposing roles of IL-17B and IL-17E (IL-17E is 
pathogenic, IL-17B is protective) is observed during mucosal inflammation [287]. 
Though there is some evidence regarding the expression of IL-17RB and its 
inflammatory responses, however its contribution to liver fibrosis is not addressed. 
 
IL-17RC is essential to signal IL-17A, IL-17F and IL-17A/F. IL-17RC will not pre-
associated with IL-17RA on its surface but, it required IL-17A to induce the 
formation of the IL-17RA-RC heterodimeric receptor complex. It has been reported 
that mice deficient in  IL-17RC have reduced EAE including reduced expression of 
CXCL1, CXCL2, CCL2, and CCL5 [301]. The role of IL-7RC in liver fibrosis has not 
yet been studied.  
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IL-17RD signals IL-17A [302], associating with IL-17RA to form a heterodimeric 
receptor complex [303] which is involved in neutrophil recruitment.  IL-17RD is 
expressed in both epithelial and endothelial cells. The role of IL-7RD in liver fibrosis 
has not yet been studied.  
 
IL-17RE signals IL-17C [304], associating with IL-17RA to form a heterodimeric 
receptor complex. IL-17RE signaling induces antibacterial mediators during 
bacterial infection [305]. IL-17RE is also implicated in autoimmune hepatitis by 
inducing the production of IL-2 from hepatic CD4+ T cells to promote the activation 
of NK cells and liver damage [306] (ref). Thus, protective role during bacterial liver 
infections and pathogenic role during autoimmune hepatitis suggest the opposing 
effects of IL-17RE signaling. Further studies are required to validate the pathogenic 
effects of IL-17RE signaling in liver fibrosis. 
 
1.6 DRUGS TARGETING IL-17 SIGNALLING 
Several monoclonal antibodies have been developed to block IL-17 signaling 
pathway and its contribution during the development of disease pathogenesis.  Two 
antibodies targeting IL-17A have been tested in clinical trials: humanized IL-17A-
specific antibodies Ixekizumab (LY2439821) and Secukinumab (also known as 
AIN457). Other antibodies targeting IL-17A are in clinical development, such as 
RG4934 and SCH-900117. Antibody targeting IL-17RA, brodalumab (AMG 827), is 
also in clinical development. Clinical outcome following the usage of these 
antibodies under different settings is discussed in section 1.7. In addition to 
monoclonal antibodies, significant efforts were made to inhibit IL-17A secretion by 
blocking key transcription factor such as RORγt [307]. This transcription factor was 
targeted using synthetic ligands such as Rho kinase inhibitors or ROCK2 inhibitors 
(SR1001) which can block the activity of RORγt [308]. Further details regarding the 
contribution of ROCK2 during disease settings is discussed in sections 1.8 and 1.9. 
Another potential inhibitor of Th17 cell differentiation is to inhibit the signaling 
pathway of phosphoinositide 3-kinase δ-subunit (PI3Kδ)[309].  Further investigation 
will be needed to determine whether any of these signaling pathway inhibitors are 
suitable to inhibit liver fibrogenesis. 
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1.7 CLINICAL RESULTS FOLLOWING THE INHIBITION OF IL-17 
SIGNALLING. 
Inhibition of IL-17A is observed for the first time during Phase I clinical trial using IL-
17A-specific antibody (secukinumab), in patients with psoriasis [310]. A single 
injection of secukinumab reduced the skin lesions covering the surface area, as well 
as the number of IL-17A producing cells in the skin biopsy samples. Secukinumab 
was also studied in the patients with rheumatoid arthritis and uveitis [310]. Further 
results of a Phase II study demonstrated the safety and efficacy of secukinumab for 
the treatment of ankylosing spondylitis [311]. Patients treated with ixekizumaban, 
another IL-17A blocking antibody during Phase II trial have shown improved clinical 
parameters in patients with rheumatoid arthritis [312]. Also, administration of IL-
17RA blocking antibody (brodalumab) demonstrated improved skin lesions in 
patients with psoriasis [313]. In contrast, brodalumab and ixekizumab had no effect 
in improving intestinal inflammation [314]. The efficacy of these IL-17 inhibitors in 
liver fibrosis is not yet studied in clinical trials, and the combination of positive and 
negative outcomes in other inflammatory diseases highlights the complexities of IL-
17-targeted treatment. Generally, the circulating level of IL-17A in normal patients is 
low [205], but IL-17A still contributes to diseases in combination with other 
cytokines. Targeting other IL-17 family cytokines also needs to be considered for 
further study. At present, drugs targeting IL-17A and IL-17RA are only in clinical 
trials. However, targeting other IL-17 family cytokines also need to be considered 
for effective therapeutic options. 
1.8 ROLE OF ROCK2 IN LIVER FIBROSIS 
Rho-associated coiled-coil forming protein kinase 2 (ROCK2) –a serine-threonine 
kinase – is an established mediator of fibrosis in multiple disease settings. ROCK2 
is activated by RhoA associated GTPase [315]. ROCK2 activation is also induced 
by pro-fibrogenic biochemical mediators which includes IL-17A [316] and TGFβ 
[317]. ROCK contains an N-terminally located kinase domain, a coiled-coiled region 
followed by a Rho-binding domain (RBD). The kinase activity is turned on when 
Rho-GTP binds to the Rho-binding domain of ROCK. Kinase activity is off when 
ROCK is intramolecularly folded between the C-terminal cluster of RBD domain and 
the PH domain to the N-terminal kinase domain [315].  
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ROCK-mediated effects are elicited by phosphorylation of down-stream targets 
including myosin light chain, LIM kinase and cofilin, which are associated with the 
regulation of actin cytoskeleton dynamics and cell contractility.[318] These 
processes underpin multiple cellular functions including cell migration activation, 
differentiation, and survival. Non-selective ROCK1/2 inhibition has been 
demonstrated to ameliorate fibrosis in experimental models of pulmonary,[319] 
cardiac,[320] renal,[321] dermal[322] and liver fibrosis[323, 324]. Thus, ROCK 
activation plays a key role in the development of fibrosis in most organs. Although 
ROCK1 and ROCK2 exhibit a high degree of homology,[325, 326] they are 
functionally non-redundant. Both isoforms have implicated roles in fibrogenesis, 
however, the efficacy of isoform specific targeting, and the distinct mechanisms by 
which the specific ROCK isoforms contribute to the pathophysiology of hepatic 
fibrosis remain an enigma. 
 
ROCK2 has been implicated to have a role in liver fibrosis associated with BDL. 
During BDL, mice treated with anti-aldosterone demonstrated decreased fibrosis 
associated with the decreased ROCK2 expression [327]. However, the function of 
ROCK2 in liver fibrosis is not defined. In addition to liver fibrosis, role ROCK2 is 
also implicated in idiopathic pulmonary fibrosis (IPF), myocardial fibrosis, and 
peritoneal fibrosis in which Rho-associated kinases are associated in cytoskeletal 
reorganization and remodeling of participating fibrotic cells [328-330]. GVHD [112, 
113] and auto-immune disease [331, 332] like SLE are also associated with ROCK2  
induced cellular and molecular functions. In the setting of GVHD, which manifests 
multiple organ fibrosis, ROCK2 is associated in promoting inflammatory cytokines 
[322]. Evidence strongly suggests the importance of ROCK2 in fibrosis and other 
disease settings.  Further study is needed to clarify the role of ROCK2 in chronic 
liver injury and fibrosis.  
1.9 ROCK2 ACTIVITY AND ITS DOWNSTREAM TARGETS 
Evidence suggests that ROCK2 activity promotes inflammation through various 
mechanisms (Figure 1-5). During GVHD and autoimmune disease like SLE, 
ROCK2 signaling mediates inflammatory responses through the phosphorylation of 
downstream transcription factors like STAT3, RORγt, and BCL6 in the targeted cell 
population [333-336]. Several studies demonstrated that T cells lacking STAT3 
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expression inhibited the expression of RORγt and downstream IL-17A production in 
acute and chronic GVHD suggesting the importance of ROCK2 in IL-17 production 
[112, 113, 337, 338].   
ROCK2-phosphorylated STAT3 also induces BCL6 expression in T follicular helper 
(Tfh) cells to promote B cell activation, differentiation, germinal center (GC) 
formation and antibody production in secondary lymphoid organs of mice with 
cGVHD  [339, 340]. These findings complement earlier studies suggesting that IL-
21 generated from Tfh cells through Bcl6 expression influence  B cells to maintain 
GCs and immunoglobulin deposition [174]. [338, 341-343]. Additionally, IL-21 
contributes to the differentiation of IL-17 producing γδT cells [344]. ROCK2 
activation is also reported in the polarization of macrophage phenotype from M1 to 
M2 to induce pathogenic responses which implicate its role in macrophage 
differentiation [345-347]. Furthermore, in support of this IL-17 which is secreted 
through ROCK activation also promotes pathogenic differentiation and function of 
macrophages [348-350]. These findings suggest that ROCK2 induce inflammation 
through activation, survival, and differentiation. These findings also specified that 
ROCK2 signaling promotes IL-17 secretion, macrophage differentiation, and IL-21 
induced B cell development. 
In addition to inflammation ROCK2 activity also contributes to cytoskeletal 
remodeling. It promotes the phosphorylation of cofilin indirectly through the LIM-
Kinase pathway, resulting in actin polymerization, stress fiber formation and cell 
migration [351, 352]. The activity of cofilin is reversibly regulated through 
phosphorylation and dephosphorylation, where the phosphorylated form (pcofilin) 
become inactive [353]. Phosphorylation of cofilin (inactive) is a factor affecting the 
actin cytoskeleton organization promoting cell adhesion and migration [353]. HSC 
isolated from steatotic livers displayed increased contractility associated with 
increased ROCK2 expression and cofilin phosphorylation [354]. Furthermore, cofilin 
also contributes to the migration of T cells, mesenchymal cells and macrophages 
[351-355]. These findings suggest that ROCK2 is involved in cell function, 
differentiation, and migration.  
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Figure 1-5ROCK2 signalling pathways: ROCK2 activates STAT3/RORγT to induce the expression 
of IL-17A and promote inflammatory responses. ROCK2-phosphorylated STAT3 also induces BCL6 
expression in T follicular helper (Tfh) cells to promote B cell activation, differentiation, germinal 
center (GC) formation and immunoglobulin production. ROCK2 promotes cell migration through 
pCofilin induced cytoskeletal remodelling. Conversely, it inhibits the expression of STAT3/Foxp3. 
However, the contribution of above mentioned ROCK2 signaling pathways in liver fibrosis in unkown. 
 
Though ROCK2 has been implicated in various diseases, surprisingly little is known 
regarding the contribution of ROCK2 in liver fibrosis. Given the importance of IL-17, 
monocytes/macrophages and immunoglobulins during liver fibrosis, the above 
findings highlight the role of ROCK2 activity in the pathogenesis of liver fibrosis. 
Supporting this, the association of ROCK2 in liver fibrosis has been reported in bile 
duct ligation (BDL) model [327]. However, the mechanistic contribution of ROCK2 in 
liver fibrosis is unexplored. KD025 is a potent and selective ROCK2 inhibitor which 
has been tested in multiple pre-clinical mouse models including GVHD [338, 342] 
and rheumatoid arthritis [356] ) and is in now in clinical trials (rheumatoid arthritis, 
idiopathic pulmonary fibrosis (IPF) and GVHD) [337]).  In multiple studies, ROCK2 
suppression of disease was associated with diminished IL-17 and IL-21 production  
[112, 113].  Hence, further studies are required to demonstrate the efficacy of 
ROCK2 inhibition in prevention and reversal of liver fibrosis and identify the key 
mechanisms inducing this effect.  
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1.10 CONCLUSION 
Despite extensive research and advances in the mechanisms responsible for the 
chronic liver disease, therapies for the effective treatment of liver fibrosis remain 
limited. However, identification of the cellular and molecular mediators of liver 
fibrosis highlights some potential therapeutic targets that are suitable for future 
development.  
 
Considerable efforts have given us a better understanding of the biological 
functions of IL-17 family cytokines. Though IL-17 cytokines have been implicated in 
liver fibrosis, many questions remain. It is unclear which cells produce and respond 
to the various IL-17 family members during liver injury. How the signaling of these 
cytokines function in the pathogenesis of liver fibrosis still needs investigation. 
Recognising that monocytes/macrophages are critical mediators of liver fibrosis, the 
role of different IL-17 family cytokines in regulating monocyte/macrophage 
recruitment and function during liver fibrogenesis still needs elucidation. Other 
interesting contributors to liver fibrosis are B cells, and although there is some 
evidence suggesting a role in liver fibrosis, further studies are required to 
understand the mechanism of B cell activation and the role of immunoglobulin 
deposition during liver fibrosis. Furthermore, inhibition of the molecule ROCK2 may 
help to understand the mechanistic interplay between inflammatory cells, including 
monocytes/macrophages and B cells, and some of their associated molecular 
mediators (IL-17, RORγt, STAT3, Bcl6, and pcofilin) in the formation of liver fibrosis. 
 
The experiments described in this thesis increase the understanding of the 
pathogenesis of chronic liver disease at both cellular and molecular levels and have 
underlined novel therapeutic approaches to inhibit disease progression. My initial 
findings highlight the contribution of IL-17RA signaling during chronic liver injury. 
Our studies also explain the contribution of B cells in liver fibrosis through GC 
formation and immunoglobulin deposition. Finally, the experiments show the 
potential of the ROCK2 inhibitor KDO25 in inhibiting the interactions between 
different cellular and molecular mediators associated with liver fibrosis. 
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1.11 STUDY OBJECTIVE. 
Hypothesis: 
Monocytes/macrophages and B cells are critical and distinct contributors to the 
initiation and perpetuation of liver fibrosis. IL-17 cytokines and ROCK signaling 
represent mechanistic and targetable pathways for the attenuation of the pro-
fibrogenic function in myeloid and B cells.  
Aims: 
1. To determine the relative contribution of IL-17A, IL-17F, and IL-17E to fibrosis 
in the TAA hepatotoxin model of CLD (Chapter 3). 
2. To determine the mechanistic contribution of B cells to liver fibrosis in response 
to TAA treatment (Chapter 4). 
3. To determine the therapeutic potential of ROCK2 inhibition for the attenuation 
of TAA-induced fibrosis and delineate mechanistic pathways (Chapter 5). 
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Chapter 2: Materials and methods 
2.1 ANIMALS AND ETHICS 
Mouse strains: 
All procedures were approved by the QIMR Berghofer Medical Research Institute 
animal ethics committee (A1503-603M P2096). Female C57Bl/6j (B6. WT, CD45.2, 
H-2b), Ptprca (B6. Ptprc, CD45.1, H-2b) mice were purchased from the Animal 
Resources Centre (W.A., Australia).  
Transgenic mouse strains: 
IL-17RA-/- (B6) [357], IL-17RB-/- (B6), IL-17A-/-  (B6) [358], IL-17F-/- (B6)  [240]  µmt-/-  
(B6)  [359], and FCγR-/- (B6) mice were bred and housed at QIMR Berghofer 
Medical Research Institute. IL-17ACre and Rosa26eYFP mice from C57BL/6 
background were provided by Dr. B Stockinger (Medical research council NIMR, 
Mill Hill, UK) and subsequently crossed by our lab at QIMR animal breeding facility 
to generate IL-17Acre/Rosa26YFP mice for experiments. All mice were housed in 
sterilized microisolator cages and received acidified autoclaved water (pH 2.5) 
during experimental housing. Approval for all mouse experiments and procedures 
obtained from the institutional animal ethics committees of the QIMR Berghofer 
Medical Research Institute. 
IL-17RBKO (IL-17RB-/-) chimeras: 
Chimeric recipients were generated using WT (B6 or Ptprca) and IL-17RB-/- (B6) 
mice as both donor and recipient cohorts. Recipients were lethally irradiated (1000 
cGy) and transplanted with 5x106 bone marrow from donars (Table 2.1). Chimeras 
were left to reconstitute for three months. Reconstitution of donor engraftment was 
confirmed by analysis of CD45.1 and CD45.2 congenic markers in peripheral blood. 
Animals were subsequently used for TAA experiments. 
 
 
 
32 
2.2 INJURY 
Thioacetamide (TAA) administration 
Liver fibrosis was induced by treating mice with TAA (Sigma) (supplemented in the 
drinking water at 300 mg/L) for 1 to 12 weeks.  Mice were transferred into clean 
cages once a week with their water was replaced with fresh TAA water at this time.  
 
KDO25 administration 
 KDO25 (provided by Bruce Blazar, University of Minnesota) was administered 
along with TAA. During 1-week TAA treatment KDO25 was administered daily in 
parallel with TAA. During 8-week TAA treatment KDO25 was administered during 
last two weeks of TAA treatments. 4 mg of KDO25 in 100 ul of 0.2 % 
methylcellulose was administered orally into each mouse. 
2.3 IMMUNOHISTOCHEMICAL ANALYSIS 
Tissue preparation:   
For paraffin embedding, the formalin-fixed liver tissues were transferred to 70% 
ethanol for storage embedding process. Paraffin embedding was done at envoi 
pathologists, Brisbane. For frozen sections, formalin fixed liver tissues were 
transferred into 30% sucrose and incubated at 4oC for 24 hrs to avoid crystal 
formation, and after which the tissues were mounted by placing in optimal cutting 
temperature (OCT) (Tissue-Tek*) embedding compound and stored at -80oC for 
long-term storage. Frozen sections were sent to QIMR histology services to cut 
slides. Slides from frozen sections were warmed to room temperature before 
staining. 
 
Sirius Red (SR) and hematoxylin and eosin (H&E) staining:   
Sirius Red (SR) and hematoxylin and eosin (H&E) staining was performed on 
deparaffinized of tissue slides using an automated slide staining machine (Leica 
Autostainer XL).  
 
 
33 
Pan-keratin (CK-WSS) and myofibroblasts activation (α-SMA) 
staining: 
For CK-WSS (bile duct and ductular epithelium and HPC)  or  α-SMA (activated 
stellate cells and myofibroblasts) staining, deparaffinised tissue slides underwent 
heat-induced antigen retrieval using Tris-EDTA buffer (10mM Tris /1 mM EDTA 
solution, pH9) in a microwave on full-power for 3 min, then 50% power for 5 min to 
break methylene bridges that cross-link proteins to expose antigenic sites. After this 
heat retrieval, tissue slides were allowed to cool and washed twice in TBS. To avoid 
non-specific background due to endogenous peroxidase present within the tissue, 
slides were pre-treated with ready to use peroxidase block (DAKO, Glostrup, 
Denmark) for 10 minutes and washed in TBS before antibody treatment. Slides 
were incubated for 1 hr with CK-WSS (1:500 dilution in TBS, DAKO) or α-SMA 
(1:500 dilution in TBS, DAKO) and washed in TBS for 2-3 minutes. Then slides 
were incubated for 30 minutes with HRP-linked anti-rabbit (Dako EnVision anti-
rabbit HRP kit) and anti-mouse (Dako EnVision anti-mouse HRP kit) ready-to-use 
secondary antibodies for CK-WSS & α-SMA respectively and washed in TBS for 2-3 
minutes. Finally, slides were stained with DAB (DAKO) as per manufacturer 
protocol to visualize the signal from the HRP conjugated secondary antibody.  
 
F4/80 staining: 
For F4/80 (monocytes and macrophages) staining, antigen retrieval on 
deparaffinised tissue slides was performed using enzymatic digestion (Carezyme 
Trypsin, Biocare Medical, Concord, CA) for 15 min at room temperature (prior to 
enzymatic digestion trypsin was pre-heated at 30 degrees for 10 minutes) and then 
washed in TBS for 5 minutes. Tissues were then blocked for 1 hour in 10% fetal calf 
serum/10% normal goat serum (diluted in TBS) to avoid non-specific binding of 
antibodies and for 30 min in peroxidase block (1% H2O2 in TBS) to avoid non-
specific staining. Slides were then incubated for 1 hr with anti-mouse F4/80 
antibody (1:400 dilution in TBS, AbDSerotec, Kidlington, UK) followed 5 minutes 
washing in TBS. Slides were further incubated with secondary antibody Goat anti-
rat (1:300 dilution in TBS, Santa Cruz) for 30 min. Finally, slides were incubated 
with streptavidin HRP (1:300 dilution in TBS, JACKSON Immuno-research) for 30 
min and stained using DAB (DAKO). 
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Peanut agglutinin (PNA) staining: 
Peanut agglutinin (PNA, Vector Laboratories) was used to stain germinal center B 
cells. For PNA staining deparaffinized tissue slides underwent heat-induced antigen 
retrieval using Tris-EDTA buffer as described above. Tissue slides were allowed to 
cool and incubated for 10 min with ready-to-use streptavidin/biotin block (Vector 
Laboratories) and washed. Tissue slides were then incubated with PNA (1:100) for 
1hr. Finally, streptavidin HRP (1:300 dilution in TBS, JACKSON Immuno-research) 
was added for 30 min followed by DAB staining (DAKO). 
IL-17A and γδ staining: 
Monoclonal antibodies that were used to stain frozen sections are biotinylated γδT 
cell receptor (Abcam) and anti-IL-17A (Abcam). Before antibody staining, frozen 
section slides were air dried overnight at room temperature. Slides were rehydrated 
in TBS for 5 minutes. Endogenous peroxidase activity was blocked by incubating 
the slides in 1% H2O2 (diluted in TBS) for 15 min at room temperature and washed 
in water for 5 minutes. Non-specific antibody binding is inhibited by incubating the 
slides in Sniper + 2% BSA (Biocare) for 30 min. Slides were further incubated in 
biotinylated γδT cell receptor (Abcam) and anti-IL-17A (Abcam) antibodies diluted in 
Sniper + 2% BSA (1:100) for 60 minutes. Finally, streptavidin HRP (1:300 dilution in 
TBS, JACKSON Immuno-research) was added for 30 min followed by DAB staining 
(DAKO). 
 
All slides stained by immunohistochemical methods were imaged with Aperio 
ScanScope XT Slide Scanner (Aperio, CA) and analyzed with Aperio ImageScope 
software (Aperio, CA).  
 
Quantitative image analysis 
For quantitative image analysis of immunolabelled slides, Aperio ImageScope 
version 12.1.0.5029 was used.  Sirius red (SR) stained collagen fibers were 
quantified using the algorithm, ‘positive pixel count V9’ with the following 
parameters: Hue value=0, Hue width=0.1, colour saturation threshold= 0.2. Total 
area analyzed per each slide was 5-10 mm2 not including capsule and portal tracts 
larger than 150 µm (Figure 2-1A). The area which is SR positive was shown as 
total positivity (Npositive/Ntotal) in annotations menu.  
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Similarly, pan-keratin (CK-WSS) stained slides were also quantified using ‘positive 
pixel count V9’ with the following parameters:  Hue value=0.1, Hue width=0.1, 
colour saturation threshold= 0.2. Cells which are CK-WSS positive were shown in 
brown colour (Figure 2-1B). Total area analyzed per each slide is 5-10 mm2 
including portal tracts. The area which is CK-WSS positive was shown as total 
positivity (NPositive/Ntotal) in annotations menu.  
 
F480 and SMA positive cells were counted manually using Aperio ImageScope. A 
total of 5 separate areas of 200 μm x 200 μm (away from central vein) were 
quantified for each slide. The average number of positive cells present in 5 separate 
areas gives some of total positive cells per slide. 
 
 
 
 
2.4 CELL ENUMERATION AND FUNCTIONAL STUDIES 
Isolation of hepatic leukocytes: 
For hepatic leukocyte isolation, livers were perfused with 2 ml of collagenase 
solution comprising hank’s based salt solution (Sigma) containing 1 mg/ml 
Collagenase Type IV (Sigma) and 0.1 mg/ml DNase I (Sigma). Liver perfusion was 
performed via the portal vein using a 26G needle. The liver was then removed and 
placed in a tube containing 7 ml of collagenase solution. A scalpel blade was used 
to dice the liver into a “slurry” and make a cell suspension. The cell suspension was 
incubated at 37°C for 40 min, and then pressed through a 70 µM cell strainer 
(Becton Dickinson). The cells were then washed twice at 500 x g for 5 minutes in 
cold wash buffer containing PBS and 2% heat-inactivated fetal bovine serum (Gibco 
A B
Figure 2-1:  Example of quantitative image analysis of (A) Sirius red 
(SR) and (B)ductular reaction (DR) using aperio image scope. 
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life technologies).  The washed cells were resuspended in 12 ml of 33% Percoll 
(Sigma) in PBS and then centrifuged at 600 x g for 15 min with no brake to separate 
cells based on their density. The supernatant containing hepatocytes was 
discarded, and red blood cells were lysed from the resulting nonparenchymal cell 
pellet by resuspending in Gey’s solution (Appendix A) and incubating for 2 min. 
Cells were then washed twice and resuspended in cold wash buffer for flow 
analysis. Cell yield was quantified using Beckman coulter counter. 
 
Hepatocyte isolation: 
Before hepatocyte isolation, mouse was anesthetized by injecting of a mixture of 
40mg/gm Ketamine and 2mg/gm Xylazine in 200 μL of saline. The liver was 
perfused via portal vein with perfusion buffer (PB) (Appendix A)  for 6 min and then 
with enzyme buffer (EB) (Appendix A)  for 6 min at 420 ml/hr using a hepatocyte 
perfusion pump (Kd Scientific pump) with the perfused blood exiting through the 
inferior vena cava. After perfusion, the liver was removed carefully and transferred 
into chilled sterile iscove’s modified Dulbecco's medium (IMDM, Sigma) containing 
10% heat-inactivated fetal bovine serum (Gibco life technologies). The liver 
membrane was opened using clean forceps to release digested cells in a single cell 
suspension. Cells were strained using a 70 μm cell strainer to remove undigested 
cells and connective tissues. The cells were washed using IMDM (Appendix A) at 
500 x g for 5 minutes, and hepatocytes will be pelleted down at the bottom. Pellet 
was resuspended in 10 ml of 50% percoll (Sigma) in 0.15 M NaCl and spun at 1800 
x g for 15 min with no brake at 20oC. Intact live hepatocytes will penetrate through 
percoll layer and were pelleted at the bottom of the tube. 
 
Flow cytometric analysis of surface staining: 
Freshly isolated hepatic leukocytes (1 x 106) were incubated with 30µl of FcBlock 
2.4G2 (BD Pharmingen, San Diego, CA) for 10 min at 4 degrees before adding 
antibody cocktail. Fluorescently-labeled antibodies used to stain the cells are listed 
in Table 2.2. Antibody cocktail was prepared by adding 0.5µl of each antibody in a 
final volume of 10µl wash buffer (Appendix A). Fc Blocked cells were incubated in 
10µl of antibody master mix in the dark for 20 minutes followed by washing with 
wash buffer for 2 minutes at 2000rpm. Fluorescent data was acquired by flow 
cytometry using LSR Fortessa (BD Biosciences) and BD FACSDiva (v7.0) software. 
Acquired live events were analysed using FlowJo software (v9.7 OR USA).  
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Compensation was accurately set among fluorescence channels specific for each 
antibody to avoid high degree of emission overlap between the channels.  
Unstained cells were used to adjust forward scatter (FSC) and side scatter (SSC) to 
clearly distinguish the live cells from dead. Compensation controls were used for 
each fluorochrome to adjust voltages. The absolute number of each cell type was 
calculated by multiplying their frequency by the total number of viable hepatic 
leukocytes per liver and normalized with liver weights. 
 
Intracellular Staining (ICS) and Flow Cytometry: 
Intracellular staining was performed by using BD Cytofix/Cytoperm™ solution kit 
(BD Bioscience). 5 x 106 of hepatic leukocytes were cultured with PMA (50 ng/ml, 
Sigma) and Ionomycin (500 ng/ml, Sigma) in the culture media (IMDM, Sigma) for 
4hr. After 1 hour of PMA/ionomycin stimulation, Brefeldin A (Biolegend) was added 
to the medium and the cells incubated for a further 3 hours. After stimulation, the 
cells were surface labeled as described above in the flow cytometry section. The 
cells were then washed in wash buffer and permeabilized with 250 μl of ready-to-
use cytoperm contained in the kit mentioned above for 20 min at room temperature. 
Permeabilised cells were washed twice using 1ml of 1X permeabilization wash 
buffer. 1X permeabilization wash buffer was prepared by diluting 20x 
permeabilization wash buffer in milliQ water to make it 1X.  Fcγ receptors were 
blocked using 2.4G2 before intracellular antibody staining to avoid non-specific 
staining. All samples were acquired on BD LSR Fortessa (BD Biosciences) using 
BD FACSDiva (v7.0) compensated as discussed earlier and analyzed with FlowJo 
software (v9.7 OR USA). 
 
Isolation of monocytes and macrophages with flow cytometry 
sorting 
After hepatic leucocyte isolation, 5-10 x 106 cells were surface stained with CD11B-
PERCPCY5.5 (Biolegend), F4/80-PE (Biolegend), LY6G-APC-CY7 (Biolegend), 
SIGLECF-PE.CF594 (Biolegend) antibodies. Antibody master mix was prepared by 
adding 0.5µl of each antibody in a final volume of 10µl wash buffer. Fcγ receptor 
block (2.4G2) was added before surface staining to avoid non-specific antibody 
staining. cells were incubated in 10ul of antibody master mix in the dark for 20 
minutes followed by washing with wash buffer for 2 minutes at 2000rpm, 
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supernatant was discarded, and cells were resuspended in 250 µl of RMPI+FCS 
(Appendix A). Monocytes and macrophages were sorted using Aria II-SSMRC-
8.18 (BD Bioscience). Cells that are positively stained for monocytes and 
macrophages were collected into the flow tubes containing RMPI+FCS. Collection 
tubes were washed and resuspended for 2 minutes at 2000rpm and cells 
resuspended in 1ml of trizol reagent for gene expression analysis.  
 
Cytokine administration 
For in vivo administration, of cytokine, a group of mice were intraperitoneally 
administered with 0.5 ug of IL-17E (R&D systems) resuspended in 0.1% BSA every 
day or with control (0.1% BSA in filter-sterilized saline) for up to 4 days. On 5th day 
liver tissues were taken for IHC and flow cytometry analysis as mentioned above 
and blood was collected for further analysis.        
 
Blood collection and processing   
All mice were terminally eye bleed to collect blood. For serum blood was collected 
in eppendorf which are allowed to clot at 4 degrees for 3-4 hours. Finally, 
eppendorf’s were spun at 10,000rpm for 10minutes to collect serum.    
2.5 GENE EXPRESSION STUDIES 
RNA extraction 
Ribonucleic acid (RNA) was extracted using Trizol Reagent (Invitrogen, Life 
Technologies) in the fume hood. RNaseZAP (Thermofisher) was used to clean 
bench surface and all equipment in order to remove RNA degradation due to 
RNAse contamination.  Liver tissue (0.2-0.4mg) and sorted cell (10 x 105 to 10 x 106 
cells) populations were resuspended in 1ml of Trizol and homogenized by repetitive 
pipetting.  200 µl of chloroform was added to the tubes and vigorously shaken for 
approximately 15 seconds, followed by incubation at room temperature for 3 min. 
Samples were then centrifuged at 12,000 x g for 15 min at 4 degrees. The aqueous 
phase (upper) was carefully transferred to a fresh tube avoiding the white 
deoxyribonucleic acid (DNA) interphase. 1 µL  glycogen (5 µg/µL-Invitrogen) diluted 
in RNase-free water (Thermofisher) and 500 µl isopropanol was added to the tubes, 
which were incubated for 30 min at -200C or overnight at -700C to induce RNA 
precipitation. Finally, the solution was centrifuged at 40C for 15 min at 12,000×g. 
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The supernatant was discarded and the pellet was resuspended in 1ml of 80% 
ethanol (diluted in RNase free water-Thermofisher) and centrifuged at 40C for 5 min 
at 7,500×g. Supernatant was discarded and the pellet was air dried and dissolved in 
10 µl of RNase-free water (Thermofisher) and stored at −80°C until cDNA 
preparation. Quantity of RNA was assessed using Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). 
Reverse transcription and cDNA amplification: 
In order to remove any DNA contamination from Trizol RNA preparations, a DNAse 
treatment was performed on each RNA sample (maximum 2 μg of RNA was used in 
total volume of 7 μL of RNase-free water) by adding containing 1 µl Invitrogen 10X 
DNAse Buffer and 1 µl Invitrogen DNAse I Enzyme to each sample. The tubes were 
vortexed and briefly spun down, then incubated for 15 min at room temperature. 
Following this, 2 µl of 12.5 mM EDTA was added to each sample and the sample 
incubated in the thermal cycler at 65ºC for 10 min. The samples were then 
immediately placed on ice for at least 1 min. Next, the reverse transcription (RT) of 
the RNA was started by adding 1 µl of 5ug/uL promega oligo dT and 1 µl of 10 mM 
dNTPs to each sample. The samples were incubated in the thermal cycler at 65ºC 
for 5 min and immediately placed on ice for 1 minute. Then, 7 µl of a master mix 
containing 4µl of 5X 1st strand buffer, 1µl of 100 mM DTT, 1µl of Promega RNAsin 
enzyme at 40U/µl and 1µl Superscript III enzyme (50 U, Invitrogen Life 
Technologies,) was added to each sample. The samples were placed in the thermal 
cycler (Applied Biosystems) and incubated at 50ºC for 60 minutes, followed by 70ºC 
for 15 minutes to inactivate the enzyme. The generated cDNA was stored at -20ºC. 
 
Quantitative real-time PCR (RT-qPCR): 
Real-time quantitative polymerization chain reaction (RT-qPCR) was performed in 
microAmp optimal PCR plates (Applied Biosystems) using SYBR Green or TaqMan 
assays. Forward and reverse primers were resuspended in DNAse/RNAse free 
water (100nmol/ml). Primer master mix solutions were prepared by pooling forward 
and reverse primers at a 1/10 dilution in DNAse/RNAse free water; final working 
primer solution was (10nmol/ml). For SYBR Green, a commercial reagent SYBR 
Green (Applied Biosystems) mix which contained AmpliTaq Gold® DNA 
Polymerase (for the DNA amplification) with syber green dye molecules was used. 
1 in 10 is a final dilution (diluted in RNase free water) of cDNA per reaction.  
Reactions were conducted in a real-Time PCR machine (ViiA™ 7 Real-Time PCR 
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System, Applied Biosystems). The Real-time PCR was performed by cycling the 
samples under the following conditions: 50°C for 2 min then 95°C for 10 min, then 
40 cycles of 95°C for 15s then 60°C (primer annealing step) for 1min, 72°C 
(Extension step) for 1 min. Product specificity was checked by applying a melting 
curve from 60°C to 95°C.   
 
At the end of the RT-PCR, the ViiA7 software (QuantStudioTM Real-Time PCR 
Software) generate the Ct values for each sample which represent the number of 
cycles required to reach the intensity of fluorescence at the threshold level.  
 
Water was used as negative control in all reactions to verify the absence of DNA 
contamination in the PCR reaction. In addition, we quantified the transcript of 
interest in the calibrator which is used as a positive control and as the reference to 
calculate the relative quantity of the transcript in the samples. Finally, the 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as an 
endogenous control gene to normalize for variations in the starting amount of RNA. 
All primer pairs were ordered from Integrated DNA technologies (Table 2-3) 
2.6 PROTEIN ANALYSIS 
Liver lysate preparation: 
0.02 to 0.06 mg of liver (right lobe) was dissected from the mouse and snap frozen 
immediately in liquid nitrogen and stored at -80°.  For liver lysate preparation, snap 
frozen liver tissue was ground in 1ml of lysis buffer (T-PER® Tissue Protein 
Extraction Reagent, Thermofisher) containing protease inhibitor tablets (Sigma). 
The sample was centrifuged at 10,000 × g for 5 minutes to pellet cell/tissue debris. 
The supernatant was collected and stored -80°.  to continue downstream analysis. 
 
Cytokine Analysis: 
Serum and liver cytokine concentrations were determined using the cytometric bead 
array kit from BD Biosciences Pharmingen and BioLegend’sLEGENDplex™ 
according to the manufacturer's protocol. 
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Protein estimation: 
Standard (STD) curves were prepared at 0, 50, 75, 100, 150, 200, 300 µg/ml 
concentrations in MilliQ water. Protein estimation was performed by dissolving 
samples at 1/100 in MilliQ water to get protein concentration within the standard 
range. In 96 well plate, add 20 µl diluted STD curve or diluted samples to each well 
in duplicate. Add 180 µl Bradford solution to each well (2ml Bradford reagent in 8 ml 
water). Incubate the plate at room temperature for 5 minutes. Read plate for 
absorbance on plate reader at 595nM. 
 
Western Blots: 
Western blotting was performed using SDS-PAGE Electrophoresis System (BIO-
RAD). 20 ug of liver lysate was electrophoresed on a 7.5 or 10% Tris gel with Tris 
running buffer. The separated proteins were blotted on to a PVDF membrane. The 
membranes were probed with primary antibodies against pSTAT3, pSTAT5, 
pCofilin, B-Actin and BCL6. HRP conjugated secondary antibodies were then 
added. Secondary antibodies were detected by using enhanced 
chemiluminescence.  
2.7 STATISTICAL ANALYSIS 
 
Given that most of the data were not normally distributed, we used A non-parametric 
Man Whitney-U test for comparison of two groups, and a non-parametric Kruskal Wallis 
(K.W) test for comparison of three or more groups. The data were summarized as 
median and interquartile range and presented as box and whisker plots. When the data 
appeared to follow normal distribution, we used a Two-way Anova test to compare the 
mean difference of two factors simultaneously between three or more groups. Here the 
data were presented as means and Standard error of the mean (SEM). Two-tailed p-
value of <0.05 was considered as statistically significant. All data were analysed using 
Prism version 7 software (GraphPad). 
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Table 2-1 Conditions for generating bone marrow chimeras. 
Recipient Donor 
Radiation 
conditioning 
Number of  
donor cells 
PTP  PTP  
1000cGy 
 
5X106 
PTP      IL-17RB-/-                                                                                       
1000cGy 
 
5X106
IL-17RB-/- PTP 1000cGy 5X106 
IL-17RB-/- IL-17RB-/- 1000cGy 5X106 
 
Table 2-2 List of antibodies for flow cytometry. 
Antibody Catalogue No. Clone 
CD3-CF594 562286; BD Horizon 145-2C11 
CD3e-Pacific Blue 100334; Biolegend 145-2C11 
CD3-PE 100308; Biolegend 145-2C11 
CD4-Pacific Blue 100428; Biolegend RM4-5 
CD4-PerCP-Cy5.5 550954; BD Pharminogen RM4-5 
CD4-APC 100412; Biolegend RM4-5 
CD8-Pacific Blue 558106; BD Pharminogen 53-6.7 
CD8-PE/Cy7 100722; Biolegend 53-6.7 
F4/80-PE 123110; Biolegend BM8 
F4/80-PE/Cy7 123114; Biolegend BM8 
IA/IE (MHC II)-FITC 107607; Biolegend M5/114.15.2 
IA/IE (MHC II)-
PE/Cy7 
107630; Biolegend M5/114.15.2 
IA/IE (MHC II)-Pacific 
Blue 
107620; Biolegend M5/114.15.2 
Ly6G-APC/Cy7 127628; Biolegend 1A8 
Mac-1 (CD11b)-
PerCP/Cy5.5 
101228; Biolegend M1/70 
NK1.1-APC 108710; Biolegend PK136 
SiglecF-AF647 562680; BD Pharminogen E50-2440 
Γδ T- BV421 118120; Biolegend Gl3 
IL-17RA (CD217)-PE 12-7182-82; eBioscience PAJ-17R 
IL-17A-AF700 506914; Biolegend TC11-18H10 
TNF-APC 506308; Biolegend MP6-XT22 
IL-6-PE 504504; Biolegend MP5-20F3 
CCL2/MCP1-AF647 1C479A; R&D Systems 24822 
LY6C-Pacific Blue 128014; Biolegend HK1.4 
CD19-FITC 101506; Biolegend 6D5 
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CCR2-APC FAB5538A; R&D Systems 475301 
CD44-PE 103008; Biolegend 1M7 
CD86-AF700 105023; Biolegend GL-1 
IFNγ- PECy7 505826; Biolegend XMG1.2 
IFNγ- Pacific Blue 505818; Biolegend XMG1.2 
IL-17F-PE 12-7471-80; eBioscience eBio18F10 
 
 
 
Table 2-3 List of primers 
Primer Forward Reverse 
IL-17RA TTCCCAAGCCAGTTGCAGA CTACGGGCAAGATGCCATTGA 
IL-17RB GGCTGCCTAAACCACGTAATG CCCGTTGAATGAGAATCGTGT 
Collagen 1-A1 CACCCCAGCGAAGAACTCATAC CCCCTTCTACGTTGTATTCAAACTG 
MMP2 TTGCAGGAGACAAGTTCTGGAGATA CACGACGGCATCCAGGTTAT 
MMP9 AGGGGCGTGTCTGGAGATTC TCCAGGGCACACCAGAGAAC 
MMP12 AGCTTTCCAAGTCTGGAGTGATG GCATGGGCTAGTGTACCACCTT 
MMP13 ACAAAGATTATCCCCGCCTCAT GGCCCATTGAAAAAGTAGATATAG
CC 
TIMP1 AAGGGCTAAATTCATGGGTTCC ACAGCCTTGAATCCTTTTAGCATC 
CSF-1 CGACATGGCTGGGCTCCC CGCATGGTCTCATCTATTAT 
TNF CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 
MCP-1 GCTGACCCCAAGAAGGAATG GTGCTTGAGGTGGTTGTGGA 
TWEAK GTACTGTCAGGTGCACTTTGATG ATCCGAAGGGAAGACCCTGG 
HPRT CCCAGCGTCGTGATTAGCG GCCACAATGTGATGGCCTCC 
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Chapter 3: IL-17A and E synergistically 
contribute to TAA-induced liver 
fibrosis. 
3.1 INTRODUCTION.  
Fibrosis is an accumulation of excess extracellular matrix (ECM) due to a perturbed 
normal wound healing response which results in tissue scarring. Prolonged chronic 
injury may cause dysregulation of normal processes and result in chronic 
inflammation orchestrated by a network of proinflammatory cytokines/chemokines, 
inflammatory infiltrates, and tissue resident cells. Events leading to fibrosis consist 
of (1) injury to the tissue, (2) recruitment of inflammatory cells, (3) release of 
proinflammatory and fibrogenic cytokines, and finally (4) activation of collagen-
producing cells. Fibrosis is the outcome in various diseases including chronic 
respiratory tract infections [360], chronic graft versus host disease (cGVHD) [361], 
systemic sclerosis [362], psoriasis [363], atherosclerosis [364], and intestinal 
diseases [365].  
 
Of the proinflammatory cytokine mediators of fibrosis, the interleukin-17 (IL-17) 
cytokine family has established role in many of the diseases mentioned above 
including psoriasis [217], GVHD [218], pulmonary fibrosis [243], Crohn's disease 
[244] as well as liver fibrosis [211, 232, 235, 249, 276, 366]. The IL-17 family is 
complex consists of multiple cytokine members with multiple receptors (as reviewed 
earlier in Chapter 1).  Of the IL-17 family cytokines, IL-17A, IL-17F, and IL-17E (IL-
25) are implicated as mediators of liver fibrosis with distinct mechanisms. IL-17A 
and IL-17F signal through a common heterodimeric receptor complex IL-17RA/IL-
17RC [178]. IL-17E also signals through IL-17RA, coupled with IL-17RB.  
Increased levels of IL-17A have been reported in patients with liver fibrosis 
associated with hepatitis B virus (HBV)  infection  and primary biliary cholangitis 
(PBC) [368]. During liver fibrosis, IL-17A is produced by γδT, CD4+, and neutrophils 
[369, 370] [235]. Mechanistically, during murine hepatotoxin (CCl4) and physical 
(BDL) injury models direct IL-17A signaling in hepatic stellate cells (HSCs) has 
been shown to induce liver fibrosis [190, 211, 366].  IL-17A also promotes liver 
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fibrosis by inducing pro-fibrogenic mediators such as IL-6, TGFβ, MMP, TNF, and 
TIMP from both resident and infiltrating cell populations [369, 370] [235]. 
Additionally, IL-17A is also associated with neutrophil infiltration by increasing the 
expression of CXCL-2 and ICAM-1 during ischemia-reperfusion injury [236, 237]. 
The role of IL-17A in monocytic infiltration [191] and pathogenic differentiation and 
function of macrophages [348] is also observed in-vitro and in rheumatoid arthritis 
(RA). This suggests the importance of IL-17A signaling in cell recruitment, 
activation, and survival during liver fibrosis. In addition to IL-17A, IL-17F also utilizes 
the IL-17RA/IL-17RC receptor complex.  While IL-17A is most abundantly studied of 
the IL-17 cytokine family, IL-17F has also been implicated as profibrogenic 
mediator. Increased serum IL-17F levels are detected in patients with hepatitis C 
virus (HCV) associated fibrosis [249]. Additionally, CD4+ and CD8+ T cells 
producing IL-17F are increased during fibrosis in mice fed with a methionine-
choline-deficient diet (MCDD) [371]. Studies in psoriasis identified the pathogenic 
nature of IL-17F through the induction of IL-6, IL-8 and CCL20 [372, 373]. Although 
a pathogenic role for IL-17F in autoimmune disease has been described, whether it 
participates similarly in liver fibrosis, is unknown and further studies are required.  
 
IL-17E signals through a heterodimeric complex of IL-17RA and IL-17RB subunits. 
The pathogenic [276] and protective effects [210] [279] of IL-17E are reported 
during parasite and BDL induced liver fibrosis respectively. Pathologically, IL-17E 
can induce liver fibrosis by upregulating the expression of smooth muscle actin 
protein (SMA) and collagen deposition [276]. The role of IL-17E is well studied in 
pulmonary diseases. Mechanistically, IL-17E is reported to induce the production of 
IL-13 and other inflammatory cytokines (IL-8, MIP-1, MCP-1, and IL-6) during in-
vitro and in-vivo studies [259, 274, 374]. Though IL-17E is reported during liver 
fibrosis, the mechanism by which it contributes to liver fibrosis is not clear.  
 
These findings highlight that blocking of IL-17A could be an effective therapy. 
However, studies related to the role of IL-17F and IL-17E during liver fibrosis are 
very limited. There is a need to investigate the relative contribution of IL-17A, IL-
17E and IL-17F cytokines for the development of optimal therapeutic strategies. 
Hence, we examined the relative, mechanistic and temporal contribution of the IL-
17 family cytokines to the initiation and perpetuation of liver fibrosis in a murine 
model of hepatoxin induced liver injury. Of all available multiple pre-clinical murine 
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models, the thioacetamide (TAA)-induced liver fibrosis model resembles all 
important properties of human liver fibrosis, which includes inflammation, 
regeneration, fiber formation and regression [18]. We have previously reported that 
TAA treatment induced two phases of liver fibrosis [20]. During the early phase 
(following 1 to 6 weeks TAA treatment) fine fibrosis radiating from the central vein is 
associated with pericentral F4/80 monocyte accumulation. During the late, 
progressive phase (following 6 to 12 weeks TAA treatment) septal fibrosis is 
associated with expansion and migration of a ductular reaction (DR). A niche of DR 
consists of cholangiocytes and hepatic progenitor cells (HPC), macrophages and 
HSCs. Also, collagen 1A, which is one of the dominant ECM, is also increased 
following TAA treatment. Hence, in the current study, we examined the impact of IL-
17A, IL-17E, and IL-17F cytokines during two phases of TAA-induced liver fibrosis. 
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3.2 RESULTS 
3.2.1 Differential contribution of IL-17 cytokine family members to TAA-
induced liver fibrosis 
In initial experiments, we examined the temporal development of liver fibrosis in 
wildtype (WT) and IL-17RA-/- mice in response to oral administration of TAA. As IL-
17RA is a critical receptor component for the signaling of IL-17A, IL-17F, and IL-
17E, IL-17RA-/- mice are devoid of signaling of all three of these cytokines. Mice 
were administered with TAA for periods of 1, 6 and 12 weeks, after which livers 
were harvested to perform sirius red (SR) staining, and aperio image analysis to 
visualize and quantify collagen deposition.  Livers from IL-17RA-/- mice exhibited 
significantly reduced TAA-induced collagen deposition at all time points as 
compared to livers from WT mice (Figure. 3.1A and D). As IL-17A and IL-17F 
utilize a common ternary complex of the IL-17RA and IL-17RC receptors for 
signaling, we next examined the relative contribution of these cytokines to TAA-
induced fibrosis using IL-17A-/- and IL-17F-/- mice.  Notably, SR staining revealed a 
significant reduction in fibrosis in livers from IL-17A-/- mice compared to livers from 
WT mice at both the 1 and 6-week time points. However, by 12 weeks fibrosis had 
increased and was equivalent to that measured in livers from TAA treated WT mice, 
indicating that fibrosis was delayed but not prevented. In contrast, IL-17F deficiency 
did not alter the induction or progression of fibrosis, as demonstrated by equivalent 
SR staining of livers from WT and IL-17F-/- mice at all time points (Figure. 3.1B and 
D). IL-17E also signals through a heterodimeric complex of IL-17RA and IL-17RB 
receptors. Thus to examine the contribution of IL-17E cytokine to TAA-induced liver 
fibrosis, we used IL-17RB-/- mice lacking IL-17E signaling, whereas IL-17A and IL-
17F signaling remain intact. SR staining of livers from TAA treated IL-17RB-/- mice 
demonstrated significantly reduced fibrosis at all time points (Figure. 3.1Cand D). 
Of note, however, there was a consistent trend, although not significant, to 
increased collagen deposition in livers from IL-17RB-/- mice compared to those from 
IL-17RA-/- mice. To further assess the impact of IL-17 signaling deficiencies on 
fibrosis, in subsequent experiments we quantified mRNA expression of Collagen 1A 
(Col1a), an established predominant collagen species evoked during liver fibrosis 
[20]. Quantitative real-time PCR (qRT-PCR) identified Col1a was dominantly 
upregulated at the 6-week time point in the livers from TAA treated WT mice 
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(Figure. 3.1E).  Compared to expression levels in WT mice at this time point, Col1a 
levels were reduced in IL-17RA-/-, IL-17A-/-, and IL-17RB-/- but not IL-17F-/- mice 
(Figure. 3.1F). However, Col1a levels were significantly reduced in IL-17RB-/- when 
compared to IL-17A-/- suggesting the strong role of IL-17E in inducing Col1a. 
 
Taken together these findings demonstrate pathogenic roles for IL-17A and IL-17E 
in TAA-induced liver fibrosis. In contrast, IL-17F signaling does not appear to 
contribute to pathogenesis in this model. Notably, IL-17RA deficiency resulted in 
attenuation of fibrosis at 1,6, and 12 weeks, including prevention of both the early 
inflammatory phase (1-6 weeks) and the later progressive phase (6-12 weeks) of 
fibrosis which characterizes this model. Importantly, however, the restricted 
absence of either IL-17A or IL-17E which require IL-17RA for signaling, only 
attenuated fibrosis at the 1 and 6-week time points. In both the IL-17A-/- and IL-
17RB-/- mice, between weeks 6 and12 there was a rapid progression of fibrosis. 
Thus, during early phase (1-6 weeks) either IL-17A or IL-17E signaling is sufficient 
to induce fibrosis demonstrating the redundant nature of these cytokines. However, 
during the late progressive phase (6-12 weeks), IL-17A and IL-17E both signaling 
together is required to promote fibrosis demonstrating the synergistic contribution of 
these cytokines. Hence, the blockade of IL-17RA is required for long-term 
protection.   
3.2.2 Signaling of IL-17 family cytokines is required for the development 
of the ductular reaction (DR). 
An expanded DR has previously been reported to be associated with fibrosis 
following 6 and 12 weeks of TAA treatment [20]. Thus, we examined the temporal 
changes in DR during TAA-induced liver fibrosis in WT and IL-17RA-/- mice (Figure. 
3.2A and D). CK-WSS (DR) staining and aperio image analysis was performed on 
the livers harvested following 1,6 and 12-week TAA treatment to visualize and 
quantify DR expansion. In support of our initial findings, DR expansion was only 
observed at 6 and 12-week whereas at 1-week only single CK-WSS+ HPC were 
evident at the portal tract. When compared to WT livers, DR expansion was 
substantially altered in the livers from IL-17RA-/- mice demonstrating reduced DR 
expansion. We next examined the relative contribution of IL-17A and IL-17F (which 
both commonly signal through IL-17RA) cytokines to DR in the livers of IL-17A-/- and 
IL-17F-/- mice following 6 and 12-week TAA treatment (Figure. 3.2B and D). 
Notably, IL-17A-/- mice displayed reduced DR expansion at 6-weeks. However, by 
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12-weeks expansion of DR had increased and was equivalent to WT mice. In 
contrast, IL-17F deficiency did not alter DR expansion, as demonstrated by 
equivalent CK-WSS staining in the livers from WT and IL-17F-/- mice at all time 
points (Figure. 3.2B and D). We next examined the contribution of IL-17E (also 
signals through IL-17RA along with IL-17RB) signaling to DR in the liver of IL-17RB-
/- (lack IL-17E signaling) mice following TAA treatment at similar time points. IL-
17RB-/- mice demonstrated significantly reduced DR expansion at 6-weeks, with 
reduced trend at 12-week time point (Figure. 3.1C and D). However, DR expansion 
was found to be significantly increased in livers from the IL-17RB-/- mice compared 
to those from IL-17RA-/- mice, once again suggesting the combined role of both IL-
17A and IL-17E during 12-weeks injury. 
 
Taken together these findings demonstrate that IL-17RA deficiency resulted in 
attenuation of DR expansion at both 6 and12 weeks. However, the restricted 
absence of either IL-17A or IL-17E which require IL-17RA for signaling only 
attenuated DR expansion at 6-weeks but not at 12-weeks. Thus, either IL-17A or IL-
17E signaling is sufficient to initiate DR. However, at 12-week reduced DR only in 
IL-17RA-/- suggests that both IL-17A and IL-17E act synergistically to maintain DR 
expansion. In contrast, IL-17F signaling does not appear to contribute to the DR. 
 
3.2.3 The IL-17 family cytokines are required for the activation of 
myofibroblasts. 
Hepatic stellate cells (HSCs) or myofibroblasts are the predominant ECM producing 
liver population and play a crucial role in the pathogenesis of liver fibrosis [31-33]. 
Activated myofibroblasts are characterized by the expression of alpha-smooth 
muscle actin (αSMA). αSMA+ activated myofibroblasts are seen at the pericentral 
regions following 1-week TAA treatment and after 6 weeks this staining progresses 
to septa linking the centrilobular regions (Fig 3.1A). Our previous finding 
demonstrated that IL-17F was not found to be a critical mediator in this (TAA) 
model. We thus investigated the individual, and combined contribution of IL-17A 
and IL-17E cytokines in activating myofibroblasts by using livers from 1 and 6-week 
TAA treated IL-17RA-/-, IL-17A-/-, IL-17RB-/- and WT mice (Figure. 3.3A and B).  
Livers from 1-week TAA treated IL-17RA-/-, IL-17A-/- and IL-17RB-/- mice exhibited 
significantly reduced SMA+ myofibroblasts at pericentral regions when compared to 
WT mice. However, pericentral SMA+ cells were significantly increased in IL-17A-/- 
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when compared to IL-17RA-/- and IL-17RB-/- (commonly inhibits IL-17E signaling), 
implicating the strong contribution of IL-17E in activating myofibroblasts at the 1-
week time point. Additionally, 6-week TAA livers from IL-17RA-/-, IL-17A-/-, and IL-
17RB-/- mice demonstrated reduced SMA+ myofibroblasts in comparison to livers 
from WT mice.  
 
Thus, we demonstrated that IL-17A or IL-17E contributes to myofibroblasts 
activation at 1-week. Notably, reduced SMA+ cells observed in the absence of IL-
17RA and IL-17RB when compared to IL-17A suggests the predominant role of IL-
17E in promoting myofibroblast activation at 1-week. However, at 6-week both IL-
17A and IL-17E equally contribute to myofibroblasts activation. Together, our 
findings suggest that both IL-17A and IL-17E cytokines contribute to myofibroblast 
activation at all times points examined, though with differing intensity. 
 
3.2.4 The IL-17 signaling is required for peri-central monocytic 
accumulation. 
To examine the temporal changes of inflammatory infiltrates during TAA-induced 
liver injury, we initially enumerated multiple myeloid (monocytes-CD11b+F4/80+, 
eosinophils -Siglec-F, and granulocytes-Ly6G) and lymphoid (T cells-CD3 and B 
cells-CD19) cell populations in WT mice following 1, 6 and 12-weeks of TAA 
treatment. Flow cytometric analysis on liver mononuclear cells demonstrated 
increased myeloid cells following 1-week TAA treatment whereas, lymphoid cells 
did not demonstrate any significant difference at all time points. This implicates the 
contribution of myeloid cells during 1-week TAA (Figure. 3.4A) (Gating strategy in 
supplementary figure 3.1). We next sought to determine the individual and 
combined contribution of IL-17A and IL-17E cytokines in promoting myeloid cell 
infiltration using WT, IL-17RA-/-, IL-17A-/- and IL-17RB-/- mice following 1-week TAA. 
Notably, IL-17RA-/- and IL-17RB-/- mice demonstrated substantially decreased 
monocytes, eosinophils, and granulocytes when compared to WT mice.  
Conversely, monocyte, eosinophil, and granulocyte numbers were equivalent 
between IL-17A-/- and WT mice (Figure. 3.4B-D). Collectively, these data 
demonstrated reduced myeloid infiltration in the absence of IL-17RA and IL-17RB 
signaling (which commonly inhibits the signaling of IL-17E cytokine) but not in the 
absence of IL-17A, highlighting the importance of IL-17E cytokine in myeloid cell 
infiltration.  
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Of all myeloid cells, monocytes are reported to be critical mediators of liver fibrosis. 
We also previously reported an increased number of F4/80+ monocytes around the 
central vein (CV) associated with fine centrilobular fibrosis following 1-week TAA 
[20], which is the predominant site of tissue injury in this model. Therefore, to 
examine the contribution of IL-17A and IL-17E cytokines in recruiting F4/80 cells at 
CV regions, we performed F4/80  IHC staining on the livers of 1-week TAA treated 
WT, IL-17RA-/-, IL-17A-/- and IL-17RB-/- mice (Figure. 3.4E and F). Livers from IL-
17RA-/- and IL-17RB-/- mice demonstrated a marked reduction in pericentral F4/80+ 
monocyte accumulation when compared to livers from WT mice. The pericentral 
accumulation of F4/80+ monocytes was also significantly reduced in IL-17A-/- in 
which absolute monocyte number was unperturbed. These findings demonstrated 
reduced F4/80+ accumulation observed in the absence of IL-17RA and IL-17RB 
suggesting that IL-17E signaling promotes the accumulation of F4/80+ monocytes 
around the CV. However, in the absence of IL-17A the degree of monocytic 
infiltration was unchanged but there was reduced accumulation of  F4/80+ cells 
around the CV, which suggests that IL-17A signaling has role in localising 
monocytes at the CV.  
 
3.2.5 IL-17E/IL-17RB signaling promotes CCL2 production for the   
recruitment of monocytes. 
Having noted the association of monocytes with TAA injury, we next examined the 
mechanism of monocyte recruitment. It has been reported that monocyte 
chemoattractant protein (MCP-1/CCL2) is a potent chemokine required for 
monocyte recruitment [76, 375]. We previously reported increased CCL2 levels 
following 1-week TAA when compared to naïve animals [20].  Therefore, to examine 
the contribution of IL-17A and IL-17E cytokines in inducing the production of CCL2 
we measured liver CCL2 protein levels in WT, IL-17RA-/-, IL-17A-/-, and IL-17RB-/- 
mice following 1-week TAA. CCL2 concentration was similar between IL-17A-/- and 
WT, but IL-17RA-/- and IL-17RB-/-  mice demonstrated significantly reduced levels of 
CCL2 (Figure 3.5A). As mentioned earlier, IL-17E utilizes both the IL-17RA and IL-
17RB receptor components for signaling we thus hypothesized that IL-17E signaling 
might promote CCL2 production. Based on this hypothesis, recombinant IL-17E  
was administered intraperitoneally (I.P) to naïve WT mice daily for four days 
(5µg/day) before harvest. Serum CCL2 levels were markedly increased in IL-17E 
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administered WT mice (Figure. 3.5B).  In tandem with increased CCL2 levels, flow 
cytometric analysis on collagen digested livers demonstrated increased monocytes 
as well as increased eosinophils and granulocytes (Figure. 3.5C), thereby 
suggesting that IL-17E promotes CCL2 production for the recruitment of monocytes 
and other myeloid cells. Additionally, to examine the cellular source for CCL2 
production, we performed intracellular staining (ICS) on cells from collagen digested 
WT and IL-17RB-/-  livers (taken 6 weeks after TAA administration), following 4-hour 
in-vitro LPS re-stimulation (20ng/ml). Notably, macrophages and eosinophils were 
demonstrated to be major producers of CCL2 through IL-17RB signaling (Figure. 
3.5D). Additionally, IL-17E treated mice exhibited increased liver collagen 
deposition (SR) and myofibroblast activation (SMA) (Figure. 3.5E). Thus, our study 
demonstrated the contribution of IL-17E cytokine in promoting CCL2 production 
from macrophages following 1-week TAA.   
3.2.6 IL-17E/IL-17RB signaling in non-hematopoietic cells contributes to 
liver fibrosis. 
Further investigations were made to determine whether the protection against TAA-
induced liver fibrosis observed in the absence of IL-17E signaling was mediated by 
cells located in either the hematopoietic or non-hematopoietic compartments. 
Chimeras were generated by transferring bone marrow cells from WT or IL-17RB–/– 
mice into lethally irradiated WT and IL-17RB–/– recipients, allowing deficient 
signalling to be confined to either the hematopoietic or non-hematopoietic cells. 
After a four-month period to allow haematopoietic reconstitution, liver fibrosis was 
induced in these mice following 6-weeks TAA treatment. Recipients lacking IL-17RB 
signaling in the non-hematopoietic compartment or both compartments (WT →IL-
17RB−/−; 17RB−/− →17RB−/−) developed significantly less fibrosis than those in which 
the signaling was intact in both compartments or the hematopoietic compartment in 
isolation (WT→WT; IL-17RB−/− →WT)(Figure. 3.6A-B). Reduced fibrosis was also 
associated with reduced accumulation of SMA+ myofibroblasts. To further assess 
the contribution of IL-17E signaling in hematopoietic or non-hematopoietic 
compartments subsequent experiments were performed to quantify mRNA 
expression of IL-17RB in the whole liver, isolated liver mononuclear cells (MNCs), 
and hepatocytes from naive and 1-week TAA treated WT mice. qRT-PCR identified 
that IL-17RB was dominantly expressed by the whole liver (consists 80% 
hepatocytes) and hepatocytes and to a lesser extent by MNCs (Figure. 3.6C). 
Together, our findings suggested that IL-17E/IL-17RB signaling in non-
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hematopoietic cells contributes to TAA-induced liver fibrosis. Notably, within the 
non-hematopoietic compartment, predominant expression of IL-17RB on 
hepatocytes suggests that IL-17E signaling on these cells may  contribute to liver 
fibrosis.  
3.2.7 IL-17A and IL-17E cytokine promote the expression of 
proinflammatory cytokines.  
Various pro-inflammatory cytokines contribute to liver fibrosis. Thus, we examined 
the contribution of IL-17A and IL-17E cytokines in inducing the expression of pro-
inflammatory cytokines by using livers from WT, IL-17RA-/-, IL-17A-/-, and IL-17RB-/- 
mice following 1 & 6-week TAA treatment. It has been reported that IL-17A directly 
or through the induction of IL-6   or TNF from macrophages activates HSCs to 
induce collagen deposition [211, 376, 377]. Consistent with reduced liver fibrosis, 1-
week TAA treated IL-17RA-/-, IL-17A-/- and IL-17RB-/- mice displayed reduced IL-6 
and Tnf expression when compared to WT (Figure. 3.7A). We also noted that 
progenitor TNF-related weak inducer of apoptosis (Tweak) which is found to be 
associated with the DR [378] was increased in the livers of WT mice following 6-
weeks TAA, but reduced in livers from IL-17RA-/-, IL-17A-/- and IL-17RB-/- mice 
(Figure. 3.7B).  These data suggest the role of IL-17A and IL-17E cytokines in 
promoting the production of Tnf and IL-6 during 1-week TAA; Tnf and Tweak during 
6-week TAA. It has been reported that macrophages are the major producers of 
pathogenic TNF and IL-6 during liver fibrosis [376]. Hence, reduced Tnf and IL-6 
observed in the absence of IL-17E signaling is due to an overall reduction in 
absolute monocyte number. However, reduced Tnf and IL-6 in livers from IL-17A-/- 
mice, with preserved monocyte number, is the direct result of ablated IL-17A 
signaling.  
 
We previously reported that the DR niche during 6-week TAA is associated with 
macrophage accumulation [20]. Colony stimulating factor (CSF-1) is essential for 
survival and differentiation of macrophages from monocytes [69] [379]. Therefore to 
examine whether  IL-17A and/or IL-17E influence Csf-1 expression, we measured 
Csf-1 mRNA levels in the livers from WT, IL-17RA-/-, IL-17A-/-, and IL-17RB-/- mice 
following 1-week TAA treatment. Our qRT-PCR results demonstrated increased 
Csf-1 expression following TAA treatment and observed a reduced trend in CSF-1R 
mRNA in livers from IL-17RA-/- and IL-17RB-/- but not in IL-17A-/- mice, once again 
emphasizing the importance of IL-17E signaling (Figure. 3.7C). Also, when studied 
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using chimeric mice to restrict IL17RB signalling to either hematopoietic or non-
hematopoietic compartments or both, there was a greater reduction in Csf-1 
expression following 6-week TAA treatment when IL-17RB signalling was blocked in 
the non-hematopoietic compartment compared with hematopoietic cells, but the 
greatest reduction occurred when all cells were IL17RB-/- (Figure. 3.7D). We have 
reported previously that CSF-1R blockade with the anti-CSF-1R monoclonal 
antibody M279 results in reduced DR development with a significant reduction in 
collagen deposition and progressive fibrosis [20]. Therefore to examine the 
pathogenic role of CSF-1 in TAA-induced liver fibrosis, WT mice were injected (I.P) 
with M279 (400ug/ml of M279/day) or control antibody for 3 days along with 1-week 
TAA. Consistent with previous findings M279 treated mice demonstrated reduced 
fibrosis (Sirius red) associated with reduced myofibroblast activation (SMA+) and 
pericentral monocyte accumulation (F4/80+) (Figure. 3.7E). Flow cytometric 
analysis of collagen digested livers highlighted decreased inflammatory monocytes 
(Ly6chi) and macrophage precursors (Ly6clo) (Figure. 3.F). Together our findings 
suggest that the signaling of IL-17RB mainly in non-hematopoietic cells promotes 
macrophage differentiation through Csf-1 whereas IL-17A signaling induces the 
production of Tnf and IL-6 through  IL-17RA signaling on hematopoietic cells 
(supplementary figure 3.3). 
3.2.8 IL-17A is predominantly expressed by  γδ T cells  following TAA 
treatment. 
Having demonstrated that IL-17A signaling was associated with TAA-induced liver 
fibrosis with an important role in inducing proinflammatory cytokines, we aimed to 
define which cell population(s) were the source of IL-17A and could be responsible 
for the observed pathogenic effect. Using IL17eYFP fate map reporter mice in 
which yellow fluorescent protein (YFP) is expressed constitutively once a cell has 
made IL-17A [380], we digested liver tissue and phenotyped the IL-17A producing 
cell populations therein. We identified CD3+ cells as the predominant IL-17A 
expressing population within the liver, which doubled in frequency following 1-week 
TAA treatment (Figure. 3.8A). Further analysis of the CD3+ subsets (γδ T, CD4+ T, 
CD8+ T, CD4negCD8neg T, natural killer (NK) and NKT cells) highlighted that γδ T 
cells were major IL-17A producing cells and found to be increased in number 
(Figure. 3.8B) and frequency (Figure. 3.8C) following 1 and 6 week TAA treatment. 
Knowing that MAIT cells are also one of the major IL-17A producing cells, we 
looked for IL-17A producing MAIT cells in livers from WT mice. 88% of MAIT cells 
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were CD4negCD8neg which are meager fraction when compared to γδ T cells 
(Figure. 3.8D). As mentioned earlier there was no striking difference in the 
frequency of IL-17A -producing CD4negCD8neg cells following 1 and 6 weeks TAA. 
3.2.9 Localization of IL-17A producing γδT cells around the central vein. 
γδ T cells are differentiated to IFNγ or IL-17A producers during the developmental 
stages in the thymus [381]. Additionally, IL-17A producing γδ T cells co-express IL-
17F [382]. Also, IL-17A synergize with TNF during inflammation [383]. Therefore, 
we characterized different γδ T cell subsets by performing ICS on naïve, and 1-
week TAA treated WT  following 4hr PMA (100ng/ml) + ionomycin (50ng/ml) 
stimulation. Notably, following 1-week TAA the increased differentiation of γδ T cells 
was restricted to the IL-17A and not the IFNγ producers (Figure. 3.9A). 
Additionally, the frequency of IL-17A producing γδ T cells was doubled with no 
change in the proportion of cells co-expressing IL-17A and IL-17F (Figure. 3.9B). 
However, the frequency of IL-17A+ TNFγδ T cells were increased 2-fold following 1-
week of TAA treatment (Figure. 3.9 C-D). Importantly, immunohistochemistry data 
revealed that in addition to F4/80+ monocytes and SMA+ myofibroblasts [20], IL-
17A-producing γδ T cells were also located around the central vein following 1 week 
of TAA treatment (Figure. 3.9E). 
3.2.10 IL-17E induced CCL2 is important in recruiting IL-17A 
producing γδT cells. 
To determine the contribution of IL-17 signaling in recruiting γδT cells, 
immunohistochemistry was performed in the livers of WT, IL-17RA-/-, IL-17A-/- and 
IL-17RB-/- mice following 1-week TAA. The recruitment of γδ T cells around central 
vein were unchanged between the livers of WT and IL-17A-/- mice.  Notably, IL-
17RA-/- and IL-17RB-/-  displayed reduced γδ T cells around the central vein when 
compared to WT (Figure. 3.10A). As mentioned earlier, IL-17E utilizes both the IL-
17RA and IL-17RB receptor components for signaling, hence reduced γδ T cells 
exhibited in the absence of IL-17RA and IL-17RB receptors demonstrate the 
importance of IL-17E signaling in promoting γδ T cells recruitment. It has been 
reported that CCL2 will promote the recruitment of IL-17A+γδ T cells through their 
expression of CCR2 [384]. In above experiments we demonstrated the role of IL-
17E cytokine in CCL2 production (section 1.2.5). Therefore, the contribution of 
CCL2 in the recruitment of γδT cells was investigated in CCL2-/- mice following TAA 
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treatment. In comparison to WT mice, 1-week TAA treated CCL2-/- mice displayed 
markedly reduced γδT around the CV (Figure. 3.10B). Additionally, flow cytometric 
analysis also confirmed the expression of CCR2 in IL-17A+ γδ T cells (Figure. 
3.10C) providing evidence that these cells were recruited to the liver in a 
CCL2/CCR2 dependent manner. As previously illustrated in Figure 3.9C, the 
frequency of IL-17A+ TNF-producing γδ T cells substantially increased following 1-
week TAA. Notably, in the absence of IL-17A, γδ T cells still produce TNF in 
response to injury (Figure. 3.10D). TNF is important in activating myofibroblasts to 
induce collagen deposition [385] . Hence, TNF production observed in the absence 
of IL-17A singling will still induce myofibroblasts activation, explaining why livers 
from 1-week TAA IL-17A-/- mice displayed increased SMA+ cells when compared to 
IL-17RA-/- and IL-17RB-/- mice, although they were significantly reduced when 
compared to WT mice (Figure 3.3). Together, our data demonstrate that though 
TNF is important in myofibroblasts activation its production from γδ T cells in the 
absence of IL-17A signaling is insufficient to induce maximum myofibroblasts 
activation, highlighting the importance of synergistic production of IL-17A and TNF 
from γδ T cells during liver fibrosis.  
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3.3 DISCUSSION 
The IL-17 family of cytokines have been shown to play an important role in chronic 
fibrosing diseases including chronic liver disease. This study provides new insight 
into the mechanistic and relative contribution of different IL-17 family cytokines 
during different phases of fibrosis in the chronic injury model using TAA 
administration.  We specifically demonstrated that IL-17A and IL-17E act 
synergistically during the pathogenesis of TAA-induced liver fibrosis. Blockade of IL-
17A and IL-17E individually demonstrated reduced fibrosis following 1 and 6-week 
TAA treatment. However, combined blockade of IL-17A and IL-17E (by blocking IL-
17RA) was required for long-term protection (12-week TAA). 
 
Monocytes are established as critical mediators of fibrosis although the nature of 
specific monocyte population(s) and the mechanism by which these cells promote 
fibrosis remain incompletely defined [386, 387]. Our data illustrate that IL-17 has an 
important role in the recruitment and differentiation of monocytes with chronic 
inflammatory injury induced by TAA. In the absence of IL-17RA (IL-17RA-/-) 
signaling there was reduced monocytic infiltration following 1-week TAA treatment 
associated with reduced myofibroblast activation  and collagen deposition. 
Additionally, the absolute number of eosinophils and granulocytes were also 
reduced in IL-17RA-/- mice. We previously demonstrated that fibrosis induced 
following 6 and 12-week TAA treatment was associated with DR expansion and 
macrophage differentiation [20] and we extended those findings here by  showing 
significantly reduced DR expansion in IL-17RA deficient mice, implicating IL-17 
signalling in the development of the DR. Thus, IL-17 family members have a key 
role in both the early inflammatory phase of injury as well as the later progressive 
phase characterized by the development of extensive fibrosis with septal formation 
associated with an expanded DR. 
 
IL-17RA is a common receptor for IL-17A and IL-17F as well as IL-17E (IL-25). Our 
study highlights the individual and combined mechanistic contribution of each these 
cytokines in promoting TAA-induced liver fibrosis during both early and late phases. 
. Following 1-week TAA, mice deficient in IL-17A demonstrated reduced monocyte 
accumulation around the CV while the absolute number in the liver was unchanged, 
suggesting a role for IL-17A signaling in sequesteration of monocytes around the 
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CV (the site of major injury) rather than recruiting them as has been found in other 
models [388]. Similarly and in contrast to recent findings observed in ischemia-
reperfusion (IR) liver injury, neutrophil infiltration also remained unchanged in IL-
17A-/- mice following TAA [236, 237] demonstrating that in the TAA model, IL-17A 
does not contribute to myeloid cell recruitment. Mice deficient in IL-17A also 
demonstrated delayed fibrosis and development of the DR at 6 weeks, but this was 
only temporary and by 12 weeks the degree of injury was similar to that seen in WT 
animals, indicating a redundant role for IL-17A in the progressive phase. 
 
Our studies provide insight into how IL-17A may promote fibrogenesis. Some 
reports have demonstrated the role of IL-17A in inducing pro-fibrogenic mediators 
such as IL-6, TGFβ, and TNF, from resident and inflammatory cells [235] and we 
confirmed IL-17A-dependent expression of the inflammatory cytokines IL-6 and 
TNF. TNF induced from macrophages in response to IL-17A increases the 
activation and survival of HSCs [389]. Additionally, IL-17A can also activate HSCs 
in STAT3 dependent manner [211]. IL-17A and TNF have synergistic interactions, 
where IL-17 enhances the expression of TNF receptor [228]. TNF improves the 
effect of IL-17 by increasing the levels of protein expression. Combined suppression 
of these synergistic cytokines results in enhanced anti-inflammatory effects [225].  
We have shown that IL-17A+TNF γδT cells were increased following TAA treatment, 
but since blockade of IL-17A alone (IL-17A-/- mice) did not prevent fibrosis these 
appear to represent only part of the stimulatory response during injury and are 
insufficient to induce strong HSC activation.  
 
During the late phase of injury we previously reported that expansion and migration 
of the DR is associated with macrophage interaction, with approximately 50% of the 
liver macrophages in contact with the DR [20]. Although IL-17A has been implicated 
in the pathogenic differentiation of macrophages suggesting a potential contribution 
to late phase fibrosis (6-12 weeks) [348-350], we found that IL-17A deficient mice 
had normal expression of CSF-1, which is essential for macrophage differentiation 
and survival [379].  IL-17A did have an effect on TWEAK expression, the major 
growth factor for HPC and the DR [390] (which is produced by macrophages and 
NK cells), likely the cause of  delayed DR development seen in IL-17A-/- mice. Next, 
we extended our study by examining which cells produced IL-17A and found that 
γδT cells were the  major producers of this cytokine. IL-17A-expressing γδT cells 
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have been implicated in other diverse liver diseases including viral hepatitis [122, 
129], Schistosoma japonicum infection [130] and chronic biliary disease [131]. Our 
finding of increased IL-17A-producing γδT cells in the centrilobular regions of 
maximal injury further support a role for these cells in the liver injury responses.  
 
While the pathogenic role of IL-17A was confirmed, IL-17F was found to be non-
pathogenic during TAA-induced liver fibrosis at all time points. 
 
Our studies indicate that IL-17E appears to have a role in the early and progressive 
liver injury in this model. IL-17E signals through a heterodimer of IL-17RA (also 
used for IL-17A and IL-17R signalling) and co-receptor IL-17RB, the latter allowing 
us to selectively inhibit IL-17E signalling using IL-17RB-/- mice in the experiments 
described above. Though IL-17E signaling is reported to protective in fulminant liver 
injury [279], we identified its role as pathogenic during TAA-induced liver fibrosis. IL-
17RB-/- mice demonstrated reduced monocytic (F4/80) infiltration and centrilobular 
accumulation following 1-week TAA treatment associated with reduced activation of 
HSC and reduced early collagen deposition around the CV. IL-17E had a role in 
monocytic infiltration. CCL2 has been reported to be an essential chemokine for 
monocyte recruitment [68, 71-75] and is also important in CCl4-induced liver fibrosis 
[76]. However, our earlier studies of TAA-induced liver fibrosis found that CCL2 
deficiency attenuated early monocyte infiltration and fibrosis but was not mediated 
exclusively by CCR2 ligation [20].. The role of IL-17 family cytokines in inducing 
chemokines during liver fibrosis is not known but some evidence suggests that IL-
17E promotes the induction of chemokines (CCL2, MIP-1) that lead to monocyte 
recruitment [259]. In the current studies, reduced CCL2 levels in IL-17RA-/- and IL-
17RB-/- but not IL-17A-/-micehighlight the importance of IL-17E in CCL2 expression. 
We have shown that macrophages, which are major producers of CCL2, 
demonstrated reduced CCL2 production in the absence of IL-17E signaling. 
Additionally, our studies identified increased CCL2 and increased monocytic 
infiltration in recombinant IL-17E administered mice, increased activation of HSC 
and sinusoidal fibrosis within days of administration. The CCL2/CCR2 axis has also 
been demonstrated to promote infiltration of IL-17 producing γδT cells in the tumor 
microenvironment [134, 384].  The role of this CCL2/CCR2 axis in recruiting γδT 
cell during liver fibrosis has not been clear and we determined that IL-17A-
producing γδT cells were recruited in a CCL2/CCR2 dependent manner. Our data 
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also revealed that IL-17RB signaling, particularly in non-hematopoietic cells 
predominantly hepatocytes, contributed to liver fibrosis. However, the role of IL-17E 
dependent IL-17RB signaling in hepatocytes is yet to be known. 
 
CSF-1 signaling, needed for macrophage differentiation and survival [379], appears 
critical for the progression of liver fibrosis and development of the DR from our 
earlier studies [20]. Here, we extended our understanding by showing the key role 
of IL-17RB signaling, in inducing the production of CSF-1 promoting late phase 
injury at 6-12 weeks. Studies in chimeric animals showed that CSF-1 production 
was greater from non-hematopoietic cells, than recruited hematopoietic cells. 
Similar to IL-17RA-/- and IL-17A-/- animals, reduced expression of IL-6 and TNFwas 
also observed in IL-17RB-/- mice due to reduced inflammatory cells that produce 
these cytokines. We were unable to determine the cellular sources of IL-17E since 
the relevant mice were not available, but a similar strategy to that used in IL-17A 
interogation could be used. IL-17E is typically expressed by a greater range of cells 
including epithelial cells and granulocytes  [255]. 
 
Thus, our study demonstrates that IL-17E signaling promotes monocyte and IL-
17+γδT recruitment through the induction of CCL2 whereas IL-17A signaling 
promotes the activation of HSCs through the induction of pro-inflammatory 
cytokines IL-6 and TNF as well as other mediators such as TWEAK during the early 
phase. IL-17RB signaling on hepatocytes is associated with production of CSF-1 
leading to macrophage differentiation and the development of fibrosis. However, 
inhibition of both IL-17A and IL-17E by blockade of IL-17RA signaling is required for 
long-term protection from progressive septal fibrosis. 
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Figure 3-1 Differential contribution of IL-17 cytokine family members to TAA-
induced liver fibrosis. (A) Histochemical staining for Sirius red in representative liver 
sections from naïve, 1, 6 and 12-week TAA-treated C57BL/6 (WT), IL-17RA-/-, (B) IL-17A-/-, 
IL-17F-/- and (C) IL-17RB-/- mice. (D) Aperio quantification of Sirius red staining (n= 4-14 
animals/group/timepoint). Data are presented as mean ± SEM. * p< 0.05 Mann Whitney-U 
test. (E) Expression of pro-fibrogenic gene Col1-A1 in whole livers from naive and time 
course TAA-treated mice (n=3-14 animals/timepoint). Data are presented as median and 
interquartile range * p< 0.05 (naïve verses 6-week TAA; naïve verses 12-week TAA),  
Mann Whitney-U test. (F) Expression of pro-fibrogenic gene Col1-A1 in whole livers from 
6-week TAA treated WT, IL-17RA-/-, IL-17A-/-, IL-17F-/- and IL-17RB-/- mice (n=9-14 
animals/time point). Data are presented as median and interquartile range *p<0.05 
**p<0.01, ***p<0.001. Kruskal Wallis (K.W) test.  
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Figure 3-2 Role of IL-17 family cytokines in the development of ductular reaction: A) 
Immunolabelling for the DR (pan-keratin) in representative liver sections from naïve, 1, 6 
and 12-week TAA-treated C57BL/6 (WT), IL-17RA-/-, (B) IL-17A-/-, IL-17F-/- and (C) IL-
17RB-/- mice. Aperio image analysis in pan-keratin stained liver sections of (D) 6 and 12-
week TAA treated mice (n=10-16 animals/group/time point). Data are presented as 
median and interquartile range. * p< 0.05,** p< 0.01, *** p< 0.001, Kruskal Wallis (K.W) 
test. 
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Figure 3-3 Role of IL-17 family cytokines in activating myofibroblasts (A) α-sma 
immunohistochemistry staining and (B) Quantification in 1 and 6-week TAA treated WT, IL-
17RA-/-, IL-17A-/-, and IL-17RB-/- livers. For ‘B’ results were shown as average of five 10 X 
20 counted areas per section (n=8-14 sections/group).  Data are presented as median and 
interquartile range. * p< 0.05 (1-week SMA: WT verses IL-17A-/-) (6-week SMA: WT verses 
IL-17A-/-; WT verses IL-17RA-/-; WT verses IL-17RB-/-), ** p< 0.01 (1-week SMA: WT 
verses IL-17RB-/-; IL-17A-/- verses IL-17RA-/-; IL-17A-/- verses IL-17RB-/-;), *** p< 0.001 (1-
week SMA: WT verses IL-17RA-/-). Mann Whitney-U test.  
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Figure 3-4 IL-17 family cytokines are required for myeloid infiltration, and pericentral 
monocyte accumulation: (A) An absolute number of monocytes, eosinophils, 
granulocytes, T, and B cells in the livers of 1,6 and 12-week TAA treated mice (n = 3-
12/group). Data are presented as median and interquartile range. * p< 0.05 (Granulocytes: 
naïve verses 1-week; naïve verses 6-week), ** p< 0.01 (Monocytes: naïve verses 1-week) 
(Eosinophils: naïve verses 1-week). Mann Whitney-U test. (B-D) An absolute number of 
monocytes, eosinophils, and granulocytes in the livers of 1-week TAA treated WT, IL-
17RA-/-, IL-17RB-/- and IL-17A-/- mice (n = 4-8/group). Data are presented as median and 
interquartile range. * p< 0.05 (1-week Monocytes: WT verses IL-17RA-/-; WT verses IL-
17RB-/-) (1-week Eosinophils: WT verses IL-17RA-/-; WT verses IL-17RB-/-) (1-week 
Granulocytes: WT verses IL-17RA-/-; WT verses IL-17RB-/-), Mann Whitney-U test. (E) 
F4/80+ Immunohistochemistry staining and (F) Quantification in 1-week TAA treated WT, 
IL-17RA-/-, IL-17A-/-, and IL-17RB-/- livers. For ‘F’ results were shown as average of five 
counted areas per section (n=8-14 sections/group). Data are presented as median and 
interquartile range. ** p< 0.01 (WT verses IL-17A-/-; IL-17RA-/- verses IL-17A-/-), *** p< 
0.001 (WT verses IL-17RA-/-; WT verses IL-17RB-/-; IL-17A-/- verses IL-17RB-/-). Mann 
Whitney-U test. 
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Figure 3-5 IL-17E induces CCL2 production for the recruitment of monocytes: (A) 
CCL2 levels were measured using cytometric bead array in the livers of WT, IL-17RA-/-, IL-
17A-. /-, and IL-17RB-/- following 1-week TAA treatment (n = 4/group). (B) Serum CCL2 
levels in naïve mice administered with 5µg/ml IL-17E for 4 days (n = 5/group). (C) An 
absolute number of monocytes, eosinophils, and granulocytes in the livers of IL-17E 
treated mice (n = 5/group). (D) Representative histograms are illustrating CCL2 
expression, where isolated liver cell fraction from 1-week TAA treated WT and IL-17RB-/- 
mice were in vitro stimulated with LPS (50ng/ml) for 4 hours and analyzed by flow 
cytometry for intracellular CCL2 expression. (E) Vehicle and IL-17E treated liver sections 
were analyzed for immunohistochemistry Sirius red and SMA staining. Data are presented 
as median and interquartile range. * p< 0.05 (Liver CCL2: WT verses IL-17RA-/-; WT 
verses IL-17RB-/-)(Serum CCL2: vehicle verses IL-17E)(Granulocytes: vehicle verses IL-
17E), ** p < 0.01 (Monocytes: vehicle verses IL-17E; Eosinophils: vehicle verses IL-17E). 
Mann Whitney-U test. 
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Figure 3-6 IL-17RB signaling in non-hematopoietic cells contributes to TAA-induced 
liver fibrosis. (A) Development of liver fibrosis in bone marrow chimeric mice was 
compared in the livers of TAA treated WT→WT, IL-17RB−/− →WT, WT→IL-17RA−/−, IL-
17RB−/− →IL-17RB−/−, and IL-17RA−/− → IL-17RA−/− by Sirius red staining and α-SMA 
immunohistochemistry. (B) Sirius red aperio image analysis (n=6 animals/time point). Data 
are presented as median and interquartile range. * p< 0.05, Kruskal Wallis (K.W) test. (C) 
A graph illustrating the expression of IL-17RB in the whole liver, MNC, and hepatocytes of 
naïve and 1-week TAA treated mice (n = 3-6/group). Data are presented as means  ±SEM 
* p< 0.05, Two-way ANOVA. 
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Figure 3-7 IL-17 family cytokines induce the production of proinflammatory 
cytokines Graphs illustrating the expression of TNF, IL-6 and TWEAK following (A)1-week 
and (B) 6-week TAA treated in WT, IL-17RA-/-, IL-17A-/-, and IL-17RB-/- (n = 3-6/group). 
Data are presented as median and interquartile range * p< 0.05 (1-week IL-16: naïve 
verses WT; WT verses IL-17RA-/-) (6-week TNF: WT verses IL-17A-/-; WT verses IL-17RA-
/-) (6-week TWEAK: WT verses IL-17RA-/-; WT verses IL-17RB-/-), ** p < 0.01 (1-week IL-
16: WT verses IL-17A-/-  ; WT verses IL-17RB-/-) (6-week TNF: WT verses IL-17RB-/-) (6-
week TWEAK: WT verses IL-17A-/-). Mann Whitney-U test. Graphs illustrating the 
expression of CSF-1 in (C) WT, IL-17RA-/-, IL-17A-. /-, and IL-17RB-/- (n 3-6/group) following 
1-week TAA treated and in (D) IL-17RB-/- bone marrow chimeras following 6-week TAA (n 
3-6/group). Data are presented as median and interquartile range * p< 0.05 (CSF-1 in 
bone marrow chimeras: B6-B6 verses IL-17RB-/-- IL-17RB-/-), (1-week CSF-1: naive verses 
WT), ** p < 0.01 (1-week CSF-1: naive verses WT). Mann Whitney-U test. (E) 
Representative images showing immunohistochemistry staining of Sirius red, SMA, and 
F4/80+ in mice treated with saline/M279 ((400µg/ml) along with 1-week TAA. (F) An 
absolute number of monocytes, Ly6chi and Ly6clo in M279 treated mice (n = 2/group). Data 
are presented as median and interquartile range. Mann Whitney-U test. 
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Figure 3-8 IL-17A is predominantly expressed by γδ T cells following TAA treatment. 
(A) Representative dot plot illustrating the frequency of CD3+IL-17AYFP+ cells in 
collagenase digested livers from naive, and 1-week TAA treated IL-17 YFP fate reporter 
mice. (B) Absolute numbers and (C) frequency of IL-17A producing γδ T cells, CD4 T, CD8 
T, CD4negCD8neg T (DN), NK and NK T cells from naïve, 1 and 6-week TAA treated IL-17 
YFP fate reporter mice (n = 6-8/group). (D) Representative contour plots are highlighting 
frequency of IL-17A producing MAIT cells. Data are presented as means ±SEM * p< 0.05 
,** p< 0.01, *** p< 0.001. Two-way ANOVA. 
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Figure 3-9 Pericentral localization of IL-17A producing γδ T cells following 1-week 
TAA. Liver cell fraction from naïve and 1-week TAA treated IL-17 YFP fate reporter mice 
were in vitro stimulated with PMA (100ng/ml)+Ionomycin (50ng/ml) for 4 hours, and 
analyzed by flow cytometry for intracellular (A) IFNγ, (D) IL-17F and (C) TNF expression in 
IL-17 producing γδ T cells (D) Fold change of IL17A+IL-17F+ and IL-17A+TNF+  producing 
γδ T cells from naïve and 1-week TAA treated IL-17 YFP fate reporter mice (n = 6-
8/group). (H) Immunohistochemistry staining of IL-17A (top panel) and γδ T cells (lower 
panel) from naïve and 1-week TAA treated livers. Black arrows indicate positive staining. 
Data are presented as means ±SEM * p< 0.05 Two-way ANOVA. 
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Figure 3-10 CCL2 mediates the infiltration of IL-17 producing γδ T cells. 
Immunolabelling staining showing (A) co-localization of γδ T cells in livers of WT, IL-17RA-
/-, IL-17A-/- and IL-17RB-/- and (B) CCL2-/- following 1-week TAA treatment. (C) 
Representative contour plots illustrating CCR2 expression on γδT+ IL-17-YFP cells. (D) 
Representative counter plots highlighting the expression of TNF in 1-week TAA treated 
WT, and IL-17A-/-  
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Supplementary figure 3-1 Gating strategy of (A) Myeloid cells and (B) IL-17A 
producing cells.  
 
Supplementary figure 3-2 production of TNF by macrophages. Representative 
histograms are illustrating TNF expression, where isolated liver cell fraction from 1-week 
TAA treated WT, IL-17RA-/- IL-17A-/- mice were in vitro stimulated with LPS (50ng/ml) for 4 
hours and analyzed by flow cytometry for intracellular TNF expression. 
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Supplementary figure 3-3 Expression of IL-17RA in hematopoietic cells. (A) A graph 
illustrating the expression of IL-17RA in the whole liver, MNC, and hepatocytes of naïve 
and 1-week TAA treated mice (n = 3-6/group). (B) Representative histograms are 
illustrating IL-17RA expression in isolated liver cell fraction. Data are presented as median 
and interquartile range * p< 0.05, Mann Whitney-U test 
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Chapter 4: Binding of B cell 
immunoglobulins to FcγR is 
associated with TAA-induced 
liver fibrosis 
4.1 INTRODUCTION 
B cells are important contributors to immune responses during both physiological 
and pathological conditions. B cells contribute to immune responses through 
multiple functions, including secretion of antibodies and inflammatory cytokines, and 
shaping T cell responses through antigen presentation [391]. The contribution of B 
cells is well documented in autoimmune diseases such as multiple sclerosis (MS) 
[392], rheumatoid arthritis (RA) [393, 394], and systemic lupus erythematosus (SLE) 
[395, 396], and diseases such as graft versus host disease (GVHD) [397]. Most of 
these autoimmune diseases are driven by a dysregulated function of immune 
network involving B cells, T cells, and other immune cells.  
 
Generally, B cells contributes to disease pathogenesis through antibody production. 
One of the mechanism through which antibodies mediate disease pathogenesis 
include ‘antibody-dependent cell-mediated cytotoxicity (ADCC)’ [398, 399]. ADCC is 
an immune mechanism through which FcγR bearing effector cells (monocytes, 
macrophages, neutrophils, mast cells, and NK cells) will ligate to antibody coated 
target cells expressing pathogen-derived antigens on their surface [176, 399]. The 
ligation of FcγR to antibody will promote phagocytosis, and induce the production 
of cytokines, chemokines, and other inflammatory mediators central to both 
protective and pathogenic properties [176]. The pathogenic property of 
autoantibody production is reported during disease pathogenesis of GVHD [397] 
[400], and MS [401]. During autoimmune diseases, B cells, under the influence of 
IL-21 produced by follicular T helper (Tfh) cells, differentiate into germinal center 
(GC) B cells to promote antibody production [174, 338, 341-343]. Recently, γδT 
cells are also reported to provide B cell help for antibody production during parasite 
infection [344, 402] [403]. These findings suggest the importance of T and B cell 
interaction to induce B cell-dependent antibody production, which in turn promotes 
FcγR mediated pathogenic function. 
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Accumulating evidence also suggests that apart from antibody production, activated 
B cells also contribute to immune responses through cytokine production. 
Production of tumor necrosis factor (TNF), IL-6 from activated B cells is observed 
during disease pathogenesis of cardiomyopathy [404] and MS [405].  
 
B cells, which represent half of the intrahepatic lymphocyte population, have also 
reported in liver fibrosis and [167]. In one study using the hepatotoxin (CCl4) 
induced liver fibrosis model, B cells were demonstrated to contribute to fibrosis 
independently of T cell activation or antibody production [168].  Conversely, another 
study using the same model demonstrated that liver fibrosis is associated with 
increased antibody production along with elevated B cell activation markers (CD44 
and CD86) and TNF production [169].  Above findings suggest the importance of 
innate B cell activity by inducing the production of TNF during liver fibrosis. 
However, the role of IgG production remains controversial. In the current studies, 
we examined the role of B cells in the TAA model of liver fibrosis, and demonstrate 
their critical role through aberrant B cell activation followed cytokine production and 
pathogenic IgG production and its binding to FcR. 
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4.2 RESULTS 
4.2.1  B cells contribute to TAA-induced liver fibrosis. 
In this study, we aimed to identify the contribution of B cells to liver fibrosis using 
TAA-induced liver fibrosis model. In initial studies, mice harboring a targeted 
deletion of the Igμ heavy chain (μmt-/-) were used to assess the role of B cells [359]. 
Wild type (WT) and μmt-/- mice were treated with TAA for a period of 6-week after 
which livers were harvested to perform immunohistochemical sirius red (SR), 
smooth muscle actin (SMA) and ductular reaction (CK-WSS+) staining to visualize 
collagen deposition, myofibroblasts activation, and expansion of ductular reaction 
(DR) respectively. Livers from μmt-/- mice displayed significantly reduced TAA-
induced collagen deposition associated with reduced activation of myofibroblasts 
and DR expansion (Figure 4.1A and B). Together our data reveal an important 
pathogenic role for B cells in TAA-induced liver fibrosis.  
4.2.2 The innate activity of B cells contributes to liver fibrosis. 
To further investigate the mechanism by which B cells contribute to TAA-induced 
liver fibrosis we initially enumerated total B cells in the dissociated livers of mice 
that were treated with TAA for 6-week. Flow cytometry results demonstrated no 
marked difference in the number of hepatic B cells (CD19+) in 6-week TAA-treated 
mice in comparison to naïve (Figure 4.2A). However, an increased number of 
activated B cell, characterized by the expression of CD44 and CD86 was noted in 
6-week TAA-treated mice in comparison to naïve (Figure 4.2A). Moreover, B cells 
isolated from the livers of mice treated with TAA for 6 weeks, produced increased 
TNF in response to PMA/Ionomycin stimulation when compared to hepatic B cells 
from uninjured mice (Figure 4.2B). As mentioned earlier TNF is a potent cytokine 
involved in the activation and survival of hepatic stellate cells [385, 406]. Taken 
together, our data identify B cell induced TNF production as a potential mechanism 
of HSC activation and collagen production during TAA induced liver fibrosis.  
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4.2.3 TAA-induced liver fibrosis is associated with antibody deposition. 
It has been reported that immunoglobulins produced following B cell activation and 
differentiation contributes to pathogenic immune responses [407]. The contribution 
of antibody production during hepatotoxin induced (CCL4) liver fibrosis is 
controversial [167][169]. Therefore, serum immunoglobulin (IgG) levels were 
measured in naive and 6-week TAA treated WT and µmt-/- mice. In comparison to 
naive, 6-week TAA treated mice demonstrated increased serum IgG levels 
whereas, these levels were significantly reduced in µmt-/- when compared to both 
naïve and 6-week TAA WT (Figure 4.3A), thus confirming the role of B cells in IgG 
production following TAA treatment. Subsequent experiments were performed to 
examine the intrahepatic distribution of IgG during liver fibrosis.  
Immunohistochemical (IHC) IgG staining was performed in the livers from naïve 
and 6-week TAA-treated mice. Compared to naïve, 6-week TAA treated displayed 
increased IgG deposition across the scar regions adhering within the septae. 
(Figure 4.3B). Taken together, our data demonstrate the association between B 
cells and antibody production following TAA treatment.  
4.2.4 Antibody binding to Fc gamma receptor (FcγR) is associated with 
TAA-induced liver fibrosis. 
One of the mechanisms through which antibodies mediate pathogenic immune 
responses is through FcγR binding [176]. FcγR is expressed by specific effector 
hematopoietic cells (Monocytes/macrophages, dendritic cells, basophils, mast cells, 
and neutrophils) to trigger pathogenic immune responses [408]. Therefore, we 
investigated the pathogenic contribution of FcγR during liver fibrosis. For this, we 
treated WT and FcγR-/- (ablated FcγR) mice with TAA for a period of 6-week after 
which livers were harvested to perform SR and SMA staining. In comparison to 
naïve, livers from FcγR-/- mice displayed significantly reduced collagen deposition 
associated with reduced activation of myofibroblasts (Figure 4.4 A and B). Serum 
IgG levels were also measured in WT and FcγR-/- mice following 6-week TAA 
treatment. When compared to WT, FcγR-/- demonstrated increased serum IgG 
levels (Figure 4.4C). In the context of increased serum IgG levels, our IHC data 
displayed reduced IgG distribution in the livers of TAA treated FcγR-/- mice 
suggests the binding of IgG to FcγR as a potential mechanism driving liver 
fibrosis. Together our data demonstrates the association between IgG and FcγR 
during TAA induced liver fibrosis. 
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4.2.5 TAA induced liver fibrosis is associated with germinal center (GC) 
formation. 
Its has been reported that B cells under the influence of IL-21 produced by follicular 
T helper (Tfh) cells, differentiate into germinal center (GC) B cells to promote 
antibody production in secondary lymphoid organs [174, 338, 341-343]. These 
findings suggest the role of GC formation in antibody production. Therefore, we next 
examined GC formation in the spleens of TAA-treated mice using peanut-agglutin 
(PNA) immunohistochemical staining. When compared to naïve, 6-weeks TAA 
treated mice displayed increased GC in the spleen which is consistent with serum 
IgG production (Figure 4.5A). Taken together, our data showed an association 
between splenic GC formation and antibody production during TAA induced liver 
fibrosis. 
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4.3 DISCUSSION 
B cells have been shown to play an important role in the pathogenesis of liver fibrosis. 
Our study identified a pathogenic role for B cells in theTAA induced liver fibrosis model 
and demonstrated GC B cell development and pathogenic antibody production. 
Characteristically, B cells are multifunctional as they express antigen-specific 
receptors, immune modulatory receptors (CD40), and pathogen targeting receptors 
including FcRs, complement receptors, and TLRs having both beneficial and 
dangerous signals [409-411]. Although B cells were identified as mediators of TAA 
induced liver fibrosis, the mechanism by which these cells promote fibrosis remains 
undefined. Consistent with previous findings, our study illustrated that mice deficient in 
B cells (µmt-/-) demonstrated reduced myofibroblast activation followed by reduced 
collagen deposition following 6-weeks TAA treatment [168, 412].  We previously 
reported that fibrosis which was, induced following 6-week TAA treatment, was 
associated with DR expansion and macrophage differentiation [20]. Extending these 
findings our current study demonstrated that mice deficient in B cells displayed 
significantly reduced DR expansion. Thus, B cells appear to play a key role during TAA 
induced liver fibrosis characterized by the development of extensive fibrosis with septal 
formation associated with an expanded DR. 
The mechanism through which B cells contribute to TAA-induced liver fibrosis is not 
clear. Therefore, to investigate the mechanism, we initially enumerated total B cell 
numbers in the liver. Our results demonstrated no marked difference in intrahepatic B 
cell number between naive and TAA treated mice. Interestingly, consistent with 
previous findings [412], intrahepatic B cell activation (characterized by the expression 
of CD44 and CD86) was increased in 6-weeks TAA treated mice. The innate function 
of activated B cells has previously been reported in CCL4 induced liver fibrosis [412]. 
Moreover, we demonstrated increased production of TNF, an important cytokine in 
HSC activation and survival during the later phases of fibrosis [385, 406]. Thus, the 
data suggests TNF secretion by activated B cells is a potential mechanism contributing 
to TAA-induced liver fibrosis. 
 
In addition to cytokine production, B cells also contribute to disease pathogenesis 
through antibody production [401]. T-cell dependent B cells activation is crucial for 
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antibody production [413]. Mechanistically, Tfh cells promote B cell activation, GC 
formation and antibody production through the production of IL-21[174, 338, 341-343]. 
Additionally, antigen-stimulated γδ T cells acquire Tfh phenotype to promote antibody 
production from B cells by up-regulating chemoattractant markers and IL-21 production 
[344] [403]. The pathogenic property of antibody production is observed during disease 
pathogenesis of GVHD [397] [400], and MS [401]. The role of antibody production 
during liver fibrosis is controversial whereby one study using the hepatotoxin (CCL4) 
model demonstrated that liver fibrosis is independent of antibody production [168]. 
Conversely,  a second study using the same model demonstrated increased IgG levels 
associated with liver fibrosis [169]. Moreover, several pathogenic auto-antibodies are 
detected in the sera of patients with the alcoholic liver disease, non-alcoholic fatty liver 
disease (NAFLD), viral hepatitis, drug-induced hepatitis, and HCC as well as 
autoimmune liver diseases which are essential for diagnosis and prognosis [172, 412, 
414, 415]. In addition to the above findings, we showed that TAA induced liver fibrosis 
was associated with increased splenic germinal centre (GC) B cells and serum IgG 
levels. IgG deposition in the livers of TAA treated mice was shown to be localized at 
the scar regions within the liver parenchyma along with macrophages demonstrating 
the close association between IgG and macrophages. Although increased IgG 
production was associated with liver fibrosis in our model, the type of antigens that 
stimulate antibody production is undefined. Nevertheless, previous findings 
documented the association of collagen-related antigens in the serum of patients with 
alcohol-induced liver fibrosis [416]. Additionally, it has also been reported that collagen 
itself is a potential self-antigen in collagen induced arthritis [417, 418]. Therefore, in 
support of the above findings, our study suggests that collagen may be an antigen 
during liver fibrosis development in the TAA model.  
Although TAA induced liver fibrosis was associated with increased antibody production, 
the mechanism by which antibodies induce liver fibrosis is unclear. It has been reported 
that antibodies will induce danger signals through direct antigen attack to clear 
pathogens or through the formation of immune complexes around the antigen and 
signal through  FcγRs to mediate cellular cytotoxicity [398, 399]. The family of FcγRs 
regulate antibody-mediated effector functions with both pro and anti-inflammatory 
responses. FcγR consists of both activating and inhibitory receptors [176]. Signaling 
through activated FcγR triggers cellular cytotoxicity, cytokine release, and 
phagocytosis whereas, signaling through inhibitory receptors downregulates effector 
functions [176]. Four different classes of FcγRs, including FcγRI, FcγRIIB, FcγRIII 
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and FcγRIV whereby each receptor signals different IgG antibodies with varying 
binding affinities [419, 420]. The evidence suggests that restoring the function of 
inhibitory FcγR in human autoimmune diseases may be a novel treatment for 
autoimmune disease patients. Similarly, inhibiting the dominant role of activating 
FcγRs prevents the pathogenic effect of autoantibodies. In the liver, FcγRs are 
predominantly expressed by macrophages with both an activating and inhibitory 
function [421].  The role of FcγRs during liver fibrosis is not defined. Our study 
illustrates that mice deficient in FcγR (FcγR -/-) demonstrated reduced myofibroblast 
activation associated with reduced collagen deposition following 6-weeks TAA 
treatment. Additionally, mice deficient in FcγR also demonstrated increased serum 
IgG levels. Although, serum IgG levels were increased, reduced IgG distribution in 
the livers FcγR-/- mice highlighted an association between IgG and FcγR in liver 
fibrosis. We also observed that IgG was sequestered around the central vein within 
the scar region along with macrophages. Previous findings reported that FcγR is 
predominantly expressed by macrophages [421]. However, we still need to investigate 
the cells that express FcγR in our model. We identified that the innate function of B 
cells and the binding of IgG to FcγR were associated with liver fibrosis. Taken 
together our study implies an association between B cells and fibrosis development. 
. 
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Figure 4-1 Contribution of B cells to TAA-induced liver fibrosis. (A) Histochemical 
staining for Sirius red (SR), smooth muscle activation (SMA), and ductular reaction (DR) 
staining in representative liver sections from 6-week TAA-treated C57BL/6 (WT) and µmt-/- 
mice.  (B) Aperio quantification of (SR) Sirius red, smooth muscle activation (SMA), and 
ductular reaction (DR) staining (n= 7-10 animals/group/time point). Data are presented as 
median and interquartile range * p< 0.05, Mann Whitney-U test. 
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Figure 4-2 B cells contribute to TAA-induced liver fibrosis through innate immune 
responses. (A) Representative graphs showing the absolute number of total B cells and 
activated B cells in naïve and 6-week TAA treated mice (n=3 to 9/group/time point) (B) 
Representative plots illustrating the production of TNF and IL-10 in naïve, and 6-week TAA 
treated mice. Data are presented as median and interquartile range * p< 0.05, Mann 
Whitney-U test & T-test. 
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Figure 4-3 Immunoglobulin production and deposition following 6-week TAA. (A) 
Serum IgG levels in naïve and 6-week TAA WT, µmt-/- mice. (n= 6-12 animals/group/time 
point) (B) Histochemical staining for IgG distribution in representative liver sections from 
naïve and 6-week TAA treated mice. Data are presented as median and interquartile 
range. * p< 0.05 (naïve verses 6-week). Mann Whitney-U test.  
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Figure 4-4 Binding of immunoglobulins to FCγR is associated with TAA-induced 
liver fibrosis. Histochemical staining for (A) Sirius red and SMA in representative liver 
sections from 6-week TAA-treated C57BL/6 (WT) and FcγR-/- mice. (B) Aperio 
quantification of SR and SMA staining (n= 6-12 animals/group/time point). (C) Serum IgG 
levels in 6-week TAA WT and, FcγR-/- mice (n= 6 animals/group/time point). Data are 
presented as median and interquartile range * p< 0.05, Mann Whitney-U test. 
 
 
 
 
 
 
 
 
 
A FcγR-/-WT 
S
ir
iu
s
 R
e
d
W T F c  R
- / -
0 . 0
0 . 5
1 . 0
1 . 5
2 . 0
F
i
b
r
o
s
i
s
 
(
A
r
e
a
 
f
r
a
c
t
i
o
n
 
%
)
*
S
M
A
300μm
300μm300μm
300μm
B
W T F c  R
- / -
0
1
2
3
s
e
r
u
m
 
I
g
G
 
(
m
g
/
m
l
)
*
W T F c  R
- / -
0
1 0
2 0
3 0
4 0
#
 
P
e
r
i
-
c
e
n
t
r
a
l
 
 
S
M
A
+
 
c
e
l
l
s
*
C
85 
 
 Figure 4-5 TAA induced liver fibrosis is associated with germinal center formation. 
Histochemical staining and quantification of PNA in mice treated with and without TAA. 
Data are presented as median and interquartile range * p< 0.05, Mann Whitney-U test. 
 
 
 
Supplementary figure: 
 
Supplementary figure 4-1 Gating strategy showing activated B cells 
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Chapter 5: KDO25 inhibits ROCK2 induced 
pathogenic effects in 
monocytes/macrophages and B 
cells following TAA treatment.  
5.1 INTRODUCTION 
Rho-associated coiled-coil forming protein kinase 2 (ROCK2) is a serine-threonine 
kinase and an established mediator of fibrosis in multiple disease settings. ROCK2 
is activated by RhoA associated GTPase [315] and is induced by multiple 
biochemical mediators including established fibrogenic mediators such as IL-17A 
[316] and TGFβ [317]. In the setting of graft versus host disease (GVHD), 
rheumatoid arthritis (RA), psoriasis, and systemic lupus erythematosus (SLE) 
ROCK2 has been shown to promote inflammatory responses [322, 332, 422]. 
Moreover, in the setting of idiopathic pulmonary fibrosis (IPF), myocardial fibrosis, 
and, peritoneal fibrosis Rho-associated kinases  function in cytoskeletal 
reorganization and remodeling of participating fibrotic cells [328-330].  
ROCK2 promotes inflammatory responses through leukocyte infiltration, activation, 
differentiation, and survival. Inflammatory responses induced by ROCK2 are 
mediated through the phosphorylation and expression of its downstream 
transcription factors such as signal transducer and activator of transcription 
3 (STAT3), RAR-related orphan receptor gamma (RORγt), and B-cell lymphoma 6 
(BCL6) in the targeted cell population [333-336]. Previously, it has been 
demonstrated that STAT3 and RORγt expression following ROCK2 activation is 
required to promote the differentiation of IL-17 producing cells during GVDH and 
autoimmunity, [112, 113, 337, 338].  Also, BCL6 expression in follicular helper cells 
(Tfh) following ROCK2 activation is reported to induce IL-21 production.  IL-21 from 
Tfh will, in turn, provide survival signals to germinal center (GC) B cells to promote 
pathogenic immunoglobulin production [338, 341-343], linking ROCK2 activity to the 
induction and perpetuation of antibody responses. Additionally, in the presence of 
IL-21, γδT cells are reported to acquire Tfh phenotype and interact with B cells in IL-
21 dependent manner to promote pathogenic antibody production against microbial 
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pathogens [175, 344]. Importantly, blocking of this signaling pathway has been 
shown to be effective in attenuating IL-17A and immunoglobulin induced 
pathogenesis in various diseases that manifest fibrosis.    
Monocytes/macrophages are established critical mediators of fibrosis. In response 
to injury, they contribute to fibrogenesis in part through their activation of 
myofibroblasts and also important in matrix remodeling through the production of 
matrix metalloproteases (MMP’s) [78, 423] [78, 81]. IL-17A, an established pro-
inflammatory cytokine, is reported to directly promote the pathogenic differentiation 
and function of macrophages [348-350]. In-vitro studies demonstrated that IL-17 
induces the production of pro-inflammatory cytokines (TNF, IL-6, and IL-1β) and 
also acts as a chemokine to recruit monocytes [191, 424]. Importantly, ROCK2 has 
been shown to promote macrophage differentiation and induce proinflammatory 
responses in a cell-intrinsic manner both in vitro and in vivo [345-347]. Thus, 
ROCK2 has a broad role in promoting inflammatory signals by inducing the 
production of IL-17A and IL-21 cytokines and promoting the pathogenic function of 
B cells and macrophages.  
A role for ROCK2 in cytoskeletal remodeling/reorganization is well established [351, 
352]. Cofilin is an actin-binding protein which regulates dynamic cytoskeletal 
reorganization [353]. Cofilin activity is reversibly regulated through phosphorylation 
and dephosphorylation where the phosphorylated form, pcofilin, is inactive [353]. 
ROCK2 induced cofilin phosphorylation contributes to actin cytoskeleton 
organization [351-354]  required for the adhesion and migration of multiple cell 
types including T cells, myofibroblasts, macrophages and cancer cells  [425] [426] 
[353] [427]. Given the importance of monocyte migration and macrophage adhesion 
within the scarred liver tissue, the above observations implicate a mechanistic role 
for macrophage specific cofilin activity in liver fibrosis.   
Surprisingly little is known regarding the contribution of ROCK2 in liver fibrosis. 
Given the importance of IL-17, monocytes/macrophages and immunoglobulins 
during liver fibrosis, the above findings highlight the role of ROCK2 activity in the 
pathogenesis of liver fibrosis. In support of this, recent findings suggest the 
association of ROCK2 in bile duct ligation (BDL) induced liver fibrosis [327]. 
However, the mechanistic contribution of ROCK2 in liver fibrosis is unexplored. 
KD025 is a potent and selective ROCK2 inhibitor which has been tested in multiple 
pre-clinical mouse models including GVHD [338, 342] and rheumatoid arthritis 
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[356] ) and is in now in clinical trials (rheumatoid arthritis, idiopathic pulmonary 
fibrosis (IPF) and GVHD) [337]).  In multiple studies, ROCK2 suppression of 
disease was associated with diminished IL-17 and IL-21 production  [112, 113].  In 
this study, we demonstrated the efficacy of ROCK2 inhibition in prevention and 
reversal of liver fibrosis in the TAA model and identified the key mechanisms 
underpinning this effect.  
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5.2 RESULTS 
5.2.1 ROCK2 signaling blockade diminishes onset of TAA-induced liver 
fibrosis, SMA+ myofibroblasts and F4/80+ cell infiltration. 
In initial experiments, we examined the contribution of ROCK2 signaling to the 
initiation of TAA-induced liver fibrosis. Mice were co-administered TAA with vehicle 
(0.4% methylcellulose, daily oral gavage) or KD025 (100 mg/kg/day, daily oral 
gavage) for a period of 1-week. KD025 treatment significantly reduced TAA-induced 
collagen deposition as demonstrated by sirius red (SR) staining and aperio image 
analysis (Figure 5.1A). Additionally, immunolabelling for smooth muscle actin (α-
SMA staining) and monocytes/macrophages (F4/80+ staining) demonstrated a 
significant reduction in the number of activated myofibroblasts and pericentral 
F4/80+ monocyte sequestration which represents characteristic features of early 
injury in this model [20] (Figure 5.1B  and C). Thus, we demonstrate a critical role 
for ROCK2 signaling in the initiation of TAA-induced liver fibrosis, highlighting the 
potential of ROCK2 inhibition as a preventive therapeutic strategy. 
5.2.2 KDO25 displays therapeutic potential for the treatment of 
established liver fibrosis. 
To establish the therapeutic potential of KD025, mice were treated with TAA for 6-
weeks to induce extensive fibrosis and then co-administered TAA with vehicle or 
KD025 for a further 2 weeks (in total 8-weeks). Livers isolated from 6-week TAA 
treated mice exhibited extensive collagen deposition and myofibroblast activation as 
demonstrated by SR and anti-SMA IHC staining (Figure 5.2 A, B). Moreover, pan-
keratin staining (CK-WSS) identified the development and expansion of a ductular 
reaction (DR) at the 6-week time point (Figure 5.2C). Notably, between the period 
of 6 and 8 weeks, there was no significant progression in collagen deposition, 
myofibroblast activation or the DR expansion. However, KD025 administration 
promoted fibrolysis as highlighted by SR staining demonstrating diminished 
collagen deposition and significant thinning of fibrotic septa (Figure 5.2 A). 
Furthermore, SMA+ myofibroblast numbers were significantly reduced in livers from 
KDO25 treated mice compared to those from vehicle-treated mice (Figure 5.2 B). 
Additionally, livers from KD025-treated mice displayed a substantially reduced DR 
in comparison to vehicle-treated animals, demonstrating the role of ROCK2 in DR 
maturation (Figure 5.2 C). As discussed in Chapter 3, Collagen1a (col1a) is the 
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dominantly expressed collagen species expressed in the liver after 6-week TAA 
administration. In line with reduced SR staining, RT-qPCR demonstrated a 
significant reduction col1a mRNA production in livers from KDO25 treated mice 
(Figure 5.2D).  
Although poorly studied, there is evidence that TAA-induced liver fibrosis is not 
readily amenable to spontaneous regression [18]. Hence, to gain greater insight into 
the anti-fibrotic efficacy of KD025 treatment, we examined the degree of 
spontaneous fibrotic regression in this model, following TAA withdrawal. Thus, mice 
were treated with TAA for a 6-week period, after which TAA administration was 
ceased for a period of 1 or 2 weeks. In line with a previous report of long-term 
persistence of fibrosis following TAA withdrawal for 12-weeks, our SR staining 
(Figure 5.3A) and aperio image analysis indicated no decrease in collagen 
deposition after 1-week withdrawal whereas, moreover, an apparent  trend toward 
fibrotic progression was evident following the 2-week withdrawal period (Figure 
5.3B). These data support that ROCK2 inhibition by KD025 activily promotes 
pathways  to attenuate collagen deposition, reverse the DR and facilitate ECM turn 
over to allow fibrotic regression.   
5.2.3 ROCK2 inhibition reduces pSTAT3 phosphorylation and RORγT 
expression. 
The mechanism through which ROCK2 inhibition attenuated liver fibrosis was 
examined by investigating the expression of its downstream targets. Given the 
confirmed role for IL-17 in this model, and that the importance of ROCK2 in IL-17 
production through STAT3 and RORγT, we next performed western blot analysis of 
pSTAT3 and RORγT expression in mice treated with TAA for 1 or 6-weeks co-
administered with vehicle or KD025. Western blotting demonstrated a significant 
reduction in STAT3 phosphorylation associated with the reduced trend in RORγT 
expression in the livers of 1-week TAA treated mice co-administered with KDO25 
when compared to vehicle-treated animals (Figure 5.4A). Similarly, administration 
of KD025 between the period of 6 and 8 weeks markedly reduced in STAT3 
phosphorylation and RORγT expression when compared to vehicle-treated (Figure 
5.4B). Intrestingly, when compared to 6-weeks TAA treatment, mice co-
administered with vehicle (0.4% methylcellulose) demonstrated increased STAT3 
phosphorylation. However, it is uncertain weather this increased STAT3 was due to 
methylcellulose. Having noted a significant decrease in pSTAT3 and RORγT levels 
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in the livers from mice treated with KDO25 we next examined the impact of KD025 
on IL-17a expression using qRT-PCR. Livers from mice co-administered with 
vehicle and TAA between 6 and 8-week exhibited no difference in IL-17a 
expression. However, following KDO25 administration IL-17a expression was 
significantly reduced (Figure 5.4C). Together, our findings demonstrate that 
protective effect of KDO25 is at least in part due to limiting pro-fibrogenic IL-17 
production.   
 
5.2.4 ROCK2 activation is required for BCL6 expression, germinal 
center formation and immunoglobulin deposition following TAA 
treatment. 
BCL6 is a known target of ROCK2, and previous studies in GVHD have identified 
that KDO25 inhibits the expression of BCL6 and its downstream IL-21 production,  
GC B cell differentiation and immunoglobulin production [338, 341-343]. Having 
demonstrated the pathogenic role of GC B cells and immunoglobulin deposition in 
the TAA model (discussed in chapter 4), we next performed western blot analysis of 
BCL6 expression in mice treated with TAA for 6-weeks co-administered with vehicle 
or KD025 for a further 2-weeks (in total 8-week TAA). Western blot analysis of livers 
from 8-week TAA+ vehicle-treated mice demonstrated increased BCL6 expression 
when compared to 6-week TAA treatment whereas, following KD025 administration  
BCL6 expression was significantly reduced (Figure 5.5A). However, it is uncertain 
weather this increased BCL6 expression in 8-week TAA+ vehicle-treated mice was 
due to vehicle (0.4% methylcellulose). As BCL6 promotes GC B cell formation 
through TFh differentiation and IL-21 production [428], in next experiments, we 
addressed whether diminished BCL6 levels were contributing to the attenuation of 
fibrosis via inhibition of GC B cell development and antibody production. In 
secondary lymphoid organs, GC develops in B cell follicles during T cell-dependent 
antibody response. GC consists of two zones; light zone and dark zone. T cells 
interact with B cells in the light zone (T cell zone) which stimulates B cells to enter 
the follicle to form dark regions (germinal center) [429-431]. Hence, we performed 
PNA/CD3/B220 immunofluorescence triple staining to identify germinal centers in 
spleens from 6-week TAA treated mice co-administered with TAA and vehicle or 
KD025-for the final 2 weeks. Consistent with diminished BCL6 expression confocal 
imaging showed KDO25 administered mice displayed reduced splenic GC’s 
formation when compared to vehicle-treated animals (Figure 5.5B). In line with 
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reduced splenic GC, KDO25 treated mice also demonstrated significantly 
decreased circulating IgG levels (Figure 5.5C) and liver IgG deposition (Figure 
5.5D). Thus, our data identify that in addition to inhibiting IL-17 production, ROCK2 
inhibition attenuates TAA-induced fibrosis through the disruption of GC B cell 
development and pathogenic antibody production.  
5.2.5 KD025 alters macrophage function by inhibiting TNF and MMP 
production.  
In addition to its effects in driving IL-17 differentiation, pSTAT3 has been reported to 
alter the functionality of cells of multiple lineages including macrophages [432, 433]. 
One of the mechanisms by which IL-17 drives fibrosis is through the production of 
proinflammatory mediators from macrophages [369, 370] [235]. Recently, IL-17A 
induced STAT3 signaling has been reported in macrophages to induce pro- 
proinflammatory mediators [191, 424]. Additionally, we also demonstrated the role 
of IL-17A in TNF production from macrophages during TAA-induced liver fibrosis 
(chapter 3). Moreover, ROCK2 signaling in macrophages has been demonstrated to 
promote an alternative M2 phenotype, similar to the profile of macrophages which 
accumulate in fibrotic tissues, suggesting the link between IL-17A, STAT3, and 
ROCK2 [345-347]. Thus, in next experiments, we addressed whether the protective 
effects of KD025 are in part mediated through the attenuation of altered 
macrophage function. Therefore, CSF-1 derived bone marrow- macrophages 
(BMDMs) were generated in-vitro to investigate if KD025 altered ROCK2 induced 
STAT3 phosphorylation in macrophages. For this CSF-1 derived BMDMs were 
cultured with KD025 (10 µM) or IL-17A (10 µM) or KDO25+IL-17A for 20 minutes to 
examine STAT3 phosphorylation using western blotting. BMDMs cultured with IL-
17A demonstrated increased STAT3 phosphorylation which was reduced following 
KDO25 or IL-17A+KDO25 (Figure 5.6A) treatment, demonstrating the role of 
KDO25 in inhibiting IL-17A mediated STAT3 phosphorylation in macrophages.  
Macrophages also induces the production of pro-inflammatory cytokines which 
include tumor necrosis factor alpha (TNF) [434, 435]. Therefore, using qRT-PCR we 
initially examined if KDO25 inhibits Tnf expression in the whole liver following TAA. 
Between the period of 6 and 8 weeks of TAA treatment, consistent to unchanged 
fibrosis Tnf expression also remained unchanged. However, treatment with KD025 
indicated a remarkable reduction in Tnf expression (Figure 5.6B). Subsequent 
experiments were performed on liver mononuclear cells (MNCs) isolated from 
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digested livers from 6-week TAA treated mice co-administered with KD025 or 
vehicle in the last 2 weeks and asked whether KD025 was altering TNF production 
from monocyte and macrophage. (Figure 5.6C). In comparison to the vehicle, 
KD025 treatment substantially reduced TNF production from both monocyte and 
macrophage populations in response to LPS stimulation. Further, CSF-1 derived 
BMDMs were cultured with KD025 (10 µM) or vehicle for 6hrs to ask weather 
KDO25 directly inhibits TNF production from macrophages. qRT-PCR analysis 
demonstrated reduced Tnf expression in BMDM cultured in KDO25 when compared 
to vehicle-treated (Figure 5.6D).  
Additionally, macrophages are also an important source of MMP’s involved in ECM 
turn over [81, 423]. Here, we demonstrated that MMP’s were significantly altered in 
BMDMs following KDO25 treatment, associated with increased MMP12 and 13 with 
a trend toward increased MMP2 (Figure 5.6E). This suggests that ROCK2 drives a 
macrophage phenotype that is inefficient in matrix turnover due to inhibition of 
MMPs. Moreover, the capacity of KD025 to promote fibrotic regression may be 
explained in part by restoring macrophage MMP production. Together, these data 
suggest the direct and indirect (through IL-17A) role of ROCK2 in altering 
macrophage function. 
5.2.6  KD025 alters macrophage migration by inhibiting the 
phosphorylation of cofilin. 
Cofilin is known target of ROCK2 implicated in cytoskeletal reorganization during 
fibrosis [328-330]. We demonstrated the importance of ROCK2 in macrophage 
functionality. Cofilin has already been shown to control macrophage adherence and 
motility [436]. Hence, our study is focused on the role of Cofilin in macrophage 
function in response to ROCK2 activation during liver injury. Initially, western blot 
analysis of  pCofilin levels in whole liver lysates was performed in 6-week TAA mice 
co-administered with KDO25 or vehicle for further 2-weeks (in total 8-weeks).  
Cofilin phosphorylation remained unchanged between 6 and 8-week TAA mice. 
However, following KDO25 administration phosphorylation of Cofilin was 
significantly reduced (Figure 5.7A). Further, CSF-1 derived BMDMs were cultured 
with KD025 (10 µM) or DMSO control for 20 min (Figure 5.7B) to ask weather 
KDO25 directly inhibits Cofilin phosphorylation in macrophages. BMDMs cultured 
with KD025 diminished phosphorylation of Cofilin, which confirming active and 
potentially pathogenic ROCK2 signaling in macrophages. Furthermore, absolute 
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macrophage numbers were examined in the livers from 8-week TAA treated mice 
co-administered with vehicle or KD025, to understand if altered macrophage 
function induced by KDO25 was actually due to reduced macrophage number. Flow 
cytometry analysis demonstrated macrophage numbers remained comparable 
between KDO25 and vehicle-treated group (Figure 5.8C). However, our F4/80 
+ IHC staining displayed that in the fibrotic liver macrophages sequester in the scar 
regions (fibrotic septa) whereas, following KD025 treatment, macrophages were 
more evenly distributed throughout the tissue (Figure 5.7D), demonstrating the role 
of KDO25 in inhibiting the macrophage adherence around the scar region. 
Additionally, IHC analysis was performed using an anti-cofilin antibody to examine 
the distribution of cofilin in the tissues. Livers from mice treated with KDO25 
displayed reduced cofilin across scar regions when compared to vehicle treated. 
Together, our data suggest that during fibrosis, in addition to altering macrophage 
phenotype, ROCK2 inhibits macrophage migration and promotes their retention in 
fibrotic septae through its inhibition of cofilin mediated cytoskeleton remodeling.  
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5.3 DISCUSSION 
ROCK2 has been shown to play an important role in inflammation and tissue 
remodeling in multiple chronic diseases that lead to fibrosis. In this study, we report 
the role of ROCK2 in promoting liver fibrosis through multiple mechanisms. We 
specifically demonstrated the role of ROCK2 in promoting proinflammatory cytokine 
IL-17A expression, pathogenic immunoglobulin production by B cells and driving 
profibrotic macrophage activity.  
ROCK2 inhibition has been reported to attenuate disease pathogenesis of GVHD 
[437], pulmonary fibrosis [328], psoriasis [438], autoimmune EAE [439], rheumatoid 
arthritis [440] and systematic lupus erythematosus [332, 439].  Inhibition of ROCK2 
in the above mentioned models is effective not only in prevention but also in the 
treatment of disease [319, 328, 437]. The established mechanisms by which ROCK 
contribute to disease pathogenesis is through IL-17A induced inflammatory 
responses [191, 424], B cells induced immunoglobulin deposition [338, 341-343], 
and pathogenic macrophage function [345-347]. Given the importance of IL-17, 
monocytes/macrophages and immunoglobulins during liver fibrosis, the above 
mechanisms highlight the role of ROCK2 activity in the pathogenesis of liver 
fibrosis. Recently, upregulation of ROCK2 expression is reported during BDL 
induced liver fibrosis [327], however, the mechanism by which ROCK2 induce liver 
fibrosis is not clear. We demonstrated that the inhibition of ROCK2 by the small 
molecule inhibitor KD025 prevented the development of fibrosis associated with 
reduced pericentral monocyte recruitment and myofibroblasts activation in 1-week 
TAA treated mice. This highlights the role of KDO25 in inhibiting the recruitment of 
inflammatory cells to prevent the development of fibrosis. In addition to prevention, 
ROCK2 inhibition also promoted the regression of established fibrosis. Herein we 
reported that mice co-administered with KD025 following 6-week TAA treatment 
promoted regression of liver fibrosis which was demonstrated by diminished 
collagen deposition and significant thinning of fibrotic septa when compared to 
vehicle-treated animals. KDO25 treatment also altered DR which is the 
characteristic feature of 6-week TAA treatment. We previously reported that F4/80+ 
monocytes/macrophages are more organized in a central-central distribution 
associated with DR niche [20]. However, following KDO25 treatment, F4/80+ cells 
that are residing within scar region were evenly distributed by altering DR. Hence, 
our study postulated that one of the anti-fibrotic property of ROCK2 inhibition is 
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through altering macrophage retention and migration to promote regression of 
fibrosis.  
Extracellular matrix (ECM) degradation also promotes fibrosis regression [441]. We 
demonstrated that during KDO25 mediated fibrotic regression Collagen1a 
(abundantly found in ECM) in the livers was significantly reduced indicating the role 
of KDO25 in collagen degradation. It has been well described that matrix 
metalloproteinases (MMPs), play a pivotal role in promoting ECM degradation that 
is essential for wound healing [442]. Of all available MMPs, the anti-fibrotic property 
of MMP-2 [443-446] and MMP-13 [447, 448] is reported in hepatotoxin (CCL4), and 
physical  (BDL) injured liver fibrosis models both by inhibiting collagen production 
and promoting collagen degradation. MMP-12 is also reported during liver fibrosis 
with conflicting results where one group demonstrated reduced fibrosis 
in Mmp12−/− animals compared with wild-type controls [449] whereas, another 
observed no difference in fibrosis between the two genotypes [450]. Macrophages 
which group with HSCs to induce collagen deposition are also observed to produce 
MMPs that control ECM turns over [78, 81]. However, the importance of ROCK2 in 
inducing MMPs from macrophages is not clear. Thus, using in-vitro CSF-1 derived 
BMDM we demonstrated that Mmp-2, Mmp-12, and Mmp-13 that are under-
expressed were upregulated following KDO25 treatment to encourage ECM 
degradation and promote fibrotic regression. Though our in-vitro findings using 
BMDM demonstrated the importance of KDO25 in inducing MMPs from 
macrophages, further studies are required to confirm these observations by using 
liver macrophage.  However, the question remains here is if macrophages are 
removed from tissue scar following KDO25 treatment, how does MMP production is 
altering ECM?  
Previous studies have shown that KD025 during disease pathogenesis limits IL-17A 
and immunoglobulin production  [319, 328, 437]. In chapter 3 and 4 we explained 
the pathogenic role of IL-17A and immunoglobulins by effecting 
monocytes/macrophages in TAA-induced liver fibrosis model (discussed below). 
Therefore, in addition to altered macrophage migration and ECM production, 
KDO25 is also important in macrophage-induced inflammatory responses. 
STAT3 and RORγt are one of the downstream targets of ROCK2 which promote 
inflammatory responses [112, 113, 337, 338]. We observed that livers (following 8-
week TAA) from KDO25 treated mice demonstrated reduced  STAT3 
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phosphorylation and RORγT expression when compared to vehicle treated. The 
reduction in pSTAT3 and RORγT attenuates differentiation of IL-17 producing cells 
leading to reduced IL-17 expression. pSTAT3 has been reported to alter the 
functionality of macrophages which are reported to be important cellular mediators 
of liver fibrosis [432, 433]. Recently, IL-17A is reported to directly activate 
macrophages in STAT3-dependent manner to induce the production of 
proinflammatory mediators [191, 424]. Moreover, ROCK2 signaling is also stated in 
macrophages to promote an alternative macrophage phenotype, similar to the 
profile of macrophages which accumulate in fibrotic tissues [345-347]. All these 
findings suggest the link between ROCK2, IL-17A, and STAT3 to induce pathogenic 
macrophage phenotype. Hence, using in-vitro CSF-1 generated bone marrow-
derived macrophages (BMDM) we demonstrated that KDO25 directly inhibited 
pSTAT3 in macrophages which was induced in response to IL-17A. We previously 
reported the role of IL-17A signaling in promoting proinflammatory (TNF) 
macrophage phenotype during liver fibrosis (Chapter 3). Here, using in-vitro and in-
vivo studies, we demonstrated that TNF production from macrophages was 
significantly reduced in response to KDO25 when compared to vehicle-treated 
during 8-week TAA treatment. Together our data demonstrated the direct (through 
pSTAT3) and indirect (through IL-17) role of ROCK2 in promoting inflammatory 
macrophage phenotype.  
Notably, when compared to 6-weeks TAA treatment, mice co-administered with 
vehicle (0.4% methylcellulose) demonstrated a mild increase in STAT3 
phosphorylation and BCL6 expression. At this stage, it is uncertain whether this was 
due to methylcellulose and further investigations are required to clarify this issue. 
Unfortunately, this is a limitation of the study as KDO25 is only soluble in DMSO or 
methylcellulose. We selected methylcellulose as the vehicle in our in 
vivo experiments as it is non-toxic and can be safely used for oral administration. 
Importantly, however, all results were compared relative to methylcellulose alone. 
Immunoglobulins will also contribute to pathogenic macrophage activation by 
binding to FCγR [407]. We demonstrated that TAA-induced liver fibrosis is 
associated with the binding of immunoglobulins to FCγR (chapter 4). B cell 
lymphoma 6 (BCL6) is also a known target of ROCK2 that contributes to B cell 
differentiation and immunoglobulin production [338, 341-343]. Mechanistically, 
BCL6 mediates the interaction between Tfh and B cells to promote B cell germinal 
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center (GC) formation and immunoglobulin production [429-431]. Although 
immunoglobulin deposition has been noted in the TAA-induced liver fibrosis 
(chapter 4), we also demonstrated increased expression of liver BCL6 and splenic 
GC formation during 8-week TAA treatment. Additionally, during KDO25 induced 
fibrotic regression we have shown reduced BCL6 expression, GC formation, and 
immunoglobulin production. Thus, our data demonstrated that KDO25 indirectly 
inhibited pathogenic macrophage function by inhibiting IL-17A and immunoglobulin 
induced proinflammatory responses. 
ROCK2 also controls macrophage adherence and migration by inducing 
cytoskeletal re-organization [436]. Cofilin is known target of ROCK2 established in 
cytoskeletal reorganization [328-330]. We demonstrated that livers (following 8-
week TAA)  from KDO25 treated mice exhibited reduced pCofilin when compared to 
vehicle treated. Cofilin has already been shown to control macrophage adherence 
and motility [436]. Therefore using, using CSF-1 generated BMDM, we 
demonstrated that KDO25 directly inhibited pCofilin in macrophages, highlighting 
the importance of ROCK2 induced pCofilin in macrophages during liver fibrosis. 
Given that KDO25 treatment promoted macrophage migration by altering their 
retention within the septae implicates the role of pCofilin in macrophage migration. 
Thus, our data demonstrated that ROCK2 inhibits macrophage migration and 
promotes their retention in fibrotic septae through its inhibition of cofilin mediated 
cytoskeleton remodeling.  
To obtain considerable understanding into the anti-fibrotic efficacy of KD025 
treatment, we examined the degree of spontaneous fibrotic regression following 
TAA withdrawal. Recent findings suggest that withdrawal of TAA for 8 weeks 
following 12-week TAA administration (IP) in rats promoted partial spontaneous 
regression [18].  This suggests that in our model for the fibrosis to promote 
spontaneous regression it might take a long time to reverse pathogenic 
inflammatory responses and ECM remodeling mechanisms. However, identifying 
the targets that cease these responses might significantly promote quick reversal of 
fibrosis. We identified ROCK2 as a dominant mediator of liver fibrosis. Taken 
together our data demonstrated a remarkable capacity for ROCK2 inhibition by 
KD025 to attenuate macrophage-induced pro-inflammatory responses mediated 
through IL-17A and IgG production. Additionally, ROCK2 inhibition also promoted 
collagen degradation by upregulating macrophage-induced MMP production to 
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allow fibrotic regression. These findings highlight that ROCK2 as a therapeutic 
target that promoted fibrosis regression by inhibiting the interaction between cellular 
and molecular mediators that contribute to liver fibrosis. 
 
Figure 5-1 KDO25 inhibits TAA-induced liver fibrosis. Histochemical staining 
and quantification of (A) Sirius red (SR) (B) smooth muscle actin (SMA), and (C) 
F4/80 in representative liver sections from 1-week TAA-treated C57BL/6 mice co-
administered with 0.4% methylcellulose vehicle control or 100mg/kg KDO25. Data 
are presented as the median and interquartile range (n=11 animals/group/time 
point). * p< 0.05, ** p< 0.01 Mann Whitney-U test. 
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Figure 5-2 KDO25 promotes regression of TAA-induced liver fibrosis. 
Histochemical staining and aperio quantification of (A) Sirius red (SR), (B) smooth 
muscle activation (SMA), and (C) Pan-keratin (CK-WSS) staining in representative 
liver sections from C57BL/6 (WT) co-administered 0.4% methylcellulose vehicle 
control or 100mg/kg KDO25 after 6-week TAA-treatment. (D) Expression of col-1a 
in whole liver (n= 6 animals/group/time point). Representative images and data are 
presented as median and interquartile range * p< 0.05 (Pericentral SMA: 6-week 
TAA verses 8-week vehicle + TAA; 6-week TAA verses 8-Week KDO25 + TAA) 
(Ductular reaction: 8-week vehicle + TAA verses 8-week KDO25 + TAA) (Col1A: 8-
week vehicle + TAA verses 8-week KDO25 + TAA), ** p<  0.01 (Collagen proportion 
area: 6-week TAA verses 8-week vehicle + TAA; 6-week TAA verses 8-Week 
KDO25 + TAA). Mann Whitney-U test.  
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Figure 5-3 TAA withdrawal does not promote fibrotic regression. (A) 
Histochemical staining and (B) Aperio quantification of sirius red (SR) staining in 
representative liver sections from C57BL/6 (WT) after 6-week TAA-treatment 
followed by TAA withdrawal for 1 and 2 weeks to investigate fibrosis regression. (n= 
3-6 animals/group/time point). Representative images and data are presented as 
median and interquartile range One-way ANOVA (K.W).  
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Figure 5-4 KDO25 inhibits STAT3 phosphorylation, RORγt, and IL-17A expression in 
the liver. To investigate whether KDO25 promotes regression of liver fibrosis through the 
inhibition of STAT3 phosphorylation, RORγt, and IL-17A expression, we initially treated 
one group of mice with TAA for 6-weeks to establish fibrosis. Subsequently, we used this 
6-week TAA treatment as a common starting point for therapeutic administration 
experiments where either KDO25 and vehicle were co-administered with TAA for the final 
two weeks (8wk total). Whole livers were assessed for STAT3 phosphorylation and RORγt 
expression using western blots and normalized to actin expression following (A) 1-week 
TAA treatment and (B) 6-week TAA treatment, co-administered with either 0.4% 
methylcellulose or 100mg/kg KDO25. (n= 5-11animals/group). (C) qRT-PCR is 
determining the expression of IL-17a in whole liver (n= 5-6 animals/group).  Data are 
presented as median with interquartile * p< 0.05, ** p< 0.01, *** p< 0.001 Mann Whitney-U 
test.  
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Figure 5-5 KDO25 inhibits BCL6 expression and germinal center formation in the 
liver.  To investigate the impact of KDO25 promotes regression through the inhibition of on 
Bcl6 expression and GC formation, we initially treated one group of mice with TAA for 6-
weeks to establish fibrosis. Subsequently, we used this 6-week TAA treatment as a 
common starting point for regression experiment where either KDO25 and vehicle were 
administered for the final two weeks (8wk total). (A) Western blots showing BCL6 
expression in whole liver following 6-week TAA treatment, co-administered with 0.4% 
methylcellulose vehicle control or 100mg/kg KDO25 for further 2-weeks (n= 5-6 
animals/group).  (B) Confocal image representing anatomic structure of germinal center 
formation (GC) in spleens using immunofluorescence triple staining stained with anti-CD3 
(red), anti-B220 (blue), and carbohydrate-peanut-agglutin (green) (n= 6 animals/group). 
(C) Serum immunoglobulin (IgG) levels (n= 4-5 animals/group) and (B) Histochemical 
staining for immunoglobulin deposition in the liver in 6-week TAA treated mice co-
administered with 0.4% methylcellulose vehicle control or 100mg/kg. KDO25 Data are 
presented as median with interquartile * p< 0.05, ** p<  0.01 Mann Whitney-U test. 
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Figure 5-6 KDO25 alters macrophage function. (A) CSF-1 generated bone narrow 
derived macrophages were used to assess STAT3 phosphorylation by treating them with 
KD025 (10 µM) or IL-17A (10 µM) or KDO25+IL-17A or nil for 20 minutes before 
performing western blot analysis. Mice treated with TAA for 6-weeks, co-administered with 
0.4% methylcellulose vehicle control or 100mg/kg KDO25 were used to determine (B) Tnf 
expression in whole liver (n-5-6 animals/group) and (C) TNF production from monocytes 
and macrophages following In-vitro LPS (100ng/ml) stimulation of liver cells. Data are 
presented as median and interquartile range * p< 0.05 (TNF liver: 6-week TAA verses 8-
week KDO25 + TAA), ** p<0.01 (TNF liver: 8-week vehicle + TAA verses 8-week KDO25 + 
TAA). Mann Whitney-U test. CSF-1 generated bone narrow derived macrophages were 
treated with KD025 (10 µM) or DMSO control for 6 hr to determine the expression of (D) 
Tnf and (E) MMP’s (n= 4 animals/group). Data are presented as median and interquartile 
range * p< 0.05 Mann Whitney-U test. 
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Figure 5-7 KDO25 alters macrophage migration. (A) Western blots determining the 
Cofilin phosphorylation in whole liver normalised with actin following 6-week TAA 
treatment, co-administered with 0.4% methylcellulose vehicle control or 100mg/kg KDO25 
(n= 5-11animals/group). (B) CSF-1 generated bone narrow derived macrophages were 
used to assess Cofilin phosphorylation by treating them with KD025 (10 µM), DMSO 
control for 20 min before performing western blot analysis. (C) An absolute number of 
macrophages in total liver PBMC’s (n =10 animals/group) and (D) Histochemical staining 
for F4/80 and cofilin in representative liver sections following 6-week TAA treatment, co-
administered with 0.4% methylcellulose vehicle control or 100mg/kg KDO25. Data are 
presented as median and interquartile range *** p< 0.001(pCofilin: 6-week TAA verses 8-
week KDO25+TAA) Mann Whitney-U test.  
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Chapter 6: Summary and Future directions  
6.1. Summary: 
Liver fibrosis is a consequence of chronic liver disease (CLD). Its progression can 
result in cirrhosis and the development of hepatocellular carcinoma (HCC). Liver 
fibrosis results from the interplay between proinflammatory cytokines/chemokines, 
inflammatory infiltrates, and tissue resident cells. Currently, there are no effective 
antifibrotics. One of the biggest challenges is to develop antifibrotic agents which not 
only inhibit the development of fibrosis but are able to reverse already established 
fibrosis. This thesis aimed to examine the different cellular and molecular mediators 
that contribute to liver fibrosis and also identify the active therapeutic target to inhibit 
progression and promote regression of fibrosis. 
 
Fibrosis was induced by treating mice with thioacetamide (TAA) for 1, 6 and 12 
weeks. TAA-induced liver fibrosis is an excellent model to investigate the various 
stages of fibrosis. The TAA model has many advantages as it is cost-effective, easy 
to administer and does not require surgical intervention. As recently described, the 
TAA liver injury model induces two phases of fibrosis [20]. After 1-6 week of TAA 
treatment, early collagen deposition is observed solely at the central vein; however, 
from 6-12 weeks injury progresses to central-central linkage with thick bands of 
collagenous septa [20]. During TAA treatment, early fibrosis is characterized by 
peri-central monocyte infiltration whereas, DR maturation with increased 
macrophage association characterizes late-stage fibrosis. Taking these parameters 
into consideration, we investigated different cellular and molecular mediators to the 
two phases of TAA-induced fibrosis.   
 
In chapter 3 identified the critical requirement of IL-17 family cytokines during two 
phases of TAA-induced liver fibrosis. We confirmed that in the absence of IL-17A 
and IL-17E signaling, fibrosis and its related parameters were reduced following 1-
6-week TAA, but not at the 12-week time point. However, fibrosis was significantly 
reduced in the absence of IL-17RA (devoid of both IL-17A and IL-17E signaling) at 
all time points examined. This study also identifies the mechanistic contributions of 
IL-17A and IL-17E cytokine during injury 1) Following TAA, IL-17E through CCL2 
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production promotes monocytic and CCR+ IL-17+γδ T cell infiltration whereas, 2) IL-
17A produced from γδ T cell contributes to peri-central monocytic sequestration 
without altering monocytic infiltration. We also demonstrated that IL-17A induces 
the production of proinflammatory cytokines (TNF and IL-6) which contribute to the 
pathogenesis of disease in this model. Thus, the inhibition of any of these signaling 
pathways (IL-7A or IL-17E) is sufficient to inhibit early liver fibrosis whereas, during 
late phase, both these cytokines synergistically contribute to disease pathogenesis.  
 
In chapter 4 we also examined the role of B cells in liver fibrosis. Two recent 
publications have identified the pathogenic effects of B cells during liver fibrosis 
which is mediated by T cell-mediated B cell activation and antibody production [168] 
[169]. We identified that in the setting of TAA-induced liver fibrosis B cell-deficient 
mice displayed reduced fibrosis associated with reduced DR expansion. We 
observed increased intrahepatic B cell activation (CD44 and CD86) in mice treated 
with TAA for 6 weeks. Functionally, activated B cells are demonstrated to induce 
pro-inflammatory gene signature producing higher levels of TNF. In addition to pro-
inflammatory gene signature activated B cells are also reported to induce the 
production of antibodies during the pathogenesis of various auto-immune diseases. 
We confirmed that TAA-induced liver fibrosis was also associated with antibody 
(IgG) deposition within the scar regions along with macrophages. The mechanism 
through which antibodies induce pathogenic effects is through FcγR ligation. We 
observed that although IgG was increased, decreased collagen deposition in the 
absence of FcγR demonstrates the importance of IgG and FcγR ligation during 
liver fibrosis. Together, our studies identified that B cells contribute to liver fibrosis 
through B cell activation, antibody deposition and its binding to FcγR. 
 
Chapter 5 identifies the role of Rho-associated kinase 2 (ROCK2) in prevention and 
treatment of TAA-induced liver fibrosis. One publication has identified the 
upregulated expression of ROCK2 in BDL induced liver fibrosis model. ROCK2 has 
an established role in IL-17A production, B cell development, and pathogenic 
macrophage function during autoimmune and inflammatory diseases. Given the 
importance of IL-17A, B cells, and macrophages in TAA model, above findings 
suggest the role of ROCK2 in our model. Here, we identified that KD025 a selective 
ROCK2 inhibitor prevented fibrosis by attenuating IL-17 production through the 
inhibition of signal transducer and activator of transcription 3 (STAT3) and RAR-
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related orphan receptor gamma  (RORγt) signaling pathways.  We also identified 
that that KDO25 attenuated splenic B cell germinal center formation and liver IgG 
deposition by inhibiting the expression of B-cell lymphoma 6 (BCL6) transcription 
factor. KDO25 has directly altered macrophage function by downregulating IL-17A 
mediated pSTAT3 expression along with reduced TNF production. We also 
confirmed the role of KDO25 in fibrotic regression. During fibrotic regression, 
KDO25 will disrupt the association between DR/F480 within the scar region and 
promotes macrophage migration away from the scar through pCofilin mediated 
cytoskeletal rearrangements. We also observed that during regression of fibrosis, 
KDO25 promotes collagen degradation by restoring the production of MMP’s (Mmp-
2, 12, and, 13.) from macrophages. Together, these data demonstrated the role of 
ROCK2 in promoting proinflammatory cytokine IL-17A expression, pathogenic 
immunoglobulin production by B cells and driving profibrotic macrophage activity. 
 
In summary, this thesis presents the mechanistic contributions of IL-17A and IL-17E 
signaling during liver fibrosis mediated through myeloid infiltration and function. 
Additionally, we also identified the mechanisms associated with B cell-induced liver 
fibrosis. Finally, we identified the therapeutic role of KDO25 in by inhibiting the 
pathogenic responses induced by different cellular (monocytes/macrophages and B 
cells) and molecular (STAT3, BCL6, IL-17A, Cofilin) mediators. 
 
6.2. Mechanism of TAA induced liver fibrosis: 
TAA has been reported to induce oxidative stress to hepatocytes which eventually 
leads to the production of DAMPS and recruitment of inflammatory mediators 
(Predominantly monocytes). Collectively, our study identified multiple cellular and 
molecular mediators that contribute to TAA-induced liver fibrosis (Figure 6-1). 
Monocytes/macrophages are reported as critical mediators of TAA-induced liver 
fibrosis. Initially, TAA-induced liver fibrosis promotes the recruitment of pericentral 
CCR2+ monocytes. Eventually, CSF-1 will promotes the differentiation of CCR2+ 
monocytes into CX3CR1+ monocytes and pathogenic macrophages.   Our data 
identified that during the early phase of TAA-induced liver fibrosis, IL-17E/IL-17RB 
signaling on macrophages will promote the recruitment of CCR2+monocyte and γδT 
cells through the production of CCL2. Subsequently, activation of RORγt and 
STAT3 in γδT cells induced the production of IL-17A in our model. Mechanistically, 
IL-17A signaling on monocytes facilitate pericentral monocytic sequestration 
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following IL-17E induced monocytes recruitment. Additionally, IL-17A signaling 
induced the production of inflammatory cytokines such as: (a) TNF from 
macrophages in STAT3 dependent manner and (b) IL-6 in the absence of IL-17A 
signaling for which the mechanism was unidentified. Finally, the redundant nature of 
both IL-17A and IL-17E during early liver fibrosis was identified whereas during late 
phase, both IL-17A and IL-7E synergistically contribute to TAA-induced liver 
fibrosis. Our study also observed that IL-17A signaling induced the production of 
TWEAK, which has been reported in the contribution of DR maturation and the 
development of fibrosis. However, further studies are required to elucidate whether 
there are additional mechanisms where IL-17 family cytokines directly or indirectly 
contribute to TAA-induced DR maturation. Other cellular mediators which were 
associated with TAA-induced liver fibrosis are B cells. Contribution of these B cells 
during TAA-induced liver fibrosis was associated with BCL6 induced B cell 
activation, germinal center formation, antibody (IgG)production and its binding to 
FcγR. We also observed that IgG was sequestered around central vein within the 
scar region along with macrophages. Previous findings reported that FcγR is 
dominantly expressed by macrophages. However, we still need to investigate the 
cells that express FcγR in our model. In order to prevent and promote the 
regression of TAA-induced liver fibrosis, ROCK2 inhibitor (KDO25) was used which 
inhibited the pathogenic responses induced by different cellular and molecular 
mediators. KDO25 a) Inhibited STAT3 and RORγt signaling pathways which in turn 
attenuated IL-17 production in the livers of TAA treated mice, b) inhibited BCL6 
expression resulting in reduced splenic B cell germinal center formation and 
diminished IgG production in the livers c) diminished STAT3 phosphorylation and 
TNF production in response to IL17A in macrophages d) diminished pCofilin 
expression from macrophage promoting regression of fibrosis through the inhibition 
of macrophage migration from fibrotic septae . Thus, these studies identify ROCK2 
as a potential therapeutic target to inhibit pathogenic responses induced by different 
cellular (monocytes/macrophages and B cells) and molecular (STAT3, BCL6, IL-
17A, Cofilin) mediators during TAA-induced liver fibrosis 
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Figure 6-1Mechanism of TAA induced liver fibrosis: 
During early phase fibrosis (1-week TAA) L-17E through IL-17RA/IL-17RB signaling induce the production of CCL2 from 
macrophages. CCL2 production promotes the recruitment of pathogenic CCR2+ monocytes and CCR2+IL-17+γδ T cell 
infiltration into the liver. IL-17A through IL-17RA signaling was required for the sequestration of monocytes around the 
central vein (CV) during 1-week TAA treatment.  IL-17A signaling also facilitate the expression IL-6 and TNF in the liver, 
both of which are established mediators of fibrosis. IL-21 production from T follicular helper cell (TFh) promotes germinal 
center B cell development and antibody (IgG) production during 6-week TAA treatment. Association of IgG and FcR on 
macrophages were shown to elicit pathogenic responses. ROCK2 has an established role in regulating IL-17A and IL-21 
production induce macrophage plasticity. KD025, a selective ROCK2 inhibitor, inhibited signal transducer and activator of 
transcription 3 (STAT3) and RAR-related orphan receptor gamma (RORγt) signaling pathways which in turn attenuated 
IL-17 production in the livers of mice following 1 and 8-week TAA treatment. KDO25 also inhibited B-cell lymphoma 6 
(BCL6) expression resulting in significantly reduced B cell germinal center formation and diminished IgG production in 
the livers of TAA treated mice. Additionally, KD025 administration significantly diminishes STAT3 phosphorylation and 
TNF production in response to IL17A in macrophages. Cofilin pathway, is another ROCK2 target which regulates 
cytoskeletal reorganization required for cytokine production, adhesion and migration. KD025 markedly diminished 
pCofilin expression from macrophage. Overall, our findings suggested the synergistic contribution of IL17A and IL-17E 
cytokines by promoting myeloid recruitment and pathogenic differentiation. Moreover, we identify a critical role for B cells 
in pathogenic IgG production and its association with FcγR. Finally, we identified ROCK2 as a potential therapeutic target 
to inhibit pathogenic responses induced by different cellular (monocytes/macrophages and B cells) and molecular 
(STAT3, BCL6, IL-17A, Cofilin) mediators during TAA induced liver fibrosis.  
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6.3.  Future work: 
 
TAA induced liver fibrosis was associated with immunoglobulin (IgG) production, 
however, the pathogenic role of IgG elicited during TAA-induced liver fibrosis is 
undefined. Having demonstrated an increased serum IgG levels in mice with 
established fibrosis, future studies on adaptive transfer of serum (containing IgG) 
from these mice to naïve WT mice might lead to understanding the pathogenicity of 
IgG in liver fibrosis. Binding of IgG to FcγR was associated with liver fibrosis. 
However, the mechanism of this binding is not found. Our study displayed that IgG 
was sequestered around central vein along with macrophages. Therefore further 
studies like macrophage depletion in FcγR-/- (prior to adaptive serum IgG 
transfer) and generation of bone marrow chimeras where FcγR is restricted to 
hematopoietic cells might reveal the binding of IgG to FcγR on macrophages.  
 
We have shown that degradation of ECM (Collagen1A) promotes regression of 
fibrosis. As per the previous findings MMPs, play a pivotal role in promoting ECM 
degradation that is essential for wound healing [442]. Our studies demonstrated that 
macrophages are an important source of MMP’s and were shown to be profoundly 
regulated by KDO25 to encourage ECM degradation and promote fibrolysis. 
Therefore further studies are required to understand the mechanisms by which 
KDO25 promotes fibrolysis.  Thus, the examination of the effects of ROCK2 
inhibition on macrophages in MMP expression and function (zymograpgy) should 
provide further insight into profibrotic mechanisms of ROCK2. Eventually, this would 
help to define the permissive role of macrophages in fibrotic regression. Although 
the importance of KDO25 in macrophages was thoroughly studied in our model, 
further studies investigating the role of KDO25 in other immune and liver resident 
cells (HSC and LSEC) using RNA sequencing would help to understand the relative 
contribution of ROCK2 among different cells.  
 
Our study identified an important role of IL-17E signaling in inducing CCL2 from 
macrophages which in turn promotes pericentral monocytic infiltration. Having 
identified that the expression of IL-17RB was largely restricted to hepatocytes future 
studies will focus on establishing the direct effects of IL-17E signaling in 
hepatocytes that promote fibrosis. Thus, administration of recombinant IL-17E to 
chimeric mice where IL-17RB signaling is restricted to non-hematopoietic cells 
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would lead to understand the profibrotic mechanisms of IL-17E induced through 
hepatocytes.  Along these lines, interrogation of IL-17E elicited hepatocyte cytokine 
and growth factors (in-vivo and in-vitro) could be used to identify the intermediate(s) 
factors responsible for the induction of CCL2 from macrophages.  Additionally, our 
lab reported that macrophages were closely associated with DR maturation during 
6-week TAA treatment which internally demonstrated the association of IL-17 
signaling with DR maturation. Further investigations on the effects of  IL-17 
signalling on macrophages (in-vitro and in-vivo) in expression and function various 
profibrotic genes associated with DR would lead to identify the mechanistic role of 
IL-17 signalling in promoting DR. 
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Appendices   
 
Appendix A: List of reagents used. 
 
• Tris-EDTA Buffer (10mM Tris Base/1 mM EDTA solution, pH9) 
Tris- 1.21gm 
EDTA- 0.37gm 
RO water- 1l 
• 0.5M EDTA: 
EDTA (disodium ethylenediamine tetraacetate.2H20)- 186.1GM 
Distilled water- 800ml 
NaOH pellets- 18-20gm 
PH- 8.0 
• WASH BUFFER: 
1X PBS – 1l 
Heat inactivated FCS (Gibco) – 20ml 
0.5M EDTA- 10ml 
• IMDM Complete: 
IMDM (SAFC)- 500ml 
Heat inactivated FCS (Gibco) – 50ml 
Pencillin/Streptamycin (Gibco) -  5ml 
L-Glut 100x (Hyclone 200mM)- 5ml 
Non-essential amino acids 100x (Gibco) – 5ml 
Sodium Pyruvate 100x (100mM)- 5ml 
2 Mercapto ethanol 100x -1ml 
• Collegenase digest solution for 10ml: 
Hank’s Based Salt Solution (HBSS)- 10ml 
133 
Collagenase Type IV (D) (Sigma)- 10mg 
1 mg/ml DNase I (Sigma)- 20μl 
• 30% Pecoll gradient for 25ml: 
Percoll (GE Healthcare #17-0891-01) - 8.44 ml 
10 x PBS -  0.94 ml 
1 x PBS - 15.63 ml 
• GEY’S lysis buffer: 
Gey’s Stock A             NH4Cl   35gm 
    KCl   1.85gm 
    Na2HPO412H2C 1.5gm (or Na2HPO4   0.63g) 
    KH2PO4  0.12gm 
    Glucose  5.0gm 
    Phenol red  50.0mg 
    Bring to 1000mls with distilled water 
Gey’s Stock B             MgCl26H2O  0.42gm 
                                      MgSO4.7H2O            0.14gm 
     CaCl2   0.34gm (or CaCl2.2H20 0.45g) 
    Bring to 100mls with distilled water 
 
Gey’s Stock C              NaHCO3  2.25gm 
             Bring to 100mls with distilled water 
1 X Gey’s Working Solution 
    20 parts stock A 
    5 parts stock B 
    5 parts stock C 
    70 parts distilled water 
    Sterile fillter 0.22μm  
• Preperfusion buffer (PB) (10×)  
NaCl                    80.00 gm 
KCl                      4.00 gm 
NaH2PO4•2H2O   0.78 gm 
Na2HPO4•12H2O 1.51 gm 
134 
NaHCO3              3.50 gm 
EGTA                  1.90 gm 
Glucose             9.00 gm 
Phenol red        0.06 gm 
Dissolved in 1 L ddH2O and adjust pH to 7.4.  
• Enzyme buffer (EB) (10×) 
NaCl                    80.00 gm 
KCl                      4.00 gm 
NaH2PO4•2H2O   0.78 gm 
Na2HPO4•12H2O 1.51 gm 
NaHCO3              3.50 gm 
HEPES               23.80 gm 
Phenol red        0.06 gm 
Dissolved in 1 L ddH2O and adjust pH to 7.4.  
[Add 20μl CaCl2(2.5M) to 100 ml of 1x EB buffer first, mixed well, then add 10 mg of 
collagenase IV before the experiment] 
• Liver lysis buffer (1ml per 0.02-0.06mg liver) 
T-PER® Tissue Protein Extraction Reagent              10ml 
Protein inhibitor tablets                                            1 
